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Drug delivery during breastfeeding: investigations of formulations and
clinical feasibility - Theresa Maier
At an age when breastfeeding is the optimal nutritional support for infants, oral
drug delivery can be challenging. In the past, the concept of drug delivery during
breastfeeding was developed as a means to address challenges in low-income coun-
tries by facilitating administration using solid dosage forms without the need for
clean water. Hereby, a silicone nipple shield, containing a formulation inside its
teat, is meant to be worn by a mother during breastfeeding, enabling drug delivery
to the sucking infant through the flow of human milk. Furthering past research,
this doctoral work aimed to investigate novel dosage forms for this application, in-
cluding a fibrous matrix and a gel formulation, as well as the clinical potential,
feasibility, and acceptability of therapeutic delivery during breastfeeding. In a clin-
ical context, a descriptive qualitative study revealed the need for alternative infant
oral drug delivery technologies in high-resource settings, and parents’ and nursing
staff’s positive response to the concept of drug delivery during breastfeeding. Find-
ings were supported by the anecdotal evidence of difficulties in infant compliance
and accurate dosing, and indicated high relevance for a use case in neonatal inten-
sive care. Formulation investigations included zinc sulphate loaded non-woven fibre
mats, and iron sulphate loaded liquid-core alginate hydrogels, using a modified and a
commercially available nipple shield design. While full release during breastfeeding
simulation was not achieved, both formulations enabled superior delivery of their
loaded therapeutic dose compared to previously studied dosage forms. In addition,
a clinical feasibility study involving the delivery of vitamin B12 from a commercially
available nipple shield during breastfeeding was conducted, supported by a qualita-
tive mixed methods approach. Results illustrated the successful delivery of vitamin
B12 to breastfed infants and unanimous maternal advocacy for the availability of
therapeutic delivery during breastfeeding in the future.
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"Children are one third of our population and all of our future."
- Select Panel for the Promotion of Child Health, 1981
Depending on the socio-economic setting, parents face a variety of challenges in
infant enteral drug delivery. In a high-resource setting, parental challenges can
comprise measuring inconvenience of liquid formulations, as well as difficulties in
administering the full dose required, mostly due to a lack of infant compliance using
existing devices, such oral syringes. Particularly the latter, if evoking defensive be-
haviour and association of therapeutic delivery as a negative experience, can make
subsequent administration increasingly difficult. In a low-resource setting, addi-
tional challenges arise due to the lack of refrigerated storage, often required for
liquid formulations, access limitations to clean water for the disintegration of solid
dosage forms, or simply the unavailability of hygienic delivery technologies. Ac-
cording to the World Health Organization (WHO), more than thirty percent of the
5.4 million child deaths worldwide before the age of five are caused by conditions
such as pneumonia, diarrhoea, malaria, HIV, and measles, and could be preven-
ted with access to simple and affordable interventions [1]. With reference to the
conditions in developing countries, the United Nations Secretary-General Progress
Report on the Every Woman Every Child Global Strategy for Women’s, Children’s
and Adolescent’s Health emphasized that “innovation is essential to achieving the
ultimate goal of ending preventable deaths among women and children and ensuring
they thrive.” ([2], page 60).
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Chapter 1
The following doctoral research aims to contribute to this objective. It investig-
ates design preferences, suitable therapeutic dosage forms, as well as the clinical
potential, feasibility, and acceptability of therapeutic delivery during breastfeeding
to contribute towards better treatment options for breastfed infants. Hereby, a sil-
icone nipple shield, containing a (semi-)solid dosage form, is placed on the mother’s
breast during breastfeeding, enabling therapeutic delivery through the flow of hu-
man milk. This approach is believed to be a promising alternative to currently
existing delivery devices, because it i) overcomes the need for clean water for the
disintegration of solid dosage forms in developing countries, ii) supports the call for
flexible solid dosage forms by the WHO as a means to support treatment of infants
and children in both high- and low-resource environments, and iii) could encourage
the prevalence of breastfeeding, particularly in developed countries [3].
The objectives of this doctoral work are two-fold:
1. To investigate novel therapeutic dosage forms for delivery from a nipple shield
into human milk, including
(a) a fibrous matrix for the delivery of zinc sulphate.
(b) a hydrogel for the delivery of iron sulphate.
2. To explore the clinical implications of therapeutic delivery during breastfeed-
ing by means of
(a) a qualitative study evaluating its potential and suitability for a high-
resource setting.
(b) a clinical study assessing its in-vivo feasibility and acceptability.
The proposed research is highly interdisciplinary, based on expertise in engineer-
ing, medicine, and natural sciences, and jointly supervised by the Department of
Chemical Engineering and Biotechnology (School of Technology), as well as the De-
partment of Paediatrics (School of Clinical Medicine). Through interaction with
patients, parents, and healthcare staff, this doctoral work aims to foster an inter-
disciplinary development approach. Ultimately, patient-centred research facilitates
the translation of scientific findings into clinical practice, and thus increases the
2
Chapter 1
likelihood of reaching those in need. Beyond the scientific scope of this thesis, it
also intends to encourage similarly cross-disciplinary research endeavours for the
application of engineering in medicine.
The presented doctoral thesis consists of seven chapters: Following an introduction
of the basic principles underlying the research of therapeutic delivery during breast-
feeding (Chapter 2), the need for alternative oral therapeutic delivery technologies
for infants is introduced (Chapter 3), and results of therapeutic delivery into human
milk from a fibrous matrix, and a liquid-core hydrogel during in-vitro breastfeeding
simulation presented (Chapter 4 and Chapter 5). Moreover, clinical feasibility and
acceptability are discussed (Chapter 6), as well as opportunities for future research
indicated (Chapter 7). A detailed outline is provided below.
Chapter 2 introduces the background underlying this doctoral thesis, amongst
others the importance, prevalence, and science of breastfeeding, as well as an over-
view of current oral infant drug delivery technologies. Subsequently, the concept of
therapeutic delivery from a silicone nipple shield during breastfeeding is introduced,
and an overview of both previous research for its development and key research
methodologies of this thesis provided.
Chapter 3 illustrates findings of a qualitative descriptive study conducted from
May to July 2016, aimed at evaluating the perspective of parents and nursing staff
on therapeutic delivery during breastfeeding in a high-resource setting.
Chapter 4 investigates the release of zinc sulphate from non-woven fibres within a
lip-containing nipple shield into human milk, comparing results to previous studies
conducted by Scheuerle et al. [4]. The chapter also provides a detailed character-
isation of the non-woven fibre mats used for zinc sulphate delivery.
Chapter 5 presents the development and characterisation of a hydrogel formulation
for delivery into human milk, subsequently used to evaluate the release of iron
sulphate into DDI water and human milk.
3
Chapter 1
Chapter 6 explores maternal expectation, experience, and acceptability of thera-
peutic delivery during breastfeeding by means of a single-centre feasibility study,
conducted from July to November 2018. The study involved the administration of
vitamin B12 from a commercially available silicone nipple shield, quantified success-
ful delivery by means of an increase in the infant’s vitamin B12 blood serum level,
and made use of a mixed methods approach.
Chapter 7 provides a summary of research findings and its synthesis with previous






Oral infant therapeutic delivery poses significant challenges and limitations with
regard to the range of delivery technologies and therapeutic formulations available.
These limitations affect patient acceptability [5, 6], defined as “the overall ability
and willingness of the patient and their caregiver to administer the medicines as
intended” ([5], p. 1243), and also decrease the effectiveness of treatments [5]. Liquid
formulations of medicines and nutrients are preferred for infants below six years
of age [7], but possess distinct disadvantages, such as dosing errors and the need
for refrigerated storage. In 2006, the WHO indicated their preference for Flexible
Solid Oral Dosage forms (FSOD), including dispersible, chewable or orodispersible
tablets [7], to address the aforementioned shortcomings for infants globally, but with
particular intend to lessen the challenges in developing countries. Flexibility in this
context relates to the use of a single formulation for different age groups, and the
possibility to have parts of the dosage form either disintegrated or swallowed as a
whole [7]. This chapter introduces a novel approach to therapeutic delivery, namely
the administration from a silicone nipple shield during breastfeeding. Since this
approach of infant therapeutic administration enables the use of solid formulations,
it also has the potential to overcome limitations in stability and excipient efficacy
of liquid medicines [8].
5
Chapter 2
2.2 Science and prevalence of breastfeeding
2.2.1 Overview
The Supplemental Nursing System, often used for formula feeding by mothers with
no or only limited human milk supply, is the only infant oral delivery device that
can be used while the infant is latched onto the mother’s breast, and was repor-
ted to be well accepted by the infant [9]. It inspired the concept of infant drug
administration during breastfeeding, which would not only provide an alternat-
ive delivery method for all infants globally, but also a solution acceptable to the
36 % of exclusively breastfed infants aged 0 − 6 months worldwide [10]. A means
of therapeutic delivery during breastfeeding would also have the additional advant-
age of advocating and facilitating the beneficial practice of breastfeeding in both
high-income and low-resource settings. Human milk is also often referred to as
“a personalised medicine for infants” ([11], p. 476) based on its nutritional and
immunological characteristics [11]. Past research has shown that children breast-
fed for longer periods of time have a decreased infectious morbidity and mor-
tality, fewer dental malocclusions, higher intelligence, as well as a lower risk of
obesity and non-communicable diseases, such as asthma and type 2 diabetes, in later
life [11–13]. According to Victora et al., the scaling up of breastfeeding alone, i.e.
without addition of any medicine/nutrient supplement, could prevent 823,000 an-
nual deaths in children under the age of five [11].
2.2.2 Prevalence of breastfeeding
Despite the beneficial impact of breastfeeding on infant health, only about 40 %
of infants in high-income countries at 6 months, and about 25 % at 12 months are
breastfed (mixed or exclusively), while rates in low- and lower-middle income coun-
tries remain close to 90 % or above [11]. At this age, most breastfed infants originate
from South Asia, sub-Saharan Africa, and certain countries in Latin America [11].
Victora et al. pointed out that on average breastfeeding prevalence decreases with
increasing material wealth, with a longer breastfeeding duration of infants in poorer
environments compared to infants in more prosperous families (see Figure 2.1) [11].
Yet, not only wealth, but also education impacts on the initiation and duration of
breastfeeding: women with a higher degree of formal education in high-resource en-
vironments are more likely to breastfeed than less educated women in low-resource
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environments [11]. Rollins et al. emphasized that women in high-resource settings
need to change their belief that breastfeeding is only beneficial to prevent diseases
affecting the poor [14]. Global breastfeeding prevalence of infants aged 12 months is
illustrated in Figure 2.2. In the UK, 81 % of babies are breastfed at the time of birth,
merely 17 % three months later [15]. Only 1 % of infants are exclusively breastfed
at the age of six months [15]. Nevertheless, the 2010 Infant Feeding Survey reported
a positive development in breastfeeding initiation and continuation, with any type
of breastfeeding increased compared to the 2005 Infant Feeding Survey [15]. In this
context, “The Baby Friendly Initiative (BFI)” is perceived as a major driver, being
particularly effective in the promotion of breastfeeding [15, 16]. BFI is a worldwide
programme focusing on breastfeeding promotion as part of a partnership between
the WHO and UNICEF [17].
Figure 2.1: Prevalence of breastfeeding in 2010 based on the country income group.
Data was obtained from 153 countries [11]. Reprinted from The Lancet, Vol. 387,
Victora, C.G., Bahl, R., Barros, A.J.D., França, G.V.A., Horton, S., Krasevec,
J., Murch, S., Sankar, M.J., Walker, N., Rollins, N.C., Breastfeeding in the 21st
century: epidemiology, mechanisms, and lifelong effect, Pages 475 − 490, copyright
(2016), with permission from Elsevier.
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Figure 2.2: Percentage of global breastfeeding rates between 1995 and 2013 [11].
Reprinted from The Lancet, Vol. 387, Victora, C.G., Bahl, R., Barros, A.J.D.,
França, G.V.A., Horton, S., Krasevec, J., Murch, S., Sankar, M.J., Walker, N.,
Rollins, N.C., Breastfeeding in the 21st century: epidemiology, mechanisms, and
lifelong effect, Pages 475 − 490, copyright (2016), with permission from Elsevier.
2.2.3 Anatomy and physiology of breastfeeding
The suck cycle of an infant during breastfeeding is illustrated in Figure 2.3. Dur-
ing breastfeeding the infant’s cavity is filled with the maternal nipple as well as a
significant part of areolar tissue, while the infant’s tongue remains in contact with
the nipple throughout the entire breastfeeding process [18, 19]. Research showed
that the negative pressure created inside the infant’s mouths through the intra-oral
vacuum is the main driving force for human milk to be drawn out from the ma-
ternal ducts [18, 20, 21]. Throughout a suck cycle, the intra-oral vacuum increases
with the lowering of the infant’s tongue from the baseline pressure, also referred to
as mean maximum pressure (−56.4 ± 31.4 mmHg [22], −64 ± 45 mmHg [21]), to
its peak vacuum or so-called mean minimum pressure (−163.2 ± 62.0 mmHg [22],
−145 ± 58 mmHg [21]), while the maternal nipple elongates and retracts rapidly
with an elongation in length by up to two fold [18]. Sucks per minute vary depend-
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ing on the age and type of feeding (’exclusive breastfeeding’ or ’mixed feeding’),
with estimated values of 46.7±12.9 sucks min-1 for exclusively breastfed infants and
41.1 ± 10.6 sucks min-1 for mixed fed infants aged 21 − 28 days, as well as





Figure 2.3: Illustration of the infant’s latch during breastfeeding. Milk flow into the
infant’s oral cavity occurs when the infant’s tongue is at its lowest point, and the
intra-oral vacuum has reached its peak. Image adapted from [24].
2.3 Infant oral therapeutic delivery
2.3.1 Common oral infant therapeutics
Most commonly used therapeutics for infants up to the age of six months include
nutritional supplements as well as drug formulations (Table 2.1). While some thera-
peutics are used for infants globally, such as antibiotics, applicability of most thera-
peutics is dependent on geographical and social factors, as well as on the infants’
gestational age. For instance, vitamin supplements are mostly used to account for
the additional needs of premature infants, as well as for infants in low-income coun-
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tries with risk of deficiency. In these locations, additional drug formulations are
also needed due to the prevalence of HIV, malaria, and tuberculosis. Dosage forms
comprise oral liquids, tablets, capsules, and powders for the preparation of oral solu-
tions. In accordance with the WHO Model List of Essential Medicines for Children,
the term ’solid oral dosage form’ is used whenever equal clinical efficacy and safety
of oral formulations is applicable [25]. Tablets and capsules have to be portioned
and disintegrated in water, formula or previously expressed human milk prior to
delivery. Liquid or disintegrated medicines and nutrients have to be measured and
administered to the infant using a delivery technology (see Table 2.2).
Therapeutic Indication Dosage form
Vitamin/mineral supplements




















Oral liquid, solid oral
dosage form
Ferrous salt [25] Supplement or
antianaemia medicine
Oral liquid, tablet




Therapeutic Indication Dosage form
Medicines for pain
Analgesics [31, 32] Pain relief Oral liquid, tablet
Medicines for epilepsy




























Treatment of diarrhoea Powder for dilution




Solid oral dosage form
Table 2.1 continued: Overview of therapeutics commonly administered to infants
up to six months of age.
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2.3.2 Currently available delivery technologies
A review of existing infant oral therapeutic delivery technologies is presented in
Table 2.2. Administration of medicines and nutrients to neonates and young infants
by means of an oral syringe is most common, while bottle feeding mothers also have
the option of mixing the drug formulation with expressed milk or formula within a
drinking bottle. Additional devices exist for infants, but are less commonly used or
might not be suitable for use, e.g. if parents have decided against the introduction of
a pacifier. Some formulations require the disintegration in water, formula or human
milk, but most commercially available infant formulations are prepared in liquid
form. With regard to the latter, dosing errors can occur [33].
Device Delivery method Note
















Therapeutic is displaced from a reservoir





Liquid is sucked from a reservoir Applicable to infants
using a dummy
Table 2.2: Overview of existing oral infant therapeutic delivery technologies.
2.3.3 Therapeutic delivery during breastfeeding
(a) Overview. To enable drug administration during breastfeeding, use of com-
mon breastfeeding adjuncts already used to support normal feeding are particularly
promising. A review of the literature suggested the application of an ultra-thin
nipple shield, a silicone device that is placed over the maternal nipple and are-
ola during breastfeeding [34]. Most commonly, nipple shields are recommended
when infant or maternal physiology challenge the establishment and continuation
12
Chapter 2
of breastfeeding [34], supporting the infant in latching onto the breast, as well as
in protecting and relieving maternal pain caused by sore nipples [35]. While ma-
ternal response to the use of nipple shields during normal feeding varies between
different mothers, including both positive maternal experience as well as handling
difficulties [34], past literature on ultra-thin contact nipple shields has shown that
there is no statistically significant change in infant human milk intake and weight
gain, while even enabling an increase in milk transfer for preterm infants [36, 37].
Moreover, as nipple shields had previously been shown to prolong the duration of
mothers breastfeeding [34], their use for medicine and nutrient delivery could poten-
tially also positively impact current breastfeeding rates. The potential to expand
the currently available options of infant oral therapeutic delivery technologies, while
at the same time encouraging the beneficial practice of breastfeeding, motivated the
initiation of a research project at the University of Cambridge’s Department of
Chemical Engineering and Biotechnology in 2010: the investigation of therapeutic
administration from a silicone nipple shield during breastfeeding. Thereby, a thera-
peutic dosage form is placed into the teat of a silicone nipple shield (see Figure 2.4).
Figure 2.4: Principle of therapeutic administration from a silicone nipple shield
during breastfeeding. To enable therapeutic administration during breastfeeding,
a therapeutic dosage form is placed into the teat of a silicone nipple shield. Be-
ing placed on the mother’s breast during breastfeeding, the therapeutic (medicine
or nutrient) is delivered to the sucking infant through the flow of human milk.
(a) Nipple shield, (b) Therapeutic. Image originally published in [38].
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When being placed on the mother’s breast during breastfeeding, it enables the thera-
peutic to be released and delivered to the sucking infant through the flow of human
milk. A wide range of possible nipple shield designs and therapeutic dosage forms
can be considered, and are discussed below.
(b) Nipple shields. Different silicone nipple shield designs could be considered for
therapeutic delivery during breastfeeding, including:
• Commercially available nipple shields: Ultra-thin contact nipple shields
are fabricated out of soft thin silicone in a shape that enables maximum skin
contact between mother and infant.
• Modified nipple shields: Modified nipple shields could potentially facil-
itate therapeutic delivery during breastfeeding, e.g. through comprising a
holder for drug placement.
(c) Suitable therapeutic dosage forms. To enable therapeutic delivery from
a silicone nipple shield during breastfeeding, a solid-like dosage form is required.
Various dosage forms exist and could be considered:
• Tablets: a therapeutic compressed into rapidly disintegrating medical tab-
lets using standard pharmaceutical methods, such as direct compression.
• Gelatin/hpmc capsules: a therapeutic in powder form enclosed within a
(pre-treated) gelatin/Hydroxypropyl Methylcellulose (HPMC) capsule to en-
able rapid release upon rupture.
• Membrane support materials: a therapeutic loaded onto inert fibrous
mats (e.g. by means of adsorption).
• Hydrogels: a therapeutic solution used for hydrogel preparation.
• Dissolvable films: a therapeutic solution used for fabrication of thin oral
matrices which dissolve in contact with mucus/the mucosal membrane.
(d) Conceptual considerations. Complete delivery of a full therapeutic dose
within the duration of one breastfeed is crucial to guarantee accurate dosing and
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treatment compliance. Varying milk composition, flow rate, and feeding pattern rep-
resent a challenge to the development of formulations with standardized
release [20]. Among others, design specifications have to account for the up to
three-fold change in absolute fat content depending on the stage of lactation, di-
etary requirements and health status of the breastfeeding mother [39], as well as
the varying human milk volume available for therapeutic disintegration based on
the pattern of milk intake [40]. With regard to the latter, a cross-sectional study
of 1-month- to 6-month-old infants by Kent et al. illustrated an average consump-
tion of 76.0 ± 12.6 g (range 0 − 240 g) during one breastfeed, with the average
intake being unrelated to the infant’s age [40]. Instead, the total amount of hu-
man milk consumed was highly dependent on whether the more or less productive
breast was used, and whether breastfeeding was unpaired, paired or
clustered [40]. Hereby, an additional breastfeed <30 minutes or >30 minutes after
the end of the first feed was defined as “paired” or “unpaired”, respectively. The
notation “clustered” refers to a feed from both breasts, following which an additional
feed from the first breast occurs within 30 minutes of finishing on the second breast.
During clustered breastfeeding, the minimum median intake from the first breast
was 42 g (IQR: 31−103 g) [40]. These findings illustrate the importance of ensuring
full therapeutic delivery ideally within 42 g of intake from the first breast, but in
any case within a total of 76 g of human milk consumed. Likewise, it has to be
ensured that therapeutic administration during breastfeeding causes no alteration
in breastfeeding behaviour, i.e. no reduction in human milk consumed, as well as no
change in infant compliance towards overall breastfeeding practices. Two additional
factors have to be considered: the concurrent timing of feeding and therapeutic ad-
ministration, as well as the dosage form’s method of disintegration. The former is
of importance only for medications, which need to be administered at a certain time
or as subsequent doses within a certain time interval. The method of disintegration
is a general design consideration, particularly focused on preventing the formation
of fragments, which could pass through the nipple shield holes and might pose a
risk of infant choking. Lastly, the concept of therapeutic administration from a
nipple shield during breastfeeding has to take into account existing BFI guidelines,
and discussions about their evaluation of therapeutic administration during breast-





The concept of using a modified nipple shield, designed to differ from commercially
available ones by comprising a holder (e.g. a lip or a mesh) for drug placement, was
proposed by a student group during a design competition in 2008. Subsequent doc-
toral research by Dr Stephen Gerrard (2010 − 2013) and Dr Rebekah L. Scheuerle
(2013 − 2017) at the Department of Chemical Engineering and Biotechnology, Uni-
versity of Cambridge, aimed to validate the scientific potential of such a modified
nipple shield, referred to as the nipple shield delivery system (NSDS), to serve as an
infant therapeutic delivery tool. Past lab-based investigations included the develop-
ment of novel setups to mimic breastfeeding, as well as the evaluation of therapeutic
release from different dosage forms using a variety of modified nipple shields. Field-
work in Kenya and South Africa consisted of interviews exploring opinions with
regard to the use of a modified nipple shield. A review of past investigations and
findings is provided below.
2.4.1 Development of setups for breastfeeding simulation
Test rag [41]. Initial therapeutic recovery experiments were conducted using a
test rag, enabling the investigation of therapeutic recovery from a filter holder into
a flowing, temperature-controlled fluid. During experiments, fluid was transferred
from a stirred reservoir by a peristaltic pump at a physiological rate through silic-
one tubing, heated in a water bath to 37°C, passed through the filter holder, and
fractions collected via a fraction collector (Figure 2.5). Neither pressure nor suction











As a result, the test rag was not capable of mimicking breastfeeding, nor of providing
insight into the ability of therapeutics to be released from a nipple shield.
Breastfeeding simulation apparatus [42]. In order to improve experimental
procedures, a breastfeeding simulation apparatus was developed. The apparatus
enabled to mimic breastfeeding by accounting for both, fluid temperature and flow
rate, as well as relevant pressure values and suction frequency, while also making it
possible to investigate the release of dosage forms within a nipple shield. As a key re-
search method used in this doctoral thesis, it will be further explained in Section 2.5.
Setup to simulate tongue movement and its applied pressure [43].
Scheuerle et al. investigated the impact of infant tongue peristalsis by means of a
Tongue Mimic System, consisting of a fluid reservoir, a heat exchanger, a peristaltic
pump, a built tongue-mimic, and a fraction collector. The tongue mimic was charac-
terised by a shaft-like structure connected to a peristaltic pump, enabling to control
the shaft’s rotation rate by varying pump speed, as well as a metal plate to mimic
the infants’ palate (see Figure 2.6). The tablet was located in a tubing between the
moving shaft and the metal plate, through which deionized (DI) water at a temper-
ature of 33.5 − 35.5°C was transferred at an approximate flow rate of 5 mL min-1.
Using two different compression settings and different rotational rates, delivery of
Sulforhodamine B (SB) dye from rapidly disintegration tablets was investigated.
Scheuerle et al. proved that not only temperature, flow rate, suction frequency, and
pressure - parameters controlled by the breastfeeding simulation apparatus - but also






Figure 2.6: Simplified illustration of the tongue mimic. Image adapted from [43].
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2.4.2 Designs of modified nipple shields
Glassfibre mesh for placement of dosage forms [42]. The initial modified
nipple shield prototype consisted of a commercially available nipple shield (Mater-
nity Silicone Nipple Shield, Boots), into which an O-ring with a fibreglass mesh was
sealed at a position 9 mm away from the teat’s inside tip. The commercially avail-
able nipple shield contains four 1 mm radius holes, to which Gerrard et al. added
eight additional holes at a distance of 5 mm away from existing ones.
Circular silicone lip for placement of dosage forms [4]. Experiments by
Scheuerle et al. made use of an advanced modified silicone nipple shield, manufac-
tured by injection moulding, and characterised by a silicone lip for drug placement
as opposed to a glassfibre mesh. The design intended for use with small dosage
forms, such as tablets, was characterised by a total teat length of 23.95 mm and a
silicone lip for drug placement 10.45 mm away from the teat’s inside tip. Through-
out this thesis, this modified nipple shield is referred to as the “lip-containing nipple
shield” or “NSDS lip-containing design”.
Silicone flap for placement of capsules [44]. In addition, research by
Scheuerle et al. also investigated a modified nipple shield for use with capsules,
comprising of a partially filled-in region between the teat’s tip and a silicone flap for
dosage form placement. It was characterised by only two holes of 2.11 mm radius,
and a reduced overall teat length of 22.51 mm, whereby the silicone flap for capsule








9 mm 10.45 mm 12.88 mm
Figure 2.7: Overview of modified nipple shield designs used for in-vitro therapeutic
delivery into human milk.
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2.4.3 Dosage form investigations
Sds delivery from non-woven fibres [41]. Gerrard et al. investigated the
release of Sodium Dodecyl Sulphate (SDS) from non-woven fibres using the breast-
feeding test rag. Hereby, circular fibre mats of 10 mm diameter, consisting of non-
woven viscose and polyester fibres (Bathfelt Texel, Québec, Canada), were loaded
with 0.07 g SDS by soaking them for 10 sec in a 30 % wt SDS solution. Left drying for
72 hours, experiments were performed into 50 mL of human milk, whereby a recov-
ery of 70 − 100 % loaded SDS was obtained.
Sulforhodamine b delivery from rapidly disintegrating tablets [42].
A number of experiments investigating the release of Sulforhodamine B (SB) dye
from rapidly disintegrating tablets within the mesh containing nipple shield were
conducted to evaluate the impact of milk fat content, flow rate, and suction pulse
rate on absolute SB recovery using the breastfeeding simulation apparatus. At a
flow rate of 5 mL min-1, suction rates of 30 and 60 pulses min-1 led to a similar
SB recovery, which improved at a pulse rate of 120 pulses min-1. At a physiological
suction frequency of 1 suck sec-1, release was neither dependent on flow rate (range:
1 − 8 mL min-1), nor on fat content (range: 2.9 − 4.2 %). In most experiments, an
absolute recovery of less than 80 % within 40 mL of milk was obtained.
Zinc sulphate delivery from rapidly disintegrating tablets [4]. Sch-
euerle et al. investigated the release of zinc sulphate from rapidly disintegrating
tablets within the lip-containing nipple shield during breastfeeding simulation ex-
periments. Four types of tablet formulations were used, characterised by different
excipients and tablet hardnesses. Within approximately 100 g of human milk, an
absolute recovery of 32 − 51 % loaded zinc sulphate was achieved.
Zinc sulphate delivery from hpmc capsules [44]. Scheuerle et al. investig-
ated the release of zinc sulphate from “treated rapidly disintegrating
capsules” [44]. Hereby HPMC capsules were loaded with a zinc sulphate lactose
mixture and dried by means of a lyophilizer until <5 % of weight change within
29.5 h was recorded. Subsequently, using the breastfeeding simulation apparatus,
delivery of zinc sulphate from the modified capsule holder containing nipple shield
into 100 mL of human milk was evaluated. As capsules failed to rupture, no release




Kenya: acceptability of the lip-containing nipple shield [45]. A qualit-
ative study was conducted by Hart et al. in Kenya to evaluate the perceived accept-
ability of the lip-containing nipple shield to prevent mother-to-child transmission
of HIV during breastfeeding, and to assess mothers’ understanding of vertical HIV
transmission. Eleven focus group discussions à 7 − 12 participants were performed,
including mothers, fathers, grandmothers, and mothers-in-law. In this low-resource
setting, use of the lip-containing nipple shield was considered “potentially accept-
able” ([45], p. 68), requiring provision to enable sustainable access and careful
consideration of associated implications for barriers of use, such as religious belief
or potential stigma. With regard to the prevention of mother-to-child transfer of
HIV, efficacy and safety of the lip-containing nipple shield for infant antiretroviral
delivery were discussed, and most participants advocated for the need of scientific
validation and recommendation by healthcare staff.
South africa: acceptability of the lip-containing nipple shield [46].
Interviews (semi-structured and focus groups) were conducted with 35 infant care-
takers and nine health workers, in the Vhembe District of Limpopo, South Africa, to
explore their opinion towards use of the lip-containing nipple shield for therapeutic
delivery. Participants responded positively, and gave preference to a disposable
see-through NSDS design. Hereby, the lip-containing nipple shield was chosen over
other designs without a lip, simply based on its circular base and thicker material,
as mothers associated less material with an increased risk for the shield to fall off the
breast. Health workers suggested a cough and de-worming medication as potential
therapeutics to be delivered from the lip-containing nipple shield. Challenges with
regard to community acceptance were raised and the need for education around the
use of the lip-containing nipple shield for therapeutic delivery stressed.
2.5 Research methods
2.5.1 Breastfeeding simulation
To ease in-vitro testing of different therapeutic dosage forms and nipple shield
designs, a breastfeeding simulation apparatus was developed by Gerrard et al.,
simulating both the process of lactation and infant feeding [42]. The apparatus
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is capable of resembling average flow rates/patterns of milk during breastfeed-
ing, as well as of mimicking, monitoring, and recording the sucking pressure of
infants [42]. It was used for investigations in Chapter 4, Chapter 5, and
Chapter 6. A process flow diagram of the apparatus is illustrated in Figure 2.8.
According to Gerrard et al. the breastfeeding simulation apparatus has the fol-
lowing characteristics [42]: Using a peristaltic pump (P1, Masterflex, Cole-Parmer
Instrument Co. Ltd., London/UK), milk is pumped through silicone tubing from
a continuously stirred reservoir (R1) into a hot water bath (heat exchanger, HX1),
controlled using a temperature sensor (TS, Digitron thermocouple, Elektron Techno-
logy, Cambridge/UK), where it is heated to a physiological temperature of
33.7 − 35.7°C. The heated milk is subsequently fed through a reservoir valve and a
non-return valve into a silicone human breast mimic (SBM), containing 25 evenly
distributed holes to imitate maternal lactiferous sinuses. Using a clamp system, the
nipple shield is held in place on the SBM in an airtight fashion, and positioned at
a 30° angle downwards from the horizontal flow direction. A funnel (R2), having
a reservoir at its lower part for fluid leaving the SBM, is connected to a vacuum
pump (P3, modified Medela swing electric breast pump, Manchester/UK) through
an airline. The vacuum pump (P3) withdraws milk from the SBM by means of a
physiological relevant breastfeeding pressure cycle (vacuum with oscillating pattern)
and is controlled by a National Instruments card (NIC, National Instruments, Aus-
tin, TX/USA), and connected to a computer system (CPU, Gigabyte Technology
Co. Ltd., UK), while a second peristaltic pump (P2, Masterflex, Cole-Parmer In-
strument Co. Ltd., London/UK) is delivering milk leaving the nipple shield through
an exit line to a fraction collector (FC, SuperFrac, GE Healthcare Sciences, Bucking-
hamshire/UK). A 2011 LabVIEW software is used to accurately control P3, while
the pressure within the airline system is measured using a SSOB002A pressure gauge
(Sensortechnics, Munich/Germany). Two 60 mL syringes, connected to the air line,
enable modification of the vacuum amplitude through adjustment of their plun-
gers. Based on the physiology of breastfeeding outlined previously, the apparatus
was designed to enable a suction frequency of 60 sucks min-1, and an approximate
flow rate of 5 mL min-1. Breastfeeding simulation experiments are conducted as
follows [42, 44]: After calibrating both P1 and P2 to have an equivalent pumping
frequency, the feed pump (P1) is turned on and milk passed into the collection reser-
voir (CR), following which air from the airline is purged and the purge valve closed
(with the feed pump P1 being on hold). Subsequently, the vacuum pump (P3) is
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started by means of the LabVIEW programme and the exit pump (P2) turned on.
As a last step the feed reservoir valve (FRV1) is opened to enable human milk flow
through the silicone breast mimic (SBM). The breastfeeding simulation experiment
is discontinued by turning off both the LabVIEW programme and the vacuum pump
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Figure 2.8: In-vitro testing is performed by means of a breastfeeding simulation ap-




2.5.2 Introduction to qualitative research
Qualitative research is often used as an initial scoping tool at the beginning of a
research project, providing a direction for the establishment of a working hypothesis,
which can be further investigated by means of quantitative research
assessments [48]. Qualitative research is an effective measure to obtain “a deeper un-
derstanding of certain aspects of human beliefs, attitudes or behaviours”
([48], p. 235), and research interviews and focus groups are the most frequently used
methods to gather data for qualitative experiments within the medical
discipline [49]. Interviews can be structured, semi-structured, and un-
structured [49]. Research presented in Chapter 3 and Chapter 6 has made use
of semi-structured interviews, the most common interview format for qualitative
medical research [49]. These interviews contain a framework created by pre-defined
questions to provide guidance, while allowing the interviewer and interviewee to
focus on certain aspects or responses more thoroughly as required [49]. In order to
analyse the qualitative data obtained, a researcher can choose between two overall
approaches: The deductive approach involves the analysis by means of a predefined
theory or framework, which is either confirmed or disproved throughout the analysis
process [50]. In contrast, when the inductive approach is used, little to no predefined
hypothesis is applied, yet a framework developed based on themes which are derived
from the data itself [50]. In both cases, the thematic content analysis is the most
common approach for qualitative data analysis, and involves the identification of
themes and examples for these themes within the interview
transcripts [50–52]. In contrast to quantitative research, analysis in qualitative ex-
periments already takes place during the first data collection, as preliminary results
can inform the subsequent interview process, for example through modification of
key questions used in semi-structured interviews [50]. Following transcription of the
interview verbatim, the thematic content analysis is defined by the following analysis
stages [50, 53, 54]:
1. Pre-reading: thorough reading of all transcripts.
2. Open coding: re-reading of the transcripts, adding notes capturing a sum-
mary or conclusion of the text’s content.
3. Initial coding framework - generation of a short list of identified categor-
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ies: Identified content categories during open coding are revised to cross out
repetitions and re-group similar categories into an overarching theme. Hereby,
parts of the text can be coded into different categories, while other parts of the
interview may not be assigned to any category. The latter applies for segments
identified as not applicable for the objectives of the conducted research.
4. Final coding framework - verification of category system: Each tran-
script is further analysed to identify and highlight data related to each cat-
egory.
2.5.3 Introduction to mixed methods research
Studies conducted based on a mixed methods approach make use of both qualit-
ative and quantitative components as part of their study design, data collection,
and analysis [55]. Mixed methods are defined as “research in which the investig-
ator collects and analyses data, integrates the findings, and draws inferences us-
ing both qualitative and quantitative approaches or methods in a single study or
program of inquiry” ([56], p.4). Use of this approach can be advantageous if the
research is of complex nature, e.g. with the intention to increase the breadth of a
study [55]. Two design options exist: i) a parallel form, whereby qualitative and
quantitative data are collected simultaneously and conclusions based on both ana-
lyses, ii) a sequential form, whereby data is collected successively, one type of data
supporting the collection of another [55]. Research in Chapter 6 makes use of a
parallel mixed methods approach.
2.5.4 Introduction to clinical studies
(a) Basic, clinical, and translational research
Basic research. Basic research focuses on lab-based investigations with the
objective of contributing knowledge and of enhancing human comprehension of
nature [57, 58]. According to Salter et al., basic research can be differentiated
as either ’curiosity-oriented’ or ’strategic’ [58]. While findings may address a range
of practical problems, the fundamental purpose of basic research does not consist in
providing actionable answers or implementable recommendations [57].
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Clinical research. Clinical research comprises the following areas of inquiry:
i) patient-oriented research that involves both human subjects or human tissues,
the latter for which patient contact was required, ii) epidemiologic and behavioural
studies, and iii) research with regard to the effectiveness of interventions and health
services [57, 59, 60]. Patient-oriented research is further classified into four types
of research studies: research on mechanisms of human disease, therapeutic inter-
ventions, clinical trials, and the development of new technologies [60]. Schuster et
al. provides the following guideline [60]: “Clinical research includes any scientific
investigation in which the unit of analysis is the person” (p. xvii).
Translational research. Translational research interconnects both basic and
clinical research, and refers to the application of basic scientific findings for clin-
ical use, for example to enhance patient treatment or diagnostics [57]. According
to the National Institutes of Health (NIH), the pathway of “bench to bedside”
consists of two translational steps, and is defined as follows [57]: “Translational
research includes two areas of translation. One is the process of applying discov-
eries generated during research in the laboratory, and in preclinical studies, to the
development of trials and studies in humans. The second area of translation con-
cerns research aimed at enhancing the adoption of best practices in the community.
Cost-effectiveness of prevention and treatment strategies is also an important part
of translational science.” In 2007, Westfall et al. proposed a third translational
step, comprising of practice-based research to support the implementation of dis-
coveries into daily clinical use [61]. The feasibility study presented in this chapter,
being based on prior preclinical development at the Department of Chemical En-
gineering and Biotechnology, relates to translational step 1.
(b) Feasibility study. Research in Chapter 6 is classified as a “pilot” or “feasibil-
ity study”, terms that are often used interchangeably. It consists of a “small study
for helping to design a further confirmatory study” ([62], p. 67) of reduced duration
and financial expenses [63]. The purpose of feasibility studies is to evaluate the
potential of an intervention, such as general safety and effectiveness, and the benefit
of allocating further resources, with the intention of subsequently investigating the
intervention at a larger scale [63–65]. Consequently, feasibility or pilot studies are
regarded as an essential initial step in the development process of an intervention,
and believed to increase its likelihood of being successful [63]. Thereby, Bowen et
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al. defines an intervention as “any program, service, policy or product that is inten-
ded to ultimately influence or change people’s social, environmental, and organiza-
tional conditions, as well as their choices, attitudes, believes, and behaviours” ([64],
p. 452). Eight focus areas of feasibility studies can be differentiated, including the
acceptability, demand, practicality, adaption, integration, expansion, and efficacy of
an intervention [64]. It is important to note that a pilot study does not aim to test
effectiveness, efficacy, or user safety of an intervention [63].
(c) Integrated Research Application System (IRAS). Since clinical research
involves the participation of human subjects, approval by major regulatory bod-
ies is needed prior to any research being undertaken. Within the UK, applica-
tions can be submitted using the Integrated Research Application System (IRAS),
a single system enabling the submission of approval requests to nine different review
bodies [66].
(d) Commonly used terminology. Common terminology in clinical research,
used in Chapter 6, is presented in Table 2.3.
Term Definition
Objective Scientific question to be answered by the clinical study [67].
Endpoint(s) A clinical study is defined by one or more endpoints. The primary
endpoint is a precise definition for reaching the study’s main
objective; it is evaluated by means of reproducible and accurate
methods [67].
Recruitment Process to identify and enrol suitable human subjects for
participation in a clinical research study; the identification is




Detailed description of criteria to define the study population, i.e.
to determine eligibility of human subjects for participation in a
clinical study [69]. A potential subject has to fulfil all inclusion
criteria to be eligible for participation, while conformity with any
of the defined exclusion criteria prohibits involvement in the
proposed study [68].







Involves informing suitable individuals about the content and
risks of a study, as well as participants’ rights; individuals who
match the inclusion/exclusion criteria, and who voluntarily decide
to participate in the proposed study, have to sign an informed
consent form to confirm their voluntary participation and




Institutional bodies, which focus on protecting those individuals
involved in clinical research, either as participants or as
researchers [68].




A parent and nursing perspective
3.1 Introduction
3.1.1 Overview
The potential of therapeutic delivery from a silicone nipple shield during breast-
feeding in a developed setting, where dosing spoons and oral syringes are readily
available, had not previously been explored. Although the concept was originally
developed as a means to address challenges in developing countries, it was hypo-
thesised that it could likewise serve as an alternative approach to common delivery
technologies in high-resource environments. Potential advantages were believed to
include the support of exclusively breastfeeding mothers, as well as the treatment of
infants with chronic or acute conditions, requiring regular or frequent medication.
More and more companies are making use of such reverse innovation by expand-
ing their offerings in developed markets with technologies originally intended for
resource-limited settings, aiming to cater towards cost-minded customers and/or
to address an existing product gab [71]. Products include lower-cost developments
with similar (cost innovations), market-tailored (good-enough innovations), or novel
functionality (frugal innovation) [71]. Therapeutic delivery during breastfeeding was
also considered as a potential means to encourage the beneficial practice of breast-
feeding, with continuation rates at the infants’ sixth postnatal months being over
50 % lower in high-resource environments compared to those in low-income set-
tings [11]. In particular, the UK exhibits one of the lowest rates in breastfeeding
establishment and continuation within Europe [15].
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Work presented in this chapter aimed to achieve the following objectives:
1. To evaluate the potential of therapeutic delivery during breastfeeding in a
high-resource environment using appropriately chosen design methodology
2. To identify design characteristics of a nipple shield intended for the use of
therapeutic administration to infants
3.1.2 Study design considerations
Experimental work in this chapter was based on the following considerations.
(a) Selection of research methodology. Based on guidance for the identifica-
tion of a working hypothesis at the beginning of a research project [48], use of a
qualitative methodology was chosen. Hereby, semi-structured interviews were pre-
ferred over structured and unstructured interview formats, aiming at providing a
certain degree of guidance while enabling the participants to direct their focus of
importance. With the objective to interview mothers, fathers, and nursing staff, the
study focused on gaining both primary and secondary information about potential
parental challenges of infant oral therapeutic delivery, and to assess the opinion of
end-users and potential groups of supporters with regard to the possible intervention
of therapeutic administration during breastfeeding.
(b) Selection of study location. Research with parents of infants in a neonatal
intensive care environment was chosen over assessment in outpatient groups or as
part of community support, since it was believed that parents having experienced a
high level of neonatal intervention, such as mechanical ventilation or total parenteral
nutrition, will be more anxious and hence more critical in assessing the potential
of therapeutic delivery during breastfeeding. The same interview environment was
thereby also regarded as a means to avoid systematic errors arising in other study
locations.
(c) Selection of nipple shields as a visual aid. Based on the concept’s novelty
and in order to support the participants’ comprehension, it was decided to provide
visual guidance in form of both a commercial contact nipple shield, potentially
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already familiar to some of the parents, and a modified nipple shield, the NSDS lip-
containing design, currently under investigation at the University of Cambridge’s
Department of Chemical Engineering and Biotechnology. Both are illustrated in
Figure 3.1. The commercially available ultra-thin contact nipple shield (Medela,
UK) for normal feeding has four holes of diameter 1.00 mm and is available in
a variety of sizes, including small, medium, and large. Corresponding values for
maximum teat diameter and teat length are illustrated in Table 3.1.
c) d) 
a) b) 
Figure 3.1: Illustration of nipple shields investigated for therapeutic delivery during
breastfeeding. Commercially available ultra-thin contact nipple shield shown from
a) the side, b) from below. Modified nipple shield with a retention lip for therapeutic
placement from c) the side, d) from below. Image adapted from [72].







Table 3.1: Maximum teat diameter and teat length for commercially available ultra-
thin contact nipple shields (Medela, UK).
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The modified nipple shield was manufactured through silicone injection moulding in
one size only, containing twelve exit holes of diameter 1.23 mm evenly spread across
the teat’s tip, a maximum teat diameter of 17.41 mm, a teat length of 23.95 mm,
and a base diameter of 75.71 mm.
3.2 Materials and methods
3.2.1 Study population and participant recruitment
The qualitative descriptive study was conducted with parents and staff on a
level 3 Neonatal Intensive and a Transitional Care Unit (NICU) of the Univer-
sity of Cambridge Addenbrooke’s Hospital NHS Trust from May to July 2016. All
parents with an inpatient infant, who had previously breastfed an infant, and/or
were intending to breastfeed or already doing so, and who were willing to provide
written informed consent for participation were eligible for inclusion. No restric-
tions regarding health status, gestational age or birth weight were applied. Eligible
staff comprised healthcare professionals whose role included supporting families to
establish breastfeeding. Staff of varied years of experience and age were recruited
by distributing information sheets on the wards, while parents were approached by
the clinical nursing staff prior to being seen by a member of the research team.
3.2.2 Interview development and data collection
The interview process aligned with established procedures for semi-structured in-
terviews [73]. Pre-defined questions were designed to (a) identify challenges of oral
infant therapeutic administration, (b) assess parents’ attitude towards nipple shields
for normal feeding, (c) evaluate the potential of therapeutic delivery from a silicone
nipple shield during breastfeeding, and (d) determine its preferred design character-
istics. An excerpt of questions is shown in Table 3.2. Both a commercially available
ultra-thin contact nipple shield and the NSDS lip-containing nipple shield were
shown to the participants. Staff were interviewed individually in private rooms on
the units, whereas interviews with parents were performed at the infant’s bedside,
while a nurse known to the parents was present. The interviews were conducted
independently from the clinical team to provide for consistency and avoid bias, and
recorded using digital voice recording software for later analysis. The interviewer
did not provide any advice regarding breastfeeding or the use of nipple shields, and
32
Chapter 3
parents were clearly informed that this was a research study, only investigating a
novel approach of infant oral therapeutic delivery.
• In the past, have you ever given any medicine to any/your baby?
Which delivery devices did you use? What was your experience?
(parents)
• After discharge, are you/your wife/your girlfriend intending to
breastfeed your baby? For what reason “no”/”yes”? (parents)
• What do you think about the nipple shields’ design characteristics
(colour, shape, size)? (parents, staff)
• Would you want to use/recommend a nipple shield device for
therapeutic delivery during breastfeeding, and if so, which
therapeutics would you like/not like to administer from a nipple
shield device during breastfeeding? (parents, staff)
Table 3.2: Excerpt of questions used in the qualitative descriptive study.
3.2.3 Data analysis
Interviews were transcribed verbatim and potentially identifiable data of parti-
cipants and their infants were anonymised during interview transcription. Analysis
was conducted through code development using the inductive approach of thematic
content analysis in the software package ATLAS.ti (Scientific Software Development
GmbH) [53, 74]. Following pre-reading of all transcripts, notes were added line-by-
line through an open coding approach, subsequently revised and re-grouped to form
an initial coding framework. These initial codes were evaluated within the research
team, particularly in discussion with Dr Kathryn Beardsall, together iteratively ad-
apted and refined into a final coding framework. Advice on overall coding practices




The study was approved and registered with the Patient Office at the University
of Cambridge Addenbrooke’s Hospital NHS Trust, and was assessed by the Ad-
denbrooke’s Hospital Research and Development Department to not require ethics
approval. All participants provided their written informed consent to be quoted
anonymously in this publication.
3.3 Results
From a total of thirty invited, twenty-eight participants were interviewed
(Table 3.3), including nine registered nurses (RNs), seven fathers and twelve moth-
ers, of which six each were parents of the same infant and were interviewed together
(Table 3.4 and Table 3.5). Three of the infants were born extremely preterm
(<28 weeks), two very preterm (28 to <32 weeks), four moderately preterm
(32 to <37 weeks), three full term (37 to <41 weeks), and one late term
(41 to <42 weeks) [75, 76]. The gestational age of the participants’ infants was
anonymised using the WHO definitions of preterm birth [76]. Two individuals had














Table 3.3: Characteristics of interview participants
(N = 28). Table originally published in [72].
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The total number of participants was determined by the point at which information






M1 Moderate to late preterm F1 Moderate to late preterm
M2 Late term F2 Late term
M3 Moderate to late preterm F3 Moderate to late preterm
M4 Extremely preterm F4 Extremely preterm
M5 Full term F5 Full term
M6 Full term F6 Full term





M12 Moderate to late preterm












RN9 Registered nurse, IBCLC® and midwife*
Table 3.5: Profession and ID of RN participants (n = 9).
*IBCLC® stands for International Board Certified Lactation Consultant®
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Interviews lasted on average 15.6 min (range 9.5 − 27.5 min), since parents were
either not able to speak about previous breastfeeding or therapeutic delivery exper-
ience, or found it emotionally challenging to discuss breastfeeding intentions, given
their infant’s present health status. Based on the responses provided, four overall
themes were identified, including current practices and challenges, perceived bene-
fits and risks, design considerations, as well as the role of healthcare professionals.
Quotations are used to illustrate key points, and if required were edited to enhance
clarity and brevity (see content in square brackets). The adjunct Mx, Fx, and RNx,
for mothers, fathers, and registered nurses respectively, refers to the participant
codes from Table 3.4 and Table 3.5.
Current practice of oral drug delivery: challenges and the need for in-
novation
Use of commonly available infant oral therapeutic delivery devices was described by
the participants as both physically and emotionally challenging, relating to either
therapeutic administration to their previous infant, or to nutrient delivery to their
inpatient newborn on the NICU. With regard to physical challenges, parents referred
to incidents, in which the infant was actively fighting therapeutic administration,
e.g. through slapping the dosing spoon or oral syringe, sudden turning of the head,
or spitting out medicine after delivery. As a consequence they also expressed their
worry about the reduction in the final dose received.
"It was a nightmare, because he wouldn’t take [the therapeutic] from a
syringe, you put it on a spoon, he flipped it. So we were never certain,
what he had." [M1]
Oral syringes were preferred over spoons for infants below the age of six months,
but some mothers perceived their appropriate handling as difficult.
"[Syringes] are not easy to put in their mouth. And they are not easy to
use. So you end up shooting quite a lot of liquid in very fast." [M1]
One mother also described her observation about the limited options available for
exclusively breastfeeding mothers.
"If you are bottle feeding, you can give the medication into the milk;
but when you are breastfeeding, you are kind of stuck when they are not
taking the medication [with a spoon or a syringe]." [M7]
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Emotionally, parents expressed their worry of hurting their struggling infant, their
feeling of guilt, and their infant’s anxiety.
"[It was] quite difficult, and she is a bit scared. [...] I feel like I am
torturing her." [laughs shyly] [M2]
Responding to a need: perceived benefits
The concept of therapeutic administration from a silicone nipple shield during
breastfeeding was well perceived and positive responses were obtained from all par-
ticipants, both in terms of practical and emotional benefits. It was felt that it could
help to achieve the delivery of a complete dose, and thereby address a commonly
held anxiety of risk with current methodologies.
"[If] the baby was gonna get all its medication, it would be an ideal idea.
Rather than trying to shove it into its cheek, and then spitting it out
the other side. We have all been there with a syringe." [M4]
"I think, mothers would probably be quite happy that their child is going
to get the full dose." [RN6]
Moreover, all participants believed that therapeutic delivery during breastfeeding
would lead to a reduction of infant distress.
"It is going to be easier than trying to put a syringe with medicine into
a baby’s mouth, and it is not going to be distressing for the baby, if it
is just going to have a breastfeed as normal." [RN5]
"[...] they’d be calmer, I think that’s the difference." [M1]
Additional statements referred to an improved relationship between mother and
infant. Mothers saw the ability to deliver nutrients while breastfeeding as a means
to foster mother-infant bonding.
"It is just another way that you can be involved in your child’s care. So
you get so many things taken away from you [on the NICU] - that you
can’t do. [...] We understand that. But it would be nice to feel a bit
more involved. [...] So with [therapeutic delivery from a silicone nipple
shield], it is a way that you can still bond with your baby, and feel like
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you are helping them instead of being completely useless. [...]
Anything that can be done to help us feel closer with our babies is
absolutely excellent." [M8]
Staff expressed the belief that therapeutic delivery during breastfeeding was an
opportunity of supporting and empowering mothers in challenging environments
like the NICU, as therapeutic delivery during breastfeeding would allow them to
regain ownership and responsibility of their infant’s care.
"In some ways we are giving ownership back to them. Giving
medication is a nursing role. [...] it’s lovely for them to think to take
ownership of that, thinking ’It is my baby, I can do that.’" [RN9]
All participants favoured use of therapeutic delivery from a silicone nipple shield
during breastfeeding, when being asked about their preference between a nipple
shield device and a medicine pacifier (dummy).
"They seem to be a bit too much in control of themselves [with a
medicine pacifier]." [M8]
Noticeably, fathers appreciated the ability of enabling therapeutic delivery while
encouraging the natural practice of infant feeding.
"This is encouraging something natural, but kind of doing it [the
therapeutic administration] at the same time [as breastfeeding]." [F5]
The delivery of nutrients was supported by all participants and the administra-
tion of medicines using a nipple shield during breastfeeding by the majority of the
interviewees, provided potential risks can be mitigated.
Comprising challenges: perceived risks
At the beginning of the interview, questions aimed at exploring the attitudes to-
wards using standard nipple shields in the process of establishing and maintaining
breastfeeding. On the NICU, nipple shields are often used as “a temporary meas-
ure” [RN1], which parents associate with the positive experience of enabling them
to breastfeed.
"If the baby really struggles, [and] a nipple shield really helps [to
achieve breastfeeding], then the parents are obviously very happy to
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learn that there is actually something that they can [do], that will help
the baby to latch." [RN4]
Staff highlighted the importance of adequate parent education and guidance.
"I think [it is important] to show them properly how to apply a nipple
shield [...] because a lot of people don’t apply it properly. You know,
they just shove it on. They don’t really realize that there is actually a
bit of a skill to apply them." [RN9]
Subsequent questions referred to the potential use of a nipple shield for therapeutic
administration. Hereby, five main areas of concern were raised. First, all par-
ticipants expressed their worry that potential undesirable therapeutic taste could
negatively affect normal feeding behaviour, if the infant was to associate human
milk with the taste of a therapeutic.
"So it is just ensuring that the [infant] would still latch." [RN8]
Furthermore, the need for rapidly disintegrating formulations was emphasized by all
participants with the objective to avoid the risk of incomplete delivery of the required
dose. RNs indicated three additional areas of concern. Firstly, they pointed out that
some mothers, for example those who are in the process of establishing breastfeeding
and those confidently feeding without a nipple shield, might be reluctant to use a
nipple shield for therapeutic delivery, if it was to adversely impact their experience
either practically or emotionally.
"They will be worrying that maybe the baby will get used to the
convenience of the silicone, and then not go back to skin-to-skin, baby’s
lips to mother’s breast." [RN6]
"My concern is that there are some mothers who feel already out of
control, that are struggling." [RN9]
Secondly, they highlighted the potential challenge of combining therapeutic admin-
istration with the time constraints of three-hourly feeds.
"You have to think of timings of feed with medication. [...] Then it’s
trying to find another method of getting the oral medication in, if it is
not during a feed time." [RN2]
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One RN additionally indicated that there could be a risk of maternal skin reaction
when medicine in the nipple shield would be in direct contact with the mother’s
skin.
"Vitamins you could do quite easily. [But] if you have the drug in there
right next to the woman’s nipple, you don’t want to give her a rash."
[RN8]
Nipple shield design considerations
When asking participants about their nipple shield design preferences, all advoc-
ated for a discrete see-through device, to be available in a range of sizes, making
therapeutic delivery directly observable, personalized, and more natural.
"I think [the nipple shield should be] see-through, because [...] I would
want to know what medicine was in there, and how much was going, has
been taken." [M1]
All participants preferred a contact nipple shield to a full circular one, as well as
material properties with reduced thickness and enhanced softness. A preference
for the ultra-thin contact nipple shield over the modified nipple shield (NSDS) was
expressed, resulting from cleanliness, fit, and practicability concerns related to the
NSDS retention lip. As the lip is protruding inwardly, many participants projected
cleaning to be challenging, with participants preferring a reusable device for high-
resource settings. RNs observed that the available space for the maternal nipple
within the modified silicone teat was significantly reduced due to the retention lip,
while the teat’s length was similar to those of commercial shields. This was seen as
particularly problematic for mothers of certain anatomy.
"[...] I think my only concern is that depending on the mother’s nipples
[...] ...that [the remaining space within the nipple shield] is quite short."
[RN9]
The lip was also considered to be a potential source of maternal discomfort, because
of its risk to rub on, or trap the mother’s nipple during breastfeeding.
"I am worried that [the lip] could catch your nipple [...]." [F5]
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"[...] part of the nipple might then try to go through [the hole in the lip],
and it might rub." [RN2]
Several parents also expressed that a commercially available device already used for
normal feeding, might enable easier handling.
"That [commercially available nipple shield] would be better. Just be-
cause if people are using these anyway [for a normal feed], it would be
easier to just use this and put the medication in, I guess." [M11]
Introducing therapeutic delivery during breastfeeding: key role of health-
care professionals
Both parents and RNs felt that it would be best to introduce the nipple shield device
for therapeutic delivery within a hospital environment, with the objective to provide
mothers more confidence for subsequent home use.
"If you have already used this in the hospital, you are used to it, you
know what you are doing, you will be more than confident to do it [at
home]." [M8]
They also indicated that the main factors driving positive perceptions of infant
therapeutic delivery technologies, and consequently of a nipple shield to aid thera-
peutic delivery, is their customary use and formal recommendation by healthcare
professionals.
"I think if someone gave this [to us] and said ’this is the way we were
giving the medicine’, then I don’t think you would question it. [...]
Because it’s... I don’t know, it’s almost less risk compared to something
[else]." [F5]
"I think whatever becomes normal. If the baby is able to latch on the
breast with a nipple shield to be able to give medication, then that’s
probably a [more] normal way than having the baby away from you, and
[squeezing] medicine down." [RN8]
RNs confirmed that they would recommend a nipple shield for therapeutic delivery




This study is the first of its kind to explore the perceived acceptability of a nipple
shield for therapeutic delivery during breastfeeding in a high-resource environment.
It thereby furthers work by Hart et al., targeted at exploring the potential of a
nipple shield for antiretroviral delivery to prevent vertical HIV transmission in a
low-resource environment [45], by exploring associated benefits, risks, and design
preferences. The study has highlighted practical and emotional challenges of par-
ents in the process of infant oral therapeutic delivery, using commercially available
delivery devices. It has provided evidence for the need of alternative infant thera-
peutic delivery technologies in high-resource settings, and suggested that a nipple
shield for delivery during breastfeeding could serve as a potential solution for breast-
feeding mothers.
Potential advantages
The responses provided by parents indicate that infant oral drug administration is
associated with physical and emotional burden. The level of emotional anxiety is
highlighted by the emotive language used, and their worry about the infant’s choking
and fear. The delivery of therapeutics during breastfeeding was perceived to have
a positive impact on the infant’s overall emotional state. The literature indicates
that the release of Oxytocin during breastfeeding in both the infant’s and mother’s
brain has the potential to decrease stress levels through counteracting certain path-
ways within the sympathetic nervous system [78], whilst also eliciting enhanced
care-giving behaviour [78, 79]. All participants confirmed that they would use and
recommend the nipple shield for nutrient delivery. This indicates the potential of
a nipple shield to be used for the daily nutrient administration to infants on the
NICU and its continuation up to six months after discharge [27, 28]. A nipple shield
for therapeutic delivery was also perceived as a means to improve mother-infant
bonding, a matter of particular relevance for parents on a Neonatal Intensive Care
Unit. In such emotionally challenging environments, building of emotional closeness
empowers parents to regain responsibility for their infants’ care, while leading to im-
proved infant outcomes [80–82]. The finding of this study to provide appropriate
maternal support by healthcare professionals while introducing a nipple shield for
therapeutic delivery aligns with past literature on the transition of responsibility in
care from clinical staff to parents of preterm infants [80–83].
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Potential challenges and requirements
The potential association of breastfeeding with the adverse taste of medicine was
raised as a concern by all participants, due to the risk that it could negatively affect
infant breastfeeding behaviour. This emphasizes the importance of therapeutic taste
masking of formulations used for delivery into human milk. Yet, while appropriate
taste masking of formulations is important to ensure, it is known that breastfed
infants are familiar with a wide range of tastes, reflecting the maternal diet [84, 85].
Moreover, human milk is itself considered to have taste masking characteristics, as
previously shown for formulations that are insoluble, characterized as irritating or
bitter-tasting [86–88]. The capacity of therapeutic delivery to enable appropriate
mixing of therapeutic and human milk was shown in previous lab-based studies using
orally disintegrating tablets [4], whereby a linear release profile was obtained for
20 min of breastfeeding simulation at physiologically relevant conditions.
Preference for delivery using a commercial nipple shield
All participants preferred a commercially available and reusable nipple shield, provid-
ing one or more of the following reasons: inability to properly clean a lip-containing
device, design limitations of a lip-containing device with regard to varying maternal
physiology, perceived user convenience of a commercially available device used for
normal feeding. This finding contrasts with prior efforts in developing a modified
lip-containing nipple shield [4, 41, 87].
Limitations
This study has elicited parents’ and staff’s views revealing the potential of thera-
peutic delivery during breastfeeding by means of a nipple shield in a high-resource
neonatal care setting. Limitations include that this is a single centre study, de-
scribing participants’ opinions only based on visual assessment of nipple shields, not
their practical use. Moreover, participants’ preference of a nipple shield may have
been biased by material appearance. It has to be noted however that most parti-
cipants provided clear reasoning for their choice based on design parameters rather
than the device’s material composition. The study was designed to explore parents’
and staff’s opinions about therapeutic delivery during breastfeeding and preferred
nipple shield design characteristics for further development. In order to determine
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the clinical feasibility, safety, and acceptability of a nipple shield for therapeutic
delivery during breastfeeding, subsequent clinical work will be required.
3.5 Conclusion
This study was the first of its kind to prove the potential of infant oral therapeutic
administration in a high-resource environment, as hypothesised in previous liter-
ature [4, 42, 45]. The following two key drivers were identified: (1) the desire to
overcome associated emotional and physical challenges with currently available in-
fant oral therapeutic delivery devices, (2) the need to foster mother-infant bonding
in neonatal special care environments, and to encourage parental empowerment.
The findings demonstrate acceptability of a nipple shield for therapeutic delivery to
address these issues, so long as concerns about potential impact on breastfeeding
can be addressed and accurate dosing ensured. Raised design concerns related to a
formerly modified lip-containing shield, and indicated preference for a commercially
available silicone nipple shield.
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Based on the need to investigate novel therapeutic dosage forms for delivery from a
nipple shield into human milk, presented research synthesizes previously conducted
investigations by exploring the release of zinc sulphate pentahydrate from non-woven
fibres during breastfeeding simulation. Neither the release properties of non-woven
fibre mats, using parameters resembling the physiological process of breastfeeding,
nor the delivery of zinc sulphate from dosage forms others than rapidly disintegrating
tablets had yet been investigated. The following objectives where defined:
1. Characterisation of non-woven fibre mats for zinc delivery into human milk
2. Quantification of zinc release from a lip-containing nipple shield into human
milk during breastfeeding simulation
3. Comparison of absolute recovery achieved with previous literature on zinc
release from rapidly disintegrating tablets
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4.1.2 Importance of zinc in neonates
The element zinc (Zn) is of great importance in the human body, as it is re-
sponsible for the activity of various proteins in major pathways of the human
metabolism [89]. In case of deficiency, not only infant growth and development, but
also the capabilities of the body’s immune system are significantly
affected [89–91]. Zinc is absorbed in the small intestine and uptake is independ-
ent of zinc status [89, 92]. Nonetheless, higher uptake is reported for term babies
in the literature, caused by a lower zinc concentration in the blood serum [89]. Es-
pecially preterm and Small for Gestational Age (SGA) neonates have an increased
risk of zinc deficiency [91], as these infants had benefited a shorter time from the
maternal zinc derived via placental transfer [89]. At the same time, they are anti-
cipated to have little intake after birth, while increasingly loosing zinc endogenously
through the gastrointestinal tract [89]. Deficiency is believed to occur within the first
1 − 2 months of life [90]. Although breastfed infants derive zinc through the con-
sumption of human milk, the available concentration might not be sufficient, as it
varies significantly between mothers (0.7−1.6 mg L-1) and the stage of lactation, and
constantly declines postpartum: while 8 − 12 mg L-1 zinc are present in colostrum,
the first milk the maternal breast produces after giving birth, only 3 − 6 mg L-1 in
human milk can be found seven days after birth, and only 1 − 3 mg L-1 another
three weeks later [89]. As a means to prevent deficiency, enteral zinc delivery of
0.8 mg kg-1 day-1 for term infants and 3 mg kg-1 day-1 for preterm neonates is re-
commended [93], while Terrin et al. noted that the recommended dose seemed to
have increased over time [89]. Zinc deficiency in neonates is associated with con-
ditions such as dermatitis, growth retardation, necrotizing enterocolitis, neurologic
damage, bronchopulmonary dysplasia, infections, and retinopathy of
prematurity [89], while its supplementation has positive impact on paediatric
survival [90]. Zinc deficiency, not only in form of severe but also as moderate de-
ficiency, is adding to “the global burden of disease” ([94], p. 1488S), as each year ap-
proximately 800,000 child deaths are documented as a result of zinc
deficiency [94]. An excerpt of the literature illustrating the positive effect of zinc
supplementation can be found in Table 4.1.
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Author Findings: Zinc supplementation...
Bhutta et al. [95]
Walker et al. [96]
...leads to significant reduction in infantile
diarrhoea and pneumonia rates in developing
countries.
Sazawal et al. [97] ...leads to a significant decrease in mortality for
small for gestational age infants.
Bhatnagar et al.
[98]
...was suggested as an adjunct to antibiotics for
the infantile treatment of bacterial infections.
Table 4.1: Excerpt of the literature illustrating positive benefits of infant zinc sup-
plementation.
In addition to the overall health promoting effects of zinc, supplementation is also
recommended by the WHO as an adjunct to oral rehydration salts for the treatment
of acute diarrhoea (20 mg zinc sulphate). Guidance is included in the WHO Model
List of Essential Medicines and the WHO Model List of Essential Medicines for
Children [25, 99]. Based on its importance for the physical development and health
of infants globally, and in order to enable comparison with previously conducted
experiments [4], zinc was chosen as the therapeutic for breastfeeding simulation
experiments in this chapter.
4.2 Materials and methods
4.2.1 Materials
(a) Human milk. The Cambridge Human Biology Research Ethics Committee
at the University of Cambridge ethically approved all human milk sample use
(HBREC.2012.01). Human milk samples from two healthy mothers, previously
screened negative for syphilis, hepatitis B and C, HIV I and II, as well as HTLV I
and II, were obtained from the Queen Charlotte’s and Chelsea Hospital Milk Bank
(Imperial College Healthcare NHS Trust). For the initial pooling and analysis, in-
dividual frozen human milk samples of 50−100 µL volume, thawed from -80°C in re-
peated cycles at 4°C overnight and at room temperature for
5 h each, were pooled, thoroughly mixed, and aliquots taken for creamatocrit and
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protein analysis. Protein quantification was conducted using a standard Bradford
Agent assay (Sigma-Aldrich, UK). All measurements were performed in triplicate
and the average taken. Cream content was evaluated in sextuplicate by means
of the creamatocrit technique according to a protocol by Lucas et al., whereby a
Sigma Microcentrifuge (SciQuip, UK) and BRAND® Haematocrit sealing compound
(Sigma-Aldrich, UK) were used [100]. Subsequently, the fat content was calculated
using the following equation: fat (g L-1) = (5.37 x creamatocrit %) + 5.28 [101]. A
total lipid content of 43.52 g L-1 measured in sextuplicate was determined. Protein
content measured in triplicate was 16.51 g L-1. Both values correspond to previously
reported literature data [40, 102, 103]. An example of human milk composition by
Emmet et al. is illustrated in Table 4.2 [102]. Milk density measurements, covering
the temperature range of 33.7 − 35.7°C, a temperature used in previous research
to simulate the milk’s temperature in the infant’s mouth during breastfeeding sim-
ulation [4], were conducted in triplicate using a hydrometer (VWR, Lutterworth,
UK). Following linear interpolation, illustrated in Figure 4.1, a density value of
1.023 g mL-1 was obtained for the median temperature during breastfeeding simula-
tion experiments. Characterised human milk was aliquoted for future experiments à
500 mL each, and stored at -80°C until further use. For the experiments conducted
in this chapter, human milk was thawed for 48 h at 4°C before use. Human milk










Water 88.2 87.4 87.1
Protein 2.0 1.5 1.3
Fat 2.6 3.7 4.1
Carbohydrate 6.6 6.9 7.2
Table 4.2: Average water, protein, fat, and carbohydrate composition of human
milk for all stages of lactation by Emmet et al. [102]. Colostrum is defined as
human milk produced within the first few days after birth, ’mature’ refers to hu-























Figure 4.1: Linear interpolation used to evaluate human milk density. Milk density
measurements for the temperature range of 33.7−35.7°C were conducted in triplicate
using a hydrometer (VWR, Lutterworth, UK). ’T’ illustrates temperature in °C, ’d’
stands for density in g mL-1.
(b) Nipple shield. To enable direct comparison of former experiments by Scheuerle
et al, investigating zinc sulphate recovery from rapidly disintegrating
tablets [4], the modified lip-containing nipple shield was used.
(c) Non-woven fibre preparation. Non-woven fibre mats, composed of 35 %
viscose and 65 % polyester, by Bathfelt Texel (Québec, Canada) were used as the
delivery matrix (see Figure 4.2). Two different types of fibre mats were evaluated:
a 235 g per square metre (g m−2) felt with targeted thickness of 1.8 mm (referred
to as fibre mat type A), and a 335 g m−2 felt with targeted thickness of 2.1 mm
(referred to as fibre mat type B).
b) a) 
Figure 4.2: Delivery matrix. Illustration of non-woven fibre mat (a) type A and
(b) type B, loaded with zinc sulphate. Image adapted from [38].
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The selection of non-woven fibres was based on previous research by
Gerrard et al. [41].
(d) Therapeutic. Zinc sulphate monohydrate was obtained from Sigma Aldrich
(Dorset, UK), and preferred over elemental zinc based on its superior solubility and
taste characteristics [4]. The chosen amount of zinc sulphate loaded onto the fibre
mats aligned with the WHO-based dose recommendation of zinc sulphate as an
adjunct to oral rehydration salts for the treatment of acute diarrhoea [25].
4.2.2 Fibre mat preparation
Fibre mat type A and type B were loaded with 6.2 mg (standard deviation
0.075 mg, n = 3) and 6.4 mg (standard deviation 0.046 mg, n = 3) of elemental zinc
respectively, by pipetting a 49 % zinc sulphate monohydrate solution
(wt/wt %) onto the fibre mats. The mats were air dried in a petri dish for
24 h at room temperature.
4.2.3 Fibre mat characterisation procedures
(a) Scanning Electron Microscope (SEM) analysis. Scanning Electron Mi-
croscope (SEM) analysis was applied to investigate both the fibre mats’ surfaces and
their cross-sections. Samples for cross-sectional visualisation were frozen in liquid
nitrogen and cross-fractured with a cooled razor plate, while samples for surface
visualisation did not require prior preparation. The resulting samples of zinc sulph-
ate loaded and unloaded fibre mats were mounted on 12.5 mm Cambridge stubs
with Silver Dag (Taab Ltd), and sputter coated with 15 nm of Iridium using a
Quorum/Emitech K575X sputter coater. Imaging was performed by using a FEI
Verios 460L at 3 kV and 25 pA with a through lens detector operated in field free
mode. Sample preparation was performed by Dr Jeremy Skepper (Cambridge Ad-
vanced Imaging Centre), who also assisted in subsequent imaging.
(b) Energy Dispersive X-Ray analysis. To confirm the presence of zinc sulph-
ate on loaded fibre mats, as well as the absence of zinc on unloaded mats, Energy
Dispersive X-Ray (EDX) analysis of the mats’ cross-section of loaded and unloaded
fibre mats was performed. For sample preparation, the mats were frozen in liquid
nitrogen and cut into appropriate size using a cooled razor blade. Following mount-
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ing using carbon DAG, the samples were carbon coated using a Quorum Q150 at
50 nm. EDX spectra were recorded using an Ametec/EDAX Energy Dispersive X-
ray spectrometer with a silicon drift detector. Analysed areas of the fibre mats were
additionally imaged using a Scanning Electron Microscope according to the oper-
ation parameters outlined previously, as well as using a concentric backscattered
electron detector (CBS). A CBS detector enables areas of higher atomic number to
appear brighter in the recorded image. Sample preparation was conducted by Dr
Karin Muller (Cambridge Advanced Imaging Centre), following which analysis was
performed collaboratively.
(c) X-ray Micro Computed Tomography (XµCT). To enable the analysis
of changes in porosity, entire fibre mats were analysed by means of X-ray Micro
Computed Tomography (XµCT) using a SkyScan 1172 high-resolution XµCT scan-
ner (Bruker, Antwerp, Belgium), combining a cone beam geometry and a 2D array
detector. During the process of XµCT, shadow projections following stepwise ro-
tations of the object at 0.25° are acquired, enabling a 3D image reconstruction of
the object following a total rotation of 180°. It is characterised by high spatial res-
olution and negligible diffraction of investigated samples. Using an isotropic voxel
size of 2.49 µm, 10 images per position were averaged, aiming to reduce noise while
increasing contrast. In approximately 3 h of acquisition time, 720 images were
obtained. Reconstruction of recorded data was performed using NRecon (Bruker,
159 v1.6.8.0), resulting data visualized in CTVox (Bruker, v3.3), and processed in
Avizo Fire (FEI Company, 160 Hillsboro, Oregon, USA, v8.1). The protocol is
based on previous literature by Markl et al. [104]. In order to differentiate solid
material from the pore space for a selected volume of interest within the centre
of the fibre mat (0.998 m3), thresholding was applied. Subsequently, volume and
surface area were calculated for the extracted solid material, while porosity values
were obtained by using the relationship between pore space volume and solid ma-
terial. XµCT measurements and data reconstruction was performed together with
Dr Daniel Markl, who also guided the data analysis process.
4.2.4 Breastfeeding simulation procedures
(a) Breastfeeding simulation. Breastfeeding simulation conditions were chosen
based on literature on breastfeeding physiology [18, 20, 21, 23]): Milk was heated
to 33.7 - 35.7°C, simulating its likely temperature inside the infant’s mouth dur-
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ing breastfeeding, and flow rate and suction frequency adjusted to approximately
5 mL min-1 and 1 suck sec-1 respectively. For each type of fibre mat, simulation
experiments were conducted in triplicate, with the human breast mimic set to an
angle of 30° downwards from the vertical axis. Temperature and pressure were
monitored throughout. The pressure range and amplitude represented values of
physiological relevance [21], and peak vacuum values of -22.78 kPa and -22.32 kPa,
as well as baseline vacuum values of -10.90 kPa and -11.38 kPa for fibre mat type
A and B respectively were recorded. An average pressure profile for both types of
fibre mats is illustrated in Figure 4.3. A total of 30 fractions, each for a duration
of 40 sec, were collected. This duration was chosen to enable comparative ana-
lysis with previously published breastfeeding simulation experiments by Scheuerle
et al. [4]. For each fraction, the weight was recorded using a Sartorius analytic bal-



































Figure 4.3: Example pressure profile during zinc delivery experiments using
the breastfeeding simulation apparatus, depicted for 10 s at t = 120 − 130 s.
Dosage forms used for delivery from a nipple shield were zinc-loaded fibre mats
a) type A, and b) type B. Experiments were conducted using an average flow rate
of approximately 5 mL min-1. Image originally published in [38].
(b) Pre-analysis preparation of collected fractions and standard solu-
tions. Preparation of collected fractions and standard solutions was performed
by Dr Rebekah L. Scheuerle, and conducted based on a published protocol by
Scheuerle et al., illustrated in the following [4, 44]. To generate zinc calibration
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curves, zinc standards (Perkin Elmer, Inc., Shelton, CT) were diluted 1:20 volu-
metrically in diluent A, consisting of a total concentration of 0.1 % nitric acid
(SPEX CertiPrep, Metuchen, NJ/USA) in ultra-high purity water. Calibration
data was retaken continuously after every few experimental samples. To evalu-
ate the elemental zinc content in human milk samples collected during breastfeed-
ing simulation studies, nine out of the 30 fractions obtained during each breast-
feeding simulation run were chosen for experimental analysis (fraction numbers
1, 2, 3, 4, 5, 7, 10, 15, 20, 30). Hereby, samples were thawed at room tem-
perature, following which a 1:20 volumetric dilution was performed using diluent
B, a diluent of ultra-high purity water (Sartorius Stedium Biotech Arium pro UV
Water polisher) with 0.002 % TritonX100 (Sigma-Aldrich, UK), as well as the in-
ternal standard 1 ppm molybdenum (SPEX CertiPrep Metuchen, NJ). To evaluate
the elemental zinc content of non-woven fibre mats used for breastfeeding simula-
tion experiments, fibre mats were added to a vial containing 1 mL rinse of ultra-
high purity water (Sartorius Stedium Biotech Arium pro UV water polisher) with
0.002 % TritonX100 (Sigma-Aldrich,UK). After two ultrasonications of 10 min each,
the vials were gently shaken overnight using a shaker plate, following which 1 mL of
rins was added. The latter was repeated for a total of three nights/days, following
which the samples were kept in a 40°C water bath overnight, and were volumet-
rically diluted in ultra-high purity water 1:10, and in diluent B 1:20. Prior to
ICP-OES analysis being conducted, sample solutions were vortexed using a Fish-
erbrand Whirlimixer (Loughborough/UK).
(c) ICP-OES. Detection of elemental zinc content was performed by Dr Re-
bekah L. Scheuerle at the MRC Human Nutrition Research Unit (Cambridge, UK)
by means of Inductively Coupled Plasma Optical Emission Spectrometry (ICP-
OES). The subsequent experimental procedure references methods by Scheuerle et
al. [4, 44]. Experiments were performed using an ICP-OES (Jobin Yvon Horiba-
ULTIMA 2C; concentric glass nebulizer with 0 − 1 mL min-1 sample flow rate,
50 mL glass cyclonic spray chamber, radial torch with a 3 mm i.d. alumina injector).
Samples were introduced to the concentric glass nebulizer through a sample probe of
0.75 mm i.d. sample tubing and 0.76 mm i.d. pump tubing using an auto-sampler
(Jobin Yvon Hribo AS500) with a flow rate of 1 mL min-1. Passing the concentric
glass nebulizer, the sample was introduced to an argon plasma containing glass cyc-
lonic spray chamber at 12 L min-1, while a radio frequency power of 1300 W and
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a sheath gas flow of 2 L min-1 was applied. Detection of zinc was performed in a
photomultiplier tube at 213.856 nm and a voltage of 605 V (kg×m2
s3×A ), detection of
molybdenum (Mo) at 202.030 nm and a voltage of 955 V (kg×m2
s3×A ), using a 0.5 sec
integration time. Data was recorded by ICP Analyst 5.4 software (Horiba, UK).
(d) Data analysis. Analysis was conducted based on a previously published
protocol by Scheuerle et al. [4], with guidance by Dr Rebekah L. Scheuerle, and
resulting calibration curves are illustrated in Figure 4.4.
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LOW CALIBRATION CURVE HIGH CALIBRATION CURVE
R  = 0.99996R  = 0.991
a) b)
c) d)
Figure 4.4: Calibration curves for a low range (0.0 − 0.5 mg L-1) and a high
range (0.5 − 50.0 mg L-1) of elemental zinc detected vs. zinc to molybdenum in-
tensity ratio to determine the elemental zinc content of a - b) loaded fibre mats,
c - d) breastfeeding simulation samples. Calibration curves were generated through
linear interpolation. ’c’ represents the elemental zinc concentration in mg L-1,
’i’ illustrates the Zn to Mo intensity ratio.
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Both curves were generated through linear interpolation, and intensity ratios cor-
rected for blank values. Using the calibration equations, the amount of elemental
zinc obtained in diluted samples is based on the intensity ratio of Zn to Mo [4].
The actual elemental zinc content of the simulation experiment samples was evalu-
ated through accounting for the factor of dilution, the sample’s weight, the density
of human milk, and the temperature during the experiment [4]. Using the values
obtained from measuring nine out of 30 samples, the concentration of zinc in the
remaining 21 human milk samples was subsequently evaluated by means of linear
interpolation. Data obtained was used to generate release profiles and to evaluate
the cumulative zinc release during each experiment, represented as a percentage of
the total amount loaded onto the non-woven fibre mats to the total amount released.
4.3 Results
4.3.1 Release of zinc from non-woven fibres
The amount of human milk passed through the nipple shield, and the absolute
recovery achieved for both fibre mat types are presented in Table 4.3. Figure 4.5
illustrates the cumulative normalised proportion of zinc released and its propagated
error, as well as the normalised proportion of zinc released in individual fractions
over time. A similar effectiveness and duration of release were observed.
Recovery
achieved [%]
Amount of human milk passed
through the shield [g]
Mat type A 64.00 ± 0.21 93.09 ± 1.08
Mat type B 61.64 ± 0.13 98.15 ± 0.97
Table 4.3: Recovery achieved and human milk passed through the nipple shield for
the delivery of zinc sulphate from Texel non-woven fibre mats using the breastfeeding






































































Fibre mat type A
Fibre mat type B
 Tablets, highest release (Scheuerle et al.)
 Tablets, lowest release (Scheuerle et al.)
Fibre mat type A
Fibre mat type B
 Tablets, highest release (Scheuerle et al.)
 Tablets, lowest release (Scheuerle et al.)
Figure 4.5: Illustration of zinc sulphate release from Texel fibre mats type A
(1.8 mm targeted thickness, 235 g m-2) and type B (2.1 mm targeted thickness,
335 g m-2), as well as from rapidly disintegrating tablets by Scheuerle et al. [4] into
human milk. a) Cumulative normalised proportion of zinc sulphate released, and
b) Normalised proportion of zinc sulphate released in each fraction over time. Re-
lease is represented as a percentage of the total amount loaded onto the non-woven
fibre mats to the total amount released. Each set of points represents the average
of three experiments, using the mean of ICP-OES triplicate measurements for each
fraction shown. Image originally published in [38].
4.3.2 Scanning Electron Microscope (SEM) analysis
To explore the fibre mats’ morphology, SEM imaging of unloaded and zinc sulph-
ate loaded Texel fibre mats type A and type B was conducted in triplicate (see
Figure 4.6 and Figure 4.7 for fibre mats’ surfaces, and Figure 4.8 and Figure 4.9 for
the fibre mats’ cross-sections). Hereby, an approximate fibre diameter of 20 µm was
identified, and it was found that both types of mats have the same fibrous structure
in spite of their difference in g m-2 and thickness. Adsorption of zinc sulphate was
observed in localized areas scattered across the mats’ network, either in form of flat
patches or clumps. The mostly uniform coating on the fibre surface is character-
ised by a cracked pattern, because of the evaporation of water from the loaded zinc
sulphate solution. Since Texel fibre mats are characterised by a porous structure,







300 µm 40 µm 5 µm
a) b) c)
300 µm 40 µm 5 µm
d) e) f)
Figure 4.6: SEM results for fibre mat type A (fibre mat surface). Illustration of
results obtained for SEM analysis of Texel fibre mat type A (1.8 mm targeted thick-
ness, 235 g m-2) at three different magnifications. Images a) - c) present unloaded
fibre mats, images d) - f) fibre mats loaded with zinc sulphate before dissolution.
Image originally published in [38].







40 µm 5 µm
d) e) f)
Figure 4.7: SEM results for fibre mat type B (fibre mat surface). Illustration of
results obtained for SEM analysis of Texel fibre mat type B (2.1 mm targeted thick-
ness, 335 g m-2) at three different magnifications. Images a) - c) present unloaded
fibre mats, images d) - f) fibre mats loaded with zinc sulphate before dissolution.
Image originally published in [38].
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500 µm 100 µm 100 µm
Figure 4.8: SEM results for fibre mat type A (fibre mat cross-section). SEM images
are depicting the cross-section of Texel fibre mat type A (1.8 mm targeted thickness,
235 g m-2) at two different magnifications. Images a) - c) present unloaded fibre
mats, images d) - f) fibre mats loaded with zinc sulphate before dissolution. Image
originally published in [38].
500 µm 100 µm 100 µm
a) b) c)






Figure 4.9: SEM results for fibre mat type B (fibre mat cross-section). SEM images
are illustrating the cross-section of Texel fibre mat type B (2.1 mm targeted thick-
ness, 335 g m-2) at two different magnifications. Images a) - c) present unloaded
fibre mats, images, d) - f) fibre mats loaded with zinc sulphate before dissolution.
Image originally published in [38].
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4.3.3 Energy Dispersive X-Ray analysis
Energy Dispersive X-Ray analysis, as well as imaging via SEM and CBS were con-
ducted as a means to chemically characterise unloaded and loaded Texel fibre mats
type A and B. Characteristic X-ray values of relevant elements can be found in
Table 4.4. Results are illustrated in Figure 4.10 and Figure 4.11.
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Figure 4.10: EDX spectra and corresponding imaging results for fibre mat type A
(fibre mat cross-section) before dissolution. Image a) and d) illustrate the EDX
spectra, images b) and e) imaging of the EDX analysed fibre mat area via SEM,
images c) and f) imaging of the EDX analysed fibre mat area via a concentric




















0.0 3.0 6.0 9.0 12.0
Photon energy [keV] 
d)










Photon energy [keV] 
200 µm 200 µm
c)b)








Figure 4.11: EDX spectra and corresponding imaging results for fibre mat type B
(fibre mat cross-section) before dissolution. Image a) and d) illustrate the EDX
spectra, images b) and e) imaging of the EDX analysed fibre mat area via SEM,
images c) and f) imaging of the EDX analysed fibre mat area via a concentric
backscatter detector (CBS). Image originally published in [38].
For unloaded and loaded samples, the EDX spectra showed presence of the elements
C and O, the building blocks of the mats’ viscose and polyester fibres, while Zn and
S were only detected in zinc sulphate loaded samples. The analysis thus confirms
the absence of zinc in unloaded samples.
4.3.4 X-ray Micro Computed Tomography (XµCT)
To investigate the fibre mats’ porosity and 3D structure, analysis via X-ray Micro
Computed Tomography (XµCT) was conducted. Loaded and unloaded Texel fibre
mats type A and Type B are illustrated in Figure 4.12 and Figure 4.13, respect-
ively. Different colours indicate material of different electron density as detected
by XµCT, red indicating low, and green high-density material. Since the materials’
elemental composition is not changing, the sample’s electron density is equivalent
to its true density values. The presented colour scale was chosen based on the dens-
ity of viscose (1.52 g cm-3) [105], polyester (1.38 g cm-3) [105], and zinc sulphate
(3.54 g cm-3) [106]. As a consequence, the unloaded fibre material of comparably
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lower density appeared in red, and zinc sulphate of comparably higher density in
blue and green colour. 3D renderings of the XµCT data for unloaded and loaded
fibre mats are illustrated in Figure 4.12 and 4.13. Through a change in the opacity
(see colour maps of the individual renderings) regions of varying densities were ob-
served. While images d) - e) depict both fibre material and zinc sulphate loaded
onto the fibre mats, indicated by the mats’ red and a blue to red colour, the blue
and green colour of image f) solely illustrates loaded zinc sulphate. This observation
is further confirmed when comparing figures of loaded with those of unloaded fibre
mats in images a) – c), in which the visible fibrous material at medium density is
only visible as a faint silhouette. Merely light blue spots of < 10 µm and sporadic-
ally larger spots of < 250 µm size are visible. Figure 4.14 illustrates that the bottom
side of fibre mat type A, unlike those of fibre mat type B, appears similar to the


































Figure 4.12: XµCT results for loaded fibre mat type A. Images generated from XµCT
measurements of a) - c) unloaded, and d) - f) zinc sulphate loaded Texel fibre mats
type A (1.8 mm targeted thickness, 235 g m-2). The colour maps were the same
for all images and only the opacity was adjusted in order to visualize components
of different densities. Red colour indicates low, green colour high-density material.
The images depict only half of the fibre mats in order to visualize the cross-section
at the centre of each sample. Image originally published in [38].
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Moreover, in alignment with SEM results, XµCT analysis confirmed an approximate
fibre diameter of 20 µm for unloaded or partially loaded fibres. The diameter of
loaded fibres could not be identified, as data illustrated the fusion of adjoined fibres
following swelling, rendering the identification of individual fibres in areas of high
zinc loading impossible. An example of representative cross-sectional cuts through
a swollen fibre cluster is illustrated in Figure 4.15. To quantify changes within the
fibre network following zinc sulphate loading, volume fraction, porosity, and total
surface area were calculated for a cubical region of interest measuring 0.998 mm3
from the fibre mats’ centre. Results are shown in Table 4.5. A decrease in porosity
can be observed as a result of an increase in solid fraction, and consequently in the
volume of solid material. This is caused by both swelling of individual fibres and
the deposit of zinc sulphate, in turn resulting in an increase in the surface area of































Figure 4.13: XµCT results for loaded fibre mat type B. Images generated by XµCT
analysis of a) - c) unloaded, and d) - f) zinc sulphate loaded Texel fibre mats
type B (2.1 mm targeted thickness, 335 g m-2). Opacity was adjusted in order to
visualize components of different densities using the same colour map. Red colour
indicates low, green colour high-density material. In order to visualize the cross-
section at the centre of each sample, only half of the fibre mats are illustrated. Image















Figure 4.14: Images generated for XµCT analysis of loaded Texel fibre mats (bottom



















Figure 4.15: Cut through zinc-loaded fibres in the y-z plane of loaded fibre mat
type B. Images a) - c) illustrate resulting cross-sectional images at different positions
in the x-direction. Zinc-loaded fibres appear swollen and fused with adjoined fibres
to form high-density fibre clusters. Image originally published in [38].




Porosity [-] 0.942 0.607 - 36
Surface area [mm2] 19.72 32.70 + 66




Porosity [-] 0.939 0.416 - 56
Surface area [mm2] 17.30 50.90 + 194
Volume [mm3] 0.061 0.583 + 856
Table 4.5: Overview of porosity, surface area, and volume of a cubical region of
interest measuring 0.998 mm3 taken from the loaded and unloaded fibre mats’ centre.




Delivery of the full dose of loaded zinc sulphate from non-woven Texel fibres within
the duration of one breastfeed, equivalent to the consumption of 76.0 ± 12.6 g of
human milk for 1-month- to 6-month-old infants was not achieved [40]. Potential
reasons include impact of milk properties, such as the accumulation of milk com-
ponents within the porous mat structure, hampering the flow of milk and hence the
delivery of zinc from the fibrous network, as well as changes in fibre conformation.
Milk properties. Although it has to be noted that the nature and adsorption
properties of a therapeutic significantly affect its release rate, recent literature by
Gerrard et al. suggests that absolute recovery is additionally dependent on both
the milk’s lipid content and distribution, as well as the overall milk composition,
including carbohydrates, proteins, and lipids. The former was confirmed, as abso-
lute release into cow’s milk was reduced to 30 − 60 % when non-homogenized milk
(5.2 % fat) was used, as opposed to a total of 70 − 90 % for use of a homo-
genized form (3.6 % fat) [41]. The latter was shown when comparing these res-
ults to the absolute recovery of 100 % into non-homogenized goat’s milk (4.0 %
fat) [41]. Both results pose difficulties to the development of a standardized pro-
tocol for therapeutic release via non-woven Texel fibre mats, as not only commer-
cially available cow’s and goat’s milk, but in particular human milk is a complex
fluid with highly variable properties. Among others, a variation of the absolute fat
content of up to three fold can be observed, as a result of the stage of lactation, di-
etary requirements and health status of the breastfeeding mother [39]. To overcome
undesired accumulation of milk components within the porous fibre network, po-
tential surface modifications, such as plasma treatment could be applied [107, 108].
Such modifications would however increase both manufacturing efforts, as well as
overall production cost of a fibre-based therapeutic insert, and potential benefits
and risks would have to be carefully assessed.
Changes in fibre conformation. Moreover, XµCT results also suggest that zinc
release is likely affected by the change in conformation, namely the swelling of loaded
fibres, decreasing porosity and the flow of human milk through the fibrous structure,
while simultaneously increasing the likelihood for milk components to accumulate.
Previous literature showed a decrease in release from low surface area to volume
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HPMC tablets [109], and similarly literature by Siepmann et al. [110] suggests that
also the release from zinc-loaded fibre clusters will likely be slowed down as a result
of their reduced surface to volume ratio. XµCT also revealed the presence of fibres of
higher density than initially anticipated based on the true density values of viscose
and polyester. The 10 − 250 µm sized spots in rendered 3D XµCT data, observ-
able at medium density values, indicates fibre accumulation and/or the presence of
impurities. Both are believed to be a result of the fibres’ manufacturing process,
and/or caused by trapped dust particles. The even distribution of zinc within the
fibrous network of fibre mat type B, which contrasts with the zinc adsorption pattern
illustrated in Figure 4.14, can be explained by the slightly larger fibre diameter and
different wetting behaviour of the two fibre mats. Liquid absorption of individual
fibres within the fibre mats is driven by capillary action, while being influenced by
the samples’ porosity [111]. It is believed that these differences also lead to the
unequal changes in porosity, surface area, and volume of fibre mat type A and B
following loading, which nonetheless do not result in a noticeable difference in re-
lease from both mats.
Comparing recovery to the literature. Overall, experimental results revealed
a 20 − 48 % superior absolute recovery of zinc sulphate from Texel non-woven fibre
mats, compared to rapidly disintegrating tablets manufactured by direct compres-
sion: research by Scheuerle et al. reported an absolute recovery of only
32 − 51 % [4]. It has to be noted however that the total elemental zinc content
of rapidly disintegrating tablets used by Scheuerle et al. (17.81 − 18.21 mg) was
higher than the amount of elemental zinc loaded onto this study’s Texel non-woven
fibre mats (6.17 − 6.40 mg) [4]. Yet, when comparing the zinc delivery within the
first 8 min, during which the main release from non-woven fibre mats had occurred,
the estimated amount of elemental zinc released from the rapidly disintegrating tab-
lets ranged between 2−4 mg, characterised by a linear release profile [4]. It thus was
significantly lower than the release from Texel non-woven fibre mats at 8 min. Not
only their superior release properties, but also the enhanced loading feasibility and
cost-effectiveness of Texel non-woven fibre mats, compared to the referenced rapidly
disintegrating tablets, confirm their potential as a therapeutic insert for delivery
from a nipple shield during breastfeeding.
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Additional investigations are needed to prove the capability of Texel non-woven
fibres to serve as a generalized matrix for oral drug administration, as well as to
explore alternative materials with suitable characteristics for delivery from a nipple
shield into human milk.
4.5 Conclusion
Texel non-woven fibre mats were investigated as a delivery matrix for zinc sulph-
ate pentahydrate. When tested during breastfeeding simulation experiments, an
absolute elemental zinc recovery of 64 % (fibre mat type A) and 62 % (fibre mat
type B) respectively in approximately 93 g and 98 g of human milk passed through
the fibre insert was achieved. Incomplete delivery may be attributed to i) the com-
plex properties of human milk, ii) accumulation of milk components within the
porous mat structures, as well as iii) structural changes of the fibre networks fol-
lowing loading, thereby hampering the delivery of zinc. Based on the non-woven
fibre mats’ release characteristics and cost-effectiveness, non-woven fibres can be
regarded as an advantageous dosage form for oral therapeutic delivery from a nipple
shield during breastfeeding simulation. Further research will be required to establish
Texel non-woven fibres as a generalized matrix for oral therapeutic delivery from a
nipple shield, and to further explore alternative fibrous materials with advantageous
characteristics for therapeutic delivery into human milk.
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Initial research on dosage forms mainly focused on rapidly disintegrating tablets
and Texel non-woven fibre mats. Since neither one enabled complete delivery of a
full dose during breastfeeding simulation experiments, investigation of alternative
formulations was required. Hydrogels were believed to overcome some of the previ-
ously encountered limitations, such as the firmness of tablets, and the uncontrollable
adsorption pattern of non-woven fibres. This chapter explores both the suitability
of hydrogels for therapeutic delivery into human milk, as well as the in-vitro feasib-
ility of commercially available ultra-thin contact nipple shields for oral therapeutic
delivery during breastfeeding. The following objectives where defined:
1. Development and characterisation of a hydrogel formulation for iron delivery
into human milk
2. Quantification of iron release from a commercially available ultra-thin contact
nipple shield into human milk during breastfeeding simulation experiments
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5.1.2 Importance of iron in neonates
Iron deficiency (ID), defined as “a state in which there is insufficient iron to main-
tain normal physiologic functions” ([112], p. 1041) and being equivalent to serum
ferritin values below 10 − 12 µg L-1 [113], is the most common single-nutrient de-
ficiency worldwide, with an estimated total of two billion people affected [114].
Iron is of significant physiological importance with 80 % of the body’s iron be-
ing present in the blood’s haemoglobin [115]. Moreover, iron is involved in the
brain’s structural development due to its functional role in enzyme catalysis, among
others for cell replication, the synthesis of neurotransmitters, and the cell’s energy
metabolism [116]. As a consequence, deficiency is reported to be associated
with a decrease in mental, motor, neurophysiological, and behavioural
abilities [117–120]. Three distinct ID phases can be differentiated: a first stage,
during which body iron stores are reduced, followed by an increase in the amount of
soluble plasma transferrin receptors during a second stage [113]. The last stage of
iron deficiency is defined as iron deficient anaemia (IDA), a condition, in which the
blood’s haemoglobin concentration is decreased and the morphology of red blood
cells altered [113]. The WHO indicates that about 500 million people suffer of
IDA [121]. Iron deficiency is particularly prevalent in the developing world [112],
due to nutritional limitations and the high level of parasitic diseases associated with
blood loss, such as malaria [122]. Nevertheless, iron deficiency is far from being a
condition solely limited to low-resource settings: Within Europe, prevalence of ID
in healthy term infants and toddlers aged 1 to 3 years is reported to be as high
as 26 % [113, 123]. Term infants are born with an iron storage of approximately
75 mg kg-1 body weight, providing a sufficient amount of iron until the infants’ 4th to
6th postnatal months of age [112, 115]. Since human milk contains only small quant-
ities of highly available iron (0.2 − 0.4 mg L-1) [124], intake from external sources is
required to guarantee adequate supply thereafter [124]. This aligns with the Amer-
ican Academy of Paediatrics’ and the World Health Organization’s recommendation
for exclusive breastfeeding until the end of the infants’ 4th and 6th months of age,
respectively [112]. Yet, earlier supplementation is required in infants whose moth-
ers have suffered health conditions leading to lower infant iron stores at the time
of birth, such as anaemia or diabetes during pregnancy as well as for preterm
infants [112]. Since eighty percent of term infants’ total body iron is acquired within
its 29th to 40th week of gestation [112], the amount of total body iron in preterm
infants is decreased at birth based on their reduced gestational age, with subsequent
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depletion during their extensive postnatal growth and rapid blood volume expan-
sion [112, 125]. As a result, preterm infants are at particular risk of developing
iron deficiency within their first six months of life. Elemental iron requirements are
estimated to amount to 2 − 4 mg kg-1 per day [112]. According to Rao et al. a total
of 25 % to 85 % of preterm infants are shown to exhibit iron deficiency during early
childhood [126]. Term infants are susceptible to developing deficiency only following
their first half year of life [112]. Ultimately, supplementation recommendations are
based on the infant’s gestational age and the type of feeding. A summary by Baker
et al. is provided as follows [112]:
1. Healthy, breastfed, term infants: Exclusively and predominantly breast-
fed, healthy term infants are recommended 1 mg of oral elemental iron per kg
body weight per day, starting at the beginning of their fifth postnatal month
until iron-containing foods are introduced.
2. Healthy, formula-fed, term infants: For healthy formula-fed infants
adequate iron supply will be guaranteed for the infants’ first 12 months of
life through the consumption of standard infant formula, characterised by an
iron content of 10 − 12 mg L-1 (see Table 5.1), as well as through introduction
of iron-comprising complementary foods starting between their 4th and 6th
months of age.
3. Breastfed, preterm infants: For exclusively and predominantly breast-
fed preterm infants, supplementation of at least 2 mg elemental iron per kg
body weight per day, from the beginning of the infants’ first to the end of their
twelfth month of age, is required (maximum: 15 mg d-1) [126]. Liquid iron
supplements can be used for exclusively breastfed infants, and in combination
with iron-fortified formula or iron-containing complementary foods.
4. Formula-fed, preterm infants: Iron-fortified formula covers the preterm
infants’ iron supplementation requirements (maximum: 15 mg d-1) [126], and
should be fed until the infants’ first year of age, with iron-containing comple-


























Aptamil First Infant Milk
Powder 0.5
Aptamil Profutura &
Aptamil First Infant Milk
Iron lactate Liquid 0.52 and 0.51
Preterm formula




SMA® PRO Gold Prem 2 Liquid,
powder
0.8
SMA® PRO Breast Milk
Fortifier
Powder 1.8
Cow & Gate Nutriprem 2
Low Birthweight Formula
Powder 1.2
Cow & Gate Nutriprem 1
and 2 LBW Formula
Iron lactate Liquid 1.6 and 1.2
Table 5.1: Iron compounds commonly used in preterm infant formula, term infant
formula, and breast milk fortifiers [127–130].
Supplementation of higher amounts of iron apply for term infants with lower iron
storage at time of birth, for preterm infants <1000 g birth weight, and for infants
with special needs based on their health condition. In contrast, infants having
received blood transfusions require a lower amount of external iron [112, 126]. Ad-
justing external iron supplementation is of importance, as the body - contrary to
other nutrients - is unable to modulate iron excretion, and iron overload is repor-
ted to have negative impact on the infants’ health [120]. For developing countries
with high prevalence of IDA (40 % or higher), the World Health Organization’s
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guidelines for iron supplementation recommend a daily oral dose of 10 − 12.5 mg
of elemental iron for three consecutive months in a year [121]. A summary of most
commonly used compounds in therapeutic formulations for the prevention or treat-
ment of iron-deficiency anaemia in infants is provided in Table 5.2. The effect of
providing external iron to meet the infants’ nutritional needs was widely studied:
among others, iron supplementation during the first six months of life in low birth
weight (LBW) infants decreased iron deficiency at 6 − 12 months of age [119, 131],
as well as the prevalence of infant behavioural problems at both 3.5 years and









Prophylaxis/treatment of iron deficiency
Sytron® Sodium
feredetate
Syrup Preterm and LBW infants
starting 4 weeks after birth
Fersamal® Ferrous
fumarate
Syrup Preterm and LBW infants
starting 4 − 6 weeks after birth
Galfer® Oral
solution
Preterm and term infants
























Drops: from 4 months of age
onward, solution: from 6 months
of age onward
Table 5.2: UK products commonly used for prophylaxis and treatment of iron defi-
ciency, as well as infant vitamin supplements [134–136].
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Siddappa et al. proved that iron deficiency in infants at one year of age is correlated
with slower motor development [116], and Angulo-Barroso et al. that in turn sup-
plementation of 1 mg elemental iron per kg body weight starting at six weeks of age
improved development of motor function [137]. The most commonly used compound
for iron supplementation is ferrous sulphate, also referred to as iron(II)sulphate, due
to its availability and low cost [126]. Ferrous sulphate has the additional advantage
that it may be administered once per day based on its high bioavailability, whereas
other iron compounds require more frequent consumption [126, 138]. It is used in
both fortified food, prophylactic and therapeutic formulations for iron supplement-
ation, and included in the WHO Model List of Essential Medicines and the WHO
Model List of Essential Medicines for Children [25, 99].
Iron was chosen for delivery during breastfeeding simulation experiments presen-
ted in this chapter, due to i) its importance for infant development and health,
ii) the prevalence of iron deficiency in both developing and developed countries,
with particular need for supplementation in breastfed infants.
5.1.3 Hydrogel fundamentals
Use of hydrogels was first suggested for biological applications in the 1960s by
Wichterle and Lim [139]. Such gels are defined as three-dimensional, cross-linked
networks of water-soluble polymers [140], and their characteristic structure are a
result of physical and chemical cross-linking: covalent and hydrogen bonds, van
der Waals bindings, or “physical entanglements” ([139], p. 1639). The ability of a
polymeric network to absorb water is caused by its hydrophilic groups, for example
-OH, -CONH-, -CONH2-, and -SO3H [139, 141]. Since the degree of hydration is
a result of the network’s physiochemical characteristics, it varies based on the net-
work’s composition and environment [139, 142]. Hydrogels are classified based on
a set of characteristics, such as side groups, mechanical, structural and physical
properties, as well as environmental responsiveness (e.g. pH, temperature, ionic
strength) [139]. For applications in biology and pharmaceutics, natural, synthetic,
and combinational polymers are used. Natural polymers have particular advant-
ages based on their biocompatibility and non-toxicity, but are prone to cause un-
desired immune responses [139]. On the other hand, synthetic polymers with their
defined structure lead to the formation of uniform and fine-tunable hydrogels [139].
The porous structure of hydrogels enables their use as drug delivery matrices,
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either through drug loading or through the conjugation of drugs to the hydrogel
network [143]. Use in drug delivery requires the hydrogel to respond to either pH
or temperature [144]. Three different mechanisms of release from hydrogel matrices
can be differentiated: release controlled by i) diffusion, ii) swelling, and iii) chemical
influences [139].
5.1.4 Formulation considerations
Prior to the development of a protocol for hydrogel fabrication, as outlined in the
chapter’s objectives, a suitable polymer system had to be chosen. An overview of
polymers considered for hydrogel formulation and selection criteria are provided in
the following.
(a) Polymer selection. Both the FDA’s GRAS (“Generally Recognized As Safe”)
list and the database of “Indirect Additives Used in Food Contact Substances” were
used as the basis for the identification of polymers considered as safe for hydrogel
fabrication with intended clinical use [145]. Amongst others, six polymer systems
were shortlisted: gelatin, methylcellulose, agar-agar, carbopol, hypromellose, and
sodium alginate cross-linked hydrogels. Each polymer system is discussed in more
detail below. Particular focus is given to its use in paediatric formulations and
research, as well as to gelation temperature. As the gelation temperature of polymer
solutions in water is based on the polymer’s molecular weight and the polymer’s
concentration in solution, only a gelation temperature range is provided.
Gelatin: The natural polymer gelatin is derived through partial hydrolysis of colla-
gen from bovine or porcine bone or skin [146, 147]. The “multi-talent” gelatin ([148],
p. XI) is water-soluble, and often used in medical and pharmaceutical applications
due to its biocompatibility and biodegradable characteristics [148, 149]. Hydrogels
from aqueous gelatin solutions are formed when being cooled down to a temperat-
ure under 30°C following heating, but re-melt again if the temperature is raised to
in-vivo conditions (approximately 40°C) [146, 150]. While chemical cross-linking is
required to increase the chemical and thermal stability of gelatin hydrogels for a
wide range of applications [146], the dissolving characteristics of gelatin at in-vivo
temperatures seem particularly suitable for delivery into human milk. As gelatin is
derived from animals, however, it might not be applicable to individuals of certain
belief or dietary restrictions. Gelatin was reported to be used in both paediatric
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formulations [151] and clinical research in infants aged three months and younger,
including its intravenous use as a gelatin-based plasma substitute during clinical
studies, and as gelatin tannate for the treatment of acute gastroenteritis [152, 153].
Methylcellulose: Methylcellulose is defined as a non-ionic polymer, which is
water-soluble and stable over a wide pH range [154]. It enables gelation of solutions
without precipitation, while exhibiting a long storage stability [155]. Due to these
favourable characteristics, it is commonly used in food, cosmetics, and pharmaceut-
ical products [155]. Among others, methylcellulose was the gelation agent of choice
for large-scale manufacture of the first medical capsules not containing gelatin [148].
In paediatric drug formulations, methylcellulose often serves as a very thin tablet
coating [156, 157]. The sol to gel transition of methylcellulose-water solutions ranges
between approximately 30 − 55°C [158, 159].
Agar-agar: Agar-agar, characterised as one of the oldest agents used for
gelation [148], is derived from algae, a dried smell-, taste-, and often also colour-less
gelatin-like compound [160]. The characteristic gelation of agar-agar is resulting
from its high molecular weight. Standard types of agar-agar dissolve at temper-
atures over 85°C, “fast-dissolving” types of agar-agar regain its liquid state in a
temperature range between 60 − 80°C [148]. Agar-agar was reported to be used in
paediatric gel formulations [161], as well as for the treatment of hyperbilirubinemia
of jaundiced full-term newborns [162].
Carbomer polymers (carbopol): Carbomers are acrylic acid polymers widely
used in the cosmetic and pharmaceutical industry [159, 163]. Advantages of car-
bomer gels are numerous, including a wide viscosity range (with high viscosity at
low carbomer concentrations), thermal stability, and good acceptance by patients
treated with carbomer-containing products [163]. Aqueous carbopol solutions gelate
above its pK a value at pH > 5.5. [159]. Use of carbopol in paediatric research was
previously reported in the literature [164, 165].
Hypromellose: Water-soluble hypromellose, also called Hydroxypropyl Methyl-
cellulose (HMPC), is a non-ionic cellulose ether [166], possessing many favourable
characteristics for use in pharmaceutical products, such as low cost, stability over
a wide pH range (pH 3.0 - 11.0), resistance against enzymes, and controlled release
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properties [166]. Its sol to gel transition occurs at a temperature between 75−90°C,
and is decreased to approximately 40°C through lowering the hydroxypropyl molar
substitution [167]. Within the class of hydrophilic matrices, hypromellose is the
most often utilized cellulose ether [166]. Due to its non-reactive and pH-neutral
properties, it is considered to be safe for the use in neonates [168]. It is commonly
used in paediatric antibiotic eye drops/ointments, aiming at keeping the corneas
moist and at preventing corneal abrasions [169], as well as in commercially available
formulations, such as Bonjela Teething Gel [170].
Sodium alginate: Sodium alginate is a non-toxic, low-cost, and biocompatible
anionic polymer, made by brown algae and bacteria [171, 172], and commonly used
in pharmaceutical and food-grade production [171, 173]. It comprises α-L-guluronic
acid and β-D-mannuronic acid residues, also referred to as G-blocks and M-blocks re-
spectively, linearly linked by 1,4-glycosidic linkages [171]. Gels are formed by cross-
linking the alginate polymer chains chemically and/or physically, whereby ionic
cross-linking, i.e. the exchange of sodium ions from the guluronic acid (G) blocks
with multivalent cations, is the most commonly applied method [171]. A variety
of cations are suitable for cross-linking, but calcium ions are most commonly used
[171, 172, 174, 175]. Elasticity and porosity of the resulting gel are a result of the
number of available G- and M-blocks [171]. Spherification represents one possible
approach of gelation [171, 176]. Three different techniques can be differentiated:
i) basic spherification: whereby an alginate solution is slowly added into a cationic
bath; ii) reverse spherification: whereby a cationic solution is added into an alginate
bath; iii) frozen reverse spherification: whereby a frozen cationic solution is added
into an alginate bath [171, 177]. Reverse and frozen reverse spherification both
enable the formation of hydrogels with a liquid core and a solid shell [176–178]. So-
dium alginate is used in commercially available formulations, and serves for example
as the main ingredient in ’Gaviscon Infant’, a medication used to treat infants aged
1−2 years with gastric regurgitation, gastroesophageal reflux, and reflux associated
with hiatus hernia [179–181].
The final selection was conducted sequentially by i) identifying polymer systems
used in paediatrics, and specifically for infants aged three months and younger,
ii) considering potential limitations of polymer systems (e.g. whether they might
interfere with any religious belief or dietary requirements), iii) taking into account
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the polymer’s characteristics, such as gelation temperature and viscosity. The latter
included considerations such as “Is the polymer system re-melting in human milk
with a temperature of 33.7 − 35.7°C, or will it release the in-vivo tracer through
diffusion or mechanically induced disintegration?” and “Is the polymer system vis-
cous enough to remain within the nipple shield, or would it likely drip out of the
nipple shield before the breastfeeding process?” Table 5.3 illustrates an overview of
important polymer characteristics, influencing polymer selection, including viscosity
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5.0 - 40.0 [187]








Table 5.3: Overview of polymer characteristics and factors considered for hydrogel
selection. Selection was based on the polymer’s properties required for delivery
during breastfeeding, as well as the polymer’s use in paediatrics, and particularly
neonatology. Thereby, “x” is indicating the applicability of a characteristic for the
relevant polymer system.
From Table 5.3, the following ranking of polymer suitability for use within an ultra-
thin contact nipple shield was created:
76
Chapter 5
1. Sodium alginate (cross-linked with calcium ions): The potential to create
hydrogels with a liquid core through reverse spherification, enabling burst
release upon mechanically induced rupture, was regarded as the most desired
option to further investigate.
2. Hypromellose: Due to its wide viscosity range and common use in paediat-
ric formulations and neonatal treatments, hypromellose was seen as a polymer
system of great interest for delivery into human milk. However, potential dif-
ficulties were projected to arise with regard to the duration of delivery, since
the overall properties of hypromellose support controlled as opposed to rapid
release.
3. Gelatin: The natural polymer gelatin was regarded as a suitable polymer
system based on its frequent use in medical and pharmaceutical applications.
Its ability to re-melt at in-vivo conditions following gelation was regarded as
particularly ideal for use with human milk at body temperature. Yet, since
gelatin is derived from bovine or porcine bone or skin, potentially interfering
with religious belief and diet preferences, its suitability was believed to be
limited.
(b) Crosslinker calcium and its physiological relevance. Due to sodium
alginate being ranked as the most favourable polymeric system for hydrogel fabric-
ation by means of spherification, the following paragraph provides further insights
into the physiological importance of its crosslinker calcium. Since excipients used in
commercially available paediatric formulations do not commonly possess additional
health benefits, the positive contribution of calcium on infant health was seen as a
particular advantage.
Calcium constitutes 1.9 % to the human body weight, whereby 99 % can be found
as calcium hydroxyapaptide in bones and teeth, contributing to their structure
and function [190]. The remaining 1 %, of which 0.9 % are present in cells and
0.1 % in extracellular fluid, fulfils vital metabolic processes, including muscle func-
tion, secretion of hormones, vascular contraction and vasodilation [190]. Calcium
is also referred to as a “threshold nutrient”, because an increase in bone mass with
increasing calcium consumption levels off after reaching its threshold requirements
for bone mechanics, and subsequently any excess calcium is excreted [191]. Human
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milk is considered to be the ideal source of calcium for term infants, exhibiting a
higher calcium bioavailability than bovine milk or formula [191, 192]. The aver-
age daily amount of calcium consumed by an exclusively breastfed infant amounts
to 200 − 300 mg [190], fulfilling the adequate intake recommendations for infants
of 0 − 12 months of age [192, 193]. Infants born prematurely, however, exhibit
higher calcium requirements, which cannot be met through human milk consumption
alone [191, 192]. In particular infants with less than 1500 g body weight at the time
of birth, also referred to as very low birth weight (VLBW) infants [194], are in
need for both calcium and phosphorus supplementation to ensure sufficient supply
for bone mineralization [191]. As fetal calcium consumption increases significantly
during the third trimester of gestation, reaching its peak of 100 − 120 mg kg-1 d-1 at
30 − 36 weeks of gestation, an infant born at 24 − 26 weeks will only possess 20 %
of a full-term infant’s whole-body calcium [191]. Literature indicates that fortifica-
tion, for example by mixing powdered fortifiers or liquid formulas with high-mineral
content and human milk, has beneficial effects for infants of less than 1500 g birth
weight [191, 192]. For bottle-fed infants, a variety of calcium-enriched formulas
exist [190–192]. The use of such formulas even following discharge is suggested
in the literature, but guidance about the optimal concentration and duration does
not exist [192]. WHO recommendations exclusively relate to the first month of
life, comprising a supplementation of 120 − 140 mg kg-1 per day [194]. The World
Health Organization recognises that supplementation is of particular importance
in low- and middle-income countries, where calcium deficiency is prevalent across
all age groups [195], and includes calcium gluconate in the complementary listing
of the WHO Model List of Essential Medicines and the WHO Model List of Es-
sential Medicines for Children [25, 99]. Using alginate gels fabricated by means of
reverse spherification and frozen reverse spherification, might therefore also have the
potential to contribute to supplementation efforts in breastfed infants, enabling to
encapsulate calcium concentrations higher than those needed for spherification.
5.2 Materials and methods
5.2.1 Materials
(a) Human milk. Experiments were conducted using human milk characterised
in Chapter 4, containing a protein content of 16.51 g L-1 and a lipid content of
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43.52 g L-1. The Cambridge Human Biology Research Ethics Committee at the Uni-
versity of Cambridge ethically approved all human milk sample use (HBREC.2012.01).
Prior to breastfeeding simulation, human milk was thawed for 48 h at 4°C.
(b) Nipple shield. Based on findings in Chapter 3, demonstrating maternal pref-
erence for the use of commercially available ultra-thin contact nipple shields for
therapeutic delivery during breastfeeding, as well as limitations of modified lip-
containing devices, research in this chapter was conducted using a medium-sized
(20 mm) commercially available ultra-thin contact nipple shield (Medela, UK).
(c) Hydrogel fabrication. For hydrogel preparation, low viscosity alginic acid
sodium salt in FCC grade (G:M ratio in the range of 61 − 65 : 39 − 35) was ob-
tained from Alfa Aesar (Lancashire, UK), calcium lactate pentahydrate from Sigma
Aldrich (Dorset, UK), salicylic acid and iron(III)sulphate pentahydrate from Fisher
Scientific (Leicestershire, UK). A preference was given to i) iron(III)sulphate over
iron(II)sulphate to prevent potential competition with Ca2+ during cross-linking
and to facilitate subsequent iron analysis, ii) calcium lactate pentahydrate over
other calcium salts, such as calcium chloride or calcium lactate gluconate, based on
its neutral taste and low cost [196].
5.2.2 Hydrogel preparation
The following solutions were prepared: i) A 0.5 % sodium alginate solution of low
viscosity alginic acid sodium salt in double deionized water (DDI). The solution
was kept at 4°C over night to remove air bubbles formed during mixing. ii) A
1 % calcium lactate pentahydrate solution, additionally containing 60 mg mL-1
ferric sulphate pentahydrate in DDI water. 500 µL solution was pipetted into each
hemispherical impression of a food-grade silicone mould, measuring approximately
2.5 cm in diameter and 1 cm in depth. The filled mould was kept at -20°C for at least
5 h. Gelation occurred when a frozen calcium lactate ferric sulphate hemisphere
was introduced into a 4°C sodium alginate bath for 2.75 min, and access sodium
alginate rinsed off through transferring formed gels into a DDI water bath. All




5.2.3 Hydrogel characterisation procedures
(a) Compression testing. Mechanical characterisation of manufactured liquid-
core hydrogels was performed by means of uniaxial compression testing. Experi-
ments were conducted in octuplicate using a H5Ks electric screw machine (Tinius
Olsen, Redhill/UK) fitted with a 5N load cell. Hereby, the manufactured hydro-
gel was positioned on a flat surface, following which a flat plate applied vertical
compression until the gel’s plastic region of formation was reached. The setup is
illustrated in Figure 5.4 a). A crosshead speed of 2 mm min-1 was chosen, and force
displacement data recorded. Because of the complex nature of liquid-core hydro-
gels, no other mechanical properties were evaluated. Measurements were performed
together with Andrew Rayment, Department of Material Science and Metallurgy,
University of Cambridge.
(b) Visual characterisation. A bespoke optical system, consisting of a high-speed
camera (Basler, Ahrensburg/Germany) and a National Instruments card (NIC, Na-
tional Instruments, Austin, TX/USA) controlled via a LabVIEW software pro-
gramme, was used to enable visual analysis of the gels’ rupture mechanism and
morphology. Calibration was performed by determining the number of pixels and
the distance in mm between the top and bottom compression plate. The resulting re-
lationship was used to calculate the hydrogels’ average wall thickness, diameter, and
height in quadruplicate based on images taken before compression testing. Hereby,
wall thickness measurements made use of the difference in colour strength of the
gel’s core and shell when visualised via the LabVIEW programme. This enabled
recognition of the solid core’s boundary. Measurements were performed together
with Andrew Rayment, Department of Material Science and Metallurgy, University
of Cambridge.
5.2.4 Breastfeeding simulation procedures
(a) Breastfeeding simulation. Delivery of iron(III)sulphate pentahydrate into
DDI water and human milk was conducted in triplicate using the breastfeeding sim-
ulation apparatus by Gerrard et al. [42]. The apparatus was operated as previously
described in Chapter 4, whereby fractions were collected for a duration of 10 sec
each, and recovery into approximately 10 g of human milk investigated. To explore
the potential of hydrogel delivery for preterm infants, who were shown to poten-
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tially benefit from the use of nipple shields to establish breastfeeding and increase
milk transfer [37], the pressure values for breastfeeding simulation were adjusted in
alignment with literature by Geddes et al. [197, 198]. A comparison of pressure
values for term and preterm infants is illustrated in Table 5.4. Figure 5.1 illustrates
exemplary average pressure profiles during breastfeeding simulation.
Pressure Term infant Preterm infant (min, max)
Baseline [mmHg] −56.4 ± 31.4 [22],
−64 ± 45 [21]
−31.1 (−60.0, −12.7) [198]
Peak [mmHg] −163.2 ± 62 [22],
−145 ± 58 [21]
−106.2 (−153.0, −65.5) [198]
Mean vacuum
[mmHg]
−114 ± 58 [21] −53.6 (−89.3, −31.5) [198],
−40.6 ± 27.8 (−126.4 , −0.4) [197]
Table 5.4: Pressure values during breastfeeding for term and preterm infants. Pres-
sure values for preterm infants are based on two studies by Geddes et al. with
infants born at 23.6 − 33.3 weeks of gestation [197, 198]. While one study included
38 infants at 5.9 ± 3.8 weeks postnatal age (1.0 − 16.3 weeks), who were able to
successfully latch and suck at the breast [197], the other study consisted of 17 in-






































Figure 5.1: Exemplary pressure profiles during iron(III)sulphate pentahydrate de-
livery into a) DDI water and b) human milk, using the breastfeeding simulation
apparatus. Pressure profiles are depicted for 10 s at t = 90 − 100 s.
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Profiles obtained align with clinically obtained data for preterm infants
([197], Figure 5). During breastfeeding simulation, mean peak vacuum values of
-64.62 ± 5.37 mmHg and -62.47 ± 1.76 mmHg, as well as mean baseline vacuum
values of -1.01 ± 0.34 mmHg and -0.92 ± 0.37 mmHg for delivery into DDI wa-
ter and human milk respectively were recorded. The mean average vacuum was
-42.91 ± 9.97 mmHg and -38.30 ± 9.71 mmHg for delivery into DDI water and
human milk.
(b) Iron detection and data analysis. Iron(III)sulphate pentahydrate in DDI
water and human milk, including both samples collected during breastfeeding sim-
ulation experiments as well as prepared standards with known concentrations for
data processing, were quantitatively analysed in triplicate as follows: 1 M hydro-
chloric acid was added in a ratio of 1 : 8 to the sample to achieve i) precipitation
of the human milk’s casein (isoelectric point: pH 4.7), ii) release of iron bound to
transferrin, a protein naturally present in human milk [199, 200]. Following mixing
by vortexing, all samples were centrifuged for 7 min at 16,112 x g. The resulting
samples contained precipitated casein and clear supernatant, enabling detection of
ferric sulphate by means of spectrophotometric analysis. From the resulting super-
natant, 20 µL were transferred to 180 µL of DDI water and 1700 µL of 0.1 % salicylic
acid solution added. Subsequently, absorbance of ferric salicylate in each sample was
measured at room temperature at λmax = 524 nm. The wavelength of maximum
absorbance was evaluated by means of absorbance scans of all calibration samples
over the wavelength range of λ = 328 − 1000 nm. An illustration of corresponding
absorbance scans and calibration curves at ferric salicylate’s maximum absorbance
in DDI water and human milk can be found in Figure 5.2. Each point represents
the average conductivity of triplicate measurements for a given concentration. The
calibration curve in DDI water was also used to assess the total amount of fer-
ric sulphate pentahydrate loaded into the liquid-core hydrogels. For this purpose,
frozen hemispheres were melted, weighted, diluted 1:1 in DDI water, and their iron
sulphate pentahydrate concentration evaluated by means of absorbance measure-
ments at λmax = 524 nm. Analysis was performed in triplicate, yielding a total of
29.59 ± 0.43 mg iron(III)sulphate pentahydrate contained within manufactured
liquid-core hydrogels, equivalent to 6.75 ± 0.10 mg of elemental iron. Based on
measured absorbance values of fractions collected during breastfeeding simulations,
release profiles were generated. Release profiles include the cumulative iron(III)-
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sulphate pentahydrate recovery of each experiment, represented as a percentage of
the total amount encapsulated within the liquid-core gel, as well as the normalised
proportion of iron(III)sulphate pentahydrate released in each fraction over time. To
do so, the amount of iron (III)sulphate pentahydrate in each fraction was assessed by
means of absorbance measurements at λmax = 524 nm using the calibration curves
in Figure 5.2, and normalised to the total amount of ferric sulphate pentahydrate
used for liquid-core hydrogel manufacture.
a) b)
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Figure 5.2: Absorbance scan for iron(III)sulphate pentahydrate samples of known
concentration at λ = 328 − 1000 nm in a) DDI water and c) human milk. The
ferric salicylate’s maximum absorbance occurred at λmax = 524 nm. Calibration
curve of iron(III)sulphate pentahydrate in b) DDI water and d) human milk at
λmax = 524 nm. All samples were pre-processed by adding hydrochloric acid to
the sample (1:8) to enable absorbance measurements following casein precipitation.
Each data point represents the average of triplicate measurements. Modified image
originally published in [47].
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To obtain i) a graph illustrating the normalized release in each fraction over time,
values were plotted for each fraction without further processing, ii) a cumulative




Fabrication of liquid-core hydrogels containing ferric sulphate was achieved by means
of frozen reverse spherification. The fabrication protocol was iteratively adapted,
including the following variables: i) type of spherification technique used to ob-
tain reproducibly uniform spheres, ii) ratio of iron(III)sulphate pentahydrate to cal-
cium lactate pentahydrate, in order to minimize precipitation of either compound,
iii) duration of gelation to control wall thickness (increasing with increasing gela-
tion time) and liquid-core content available for delivery, iv) size of the hydrogel in
order to maximize its liquid load, but to also enable sufficient milk flow through
the nipple shield’s silicone teat. Spherification and compound ratio were assessed
visually, while the variables gel size and gelation time were evaluated by means of
breastfeeding simulation experiments. Optimising the fabrication process aimed at
providing the required stability for gel handling, while at the same time maintaining
the gel’s mechanical sensitivity to enable rapid rupture. A range of gelation times
between 1 min to 5 min were assessed, and gels stable enough for handling tested
by means of breastfeeding simulation experiments. Shorter gelation duration was
required for smaller amounts of liquid to be encapsulated than for larger amounts in
order to achieve the same hydrogel stability. Each impression within the food-grade
silicone mould was filled with 500 µL of the prepared calcium lactate pentahydrate
and iron(III)sulphate pentahydrate solution, and subsequently frozen at -20°C. Gel
formation occurred when the frozen hemisphere was exposed to a 4°C sodium algin-
ate bath for 2.75 min. An illustration of the gel’s manufacturing process is provided
in Figure 5.3. Gelation occurs through an exchange of sodium ions from the gu-
luronic acid blocks of alginate with calcium cations from the frozen hemisphere,












Figure 5.3: Schematic of the frozen reverse spherification process for the manu-
facture of iron(III)sulphate pentahydrate liquid-core hydrogels. One alginate chain
can be linked with several other chains through calcium cations and form a three-
dimensional gel network [171]. Image originally published in [47].
5.3.2 Compression testing and visual characterisation
Figure 5.4 b) illustrates a typical force-displacement graph, Figure 5.5 displays the
gel’s rupture during compression testing. Release of the hydrogel’s liquid core occurs
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Figure 5.4: a) Simplified schematic of the experimental setup used for uniaxial
compression testing of manufactured liquid-core hydrogels. b) Representative force-
displacement graph for liquid-core sodium alginate hydrogels, fabricated via frozen
reverse spherification. Image originally published in [47].
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Average values for wall thickness, diameter, and height of manufactured liquid-core
hydrogels, as well as compression force required for gel rupture are summarised in
Table 5.5. Obtained values are compared to previously published data of both
i) rapidly disintegrating tablets for zinc delivery into human milk by Scheuerle
et al. [4], ii) Liquid-core alginate Hydrogel Beads by Tsai et al. [176, 178, 201].










0.44 ± 0.10 a Not provided N/A
Diameter
[mm]
14.28 ± 0.85 a Range:




4.91 ± 0.28 a 4.65 ± 0.03
Compression
force [N]
0.245 ± 0.103 b 1.26 d [176] 22, 000
Table 5.5: Overview of average wall thickness, diameter, height, and compression
force of liquid-core hydrogels used for iron sulphate delivery into DDI water and
human milk. Data obtained was compared to literature data by both Scheuerle
et al. and Tsai et al., using rapidly disintegrating tablets for zinc delivery into
human milk [4], and Liquid-core alginate Hydrogel Beads (LHBs) for chlorogenic
acid delivery into simulated intestinal fluid [176, 178], respectively. Table originally
published in [47].
a Values were measured in quadruplicate.
b Values were measured in octuplicate.
c Values taken from [4], referring to tablet type 2.







Figure 5.5: Illustration of the liquid-core hydrogel’s deformation during compres-
sion testing. Rupture and release of the hydrogel’s liquid core occurs following the
formation of a pinhole in image f). Image originally published in [47].
5.3.3 Release of iron from liquid-core hydrogels
Breastfeeding simulation experiments evaluated both the delivery into DDI water
and human milk. The amount of DDI water and human milk passed through the
nipple shield, and absolute recovery data, are summarised in Table 5.6.
Recovery
achieved [%]
Amount of fluid passed
through the device [g]
Ddi water 54.43 ± 4.16 10.45 ± 0.14
Human milk 44.35 ± 5.43 10.58 ± 0.09
Table 5.6: Recovery achieved and fluid passed through the nipple shield for the




An approximately 10 % increased recovery of ferric sulphate pentahydrate was
achieved into DDI water compared to delivery into human milk. Figure 5.6 illus-
trates the cumulative normalised proportion of ferric sulphate pentahydrate released
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Figure 5.6: Release of ferric sulphate from sodium alginate hydrogels into DDI water
and human milk. a) Cumulative normalised proportion of ferric sulphate released.
b) Normalized proportion of ferric sulphate released in each fraction over time.
Release is represented as a percentage of the total amount loaded within the sodium
alginate hydrogels to the total amount released. Each set of points represents the
average of three experiments, using the mean of absorbance triplicate measurements
for each fraction shown.
5.4 Discussion
Despite the hydrogel’s rapid release properties, full release during breastfeeding
simulation experiments within 2 min was not achieved. Potential reasons for iron
retention include a combination of both iron precipitation and iron inclusion within
the shell’s solid core. Liquid-core hydrogels possess a range of advantages, but also
require further considerations for improvement.
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Recovery and iron retention. In spite of the incomplete delivery from liquid-
core hydrogels, recovery of ferric sulphate pentahydrate achieved within 2 min of
breastfeeding simulation was superior to previously studied dosage forms. Release
of zinc sulphate pentahydrate from rapidly disintegrating tablets and non-woven
fibres in approximately 10 g of human milk (equivalent to 2 min of breastfeeding
simulation) resulted in only 3 − 5 % and 29 − 31 % recovery, respectively [4, 38].
Gradual release as opposed to burst release can be attributed to the hydrogel’s
release mechanism, visualised during uniaxial compression testing, which merely
entails the formation of a pinhole in the hydrogel’s solid shell. As small amounts of
ferric sulphate pentahydrate were still released after 10 g of human milk had passed
through the nipple shield, it can be hypothesised that marginal liquid residues
were still contained within the gel’s solid shell. At the same time, the difference
between the amount loaded into the hemispherical silicone mould as part of the hy-
drogels’ fabrication process, and the amount recovered in collected fractions during
breastfeeding simulation, results from a combination of both iron retention within
the hydrogel’s core shell, as well as within the complex apparatus’ network. The
former is a result of ferric sulphate being enclosed within the cross-linked alginate
polymer chains, with the gel’s solid shell being retained in the nipple shield dur-
ing experimental procedures. Iron-casein precipitates occur when ferric sulphate
comes in contact with human milk, as Fe3+ causes the neutralization of the ca-
sein’s negative charge by binding to its Pser clusters [202]. Since resuspension of
precipitated casein can only be achieved in collected fractions by adjusting the pH
during pre-analysis processing, precipitated ferric sulphate trapped within the ap-
paratus cannot be recovered. Comparing both the absolute recovery achieved during
breastfeeding simulation experiments into human milk and into DDI water respect-
ively, about 10 % of undelivered ferric sulphate pentahydrate can be attributed
to such precipitation effects. Although in-vitro experiments yielded only insuffi-
cient delivery of the loaded dose, it has to be noted that a breastfed infant would
be directly latched onto the nipple shield, which contains the hydrogel, preventing
loss of therapeutic precipitates, and would feed for a seven times extended period
of time, as shown by Kent et al. [40].
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Advantages. In addition to their release properties, liquid-core hydrogels are char-
acterised by distinct advantages, indicating their preferred use as a dosage form for
therapeutic delivery from a nipple shield during breastfeeding. Firstly, liquid-core
hydrogels are the first dosage form studied during breastfeeding simulation that
enable therapeutic release by means of a mechanically induced release mechanism,
i.e. the rupture of the hydrogels’ solid shells as a result of flow rate, suction fre-
quency, and vacuum applied. Comparison of manufactured gels to LHBs by Tsai
et al. [176, 178] indicated a five-fold lower compression force needed to initiate
rupture, presumably caused by the comparatively large amount of liquid enclosed
within the manufactured hydrogels, leading to a marginal sphericity. The larger
diameter of liquid-core hydrogels enables their central positioning within the nipple
shield teat, and also increases the dosage form’s surface area for human milk contact
and hence subsequent rupture. Liquid-core hydrogels consequently address previous
limitations of rapidly disintegrating tablets, non-woven fibres, and HPMC capsules
for which the milk’s fat content, homogeneity, and macromolecule composition signi-
ficantly altered the dosage form’s release properties. As milk composition is known
to vary among others based on the maternal diet and the stage of lactation [39], the
dependence of absolute recovery on the milk’s properties was perceived as particu-
larly problematic for the exploration of suitable formulations and the definition of
widely applicable findings. In addition, sodium alginate hydrogels manufactured via
frozen reverse spherification enable the production of low-cost dosage forms, using
both a biocompatible, non-toxic polymer and the essential element calcium in form
of calcium lactate, particularly advantageous for infant therapeutic formulations due
to its neutral taste [196]. Since manufacture of liquid-core hydrogels does not require
use of harmful or problematic excipients often present in other infant formulations,
they might serve as a possible response to the consistently emphasized need for more
appropriate paediatric formulations and their inclusion into pharmaceutical product
portfolios [87, 157]. When considering the chosen therapeutic as part of this study,
ferric sulphate delivery from a nipple shield during breastfeeding seems particularly
suitable, as prolonged exposure of iron to milk products over time, e.g. through milk
or yoghurt supplementation, results in both undesired change of odour and flavour,
as well as the milk’s rancidity due to iron-induced lipid oxidation [202].
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Considerations: Three additional areas of discussion arise with regard to the hy-
drogels’ potential in-vivo use: taste masking requirements, implications of the hy-
drogel’s soft texture, as well as improvements of stability and calcium/therapeutic
solubility. Although fast release of therapeutics is preferred to enable the deliv-
ery of a full dose even during short feeds, it also increases the overall ratio of
human milk to therapeutic, reinforcing the concern that bitter or irritating tast-
ing medication could negatively affect the infant’s breastfeeding compliance. While
liquid-core hydrogels enable 38.16 ± 0.06 % absolute ferric sulphate pentahydrate
recovery already within the first minute of breastfeeding simulation, it is important
to note that breastfed infants are acquainted with a wide range of tastes as a result
of the maternal diet [84, 85], and that human milk itself comprises taste masking
properties [86]. Likewise, encapsulation of commercially available paediatric liquid
formulations, characterised by already optimised taste masking properties to enable
their delivery by means of oral syringes or dosing spoons for neonates and tod-
dlers respectively, provides a feasible means to address taste masking concerns and
serves as a potential mitigation strategy. The hydrogel’s soft texture also enables to
mitigate potential infant or maternal discomfort due to large solid tablets or cap-
sules within the nipple shield’s teat. The potential to use commercially available
nipple shields for therapeutic delivery during breastfeeding is believed to enhance
user acceptability over a modified nipple shield device. Final areas of considera-
tion comprise both the liquid-core hydrogel’s stability and shelf life characteristics,
as well as calcium/therapeutic solubility. According to Tsai et al., the former can
be improved via a secondary gelation step [176, 178, 201], whereby hydrogels are
immersed into a Ca2+ solution following cross-linking to enable the permeation of
Ca2+ into the previously unoccupied blocks within the hydrogels’ core shell struc-
ture [201]. This approach was shown to increase hardness and storage stability of
LHBs produced by means of reverse spherification, but likewise also decreased the
rate of encapsulated therapeutic release over time [176, 178, 201]. It has to be noted
however, that experiments by Tsai et al. were conducted without agitation, and that
the environment during breastfeeding simulation, exposing hydrogels to repetitive
mechanical stress, is of a significantly different nature [176, 178, 201]. Consequently,
it can be hypothesised that secondary gelation has the potential to significantly im-
prove the hydrogel’s mechanical stability for handling and storage purposes, while
at the same time causing a less pronounced alteration in therapeutic release. In
fact, findings by Scheuerle et al. give reason to expect an even improved rate of
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therapeutic release during in-vivo breastfeeding, as infant tongue peristalsis, shown
to be an important driver for dosage form disintegration [43], cannot be mimicked
using the breastfeeding simulation apparatus. Solubility considerations refer to the
overall availability of calcium lactate pentahydrate for hydrogel gelation, which can
be affected by both the temperature decrease during the spherification’s freezing
step, as well as the solution’s overall concentration of calcium lactate pentahydrate
and therapeutic. Since calcium ions are required to enable gelation, therapeutic- and
concentration-dependent effects make it necessary to consistently optimise both the
cross-linking protocol and the chosen concentration of calcium lactate pentahydrate
with respect to the type and concentration of therapeutic used.
5.5 Conclusion
Liquid-core hydrogels for the delivery of iron sulphate pentahydrate were fabricated
by means of frozen reverse spherification. When tested during breastfeeding simula-
tion experiments, a total recovery of 44.35±5.43 % and 54.43±4.16 % was achieved
after 10.58±0.09 g human milk and 10.45±0.14 g DDI water respectively had passed
through the hydrogel-containing nipple shield. These results highlight their superior
release properties to previously studied dosage forms. In addition, sodium alginate
calcium lactate hydrogels benefit from their low cost, ease of fabrication, and high
safety profile. Based on the hydrogel’s soft texture and its compatibility with a
commercially available nipple shield, an enhanced acceptability for in-vivo use may
be anticipated. Additional research is needed to increase the hydrogel’s stability
characteristics to facilitate both hydrogel handling and storage.
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Work presented in this chapter was encouraged by the positive feedback of par-
ents and nursing staff as part of the qualitative descriptive study, presented in
Chapter 3, and furthers previous in-vitro research conducted at the Department of
Chemical Engineering and Biotechnology. While in-vitro breastfeeding simulation
experiments are an important component for research and development, breastfeed-
ing is a complex process with significant differences between mother-infant dyads,
ultimately limiting lab-based simulation validity. The single-centre study presented
in this chapter therefore aimed to investigate therapeutic delivery during breast-
feeding in a clinical context, focusing on both its feasibility as well as maternal
expectation, experience, and acceptability. The following objectives where defined:
1. Primary objective: demonstration of therapeutic delivery during breastfeed-
ing. (Endpoint: change in systemic concentration post study feed)
2. Secondary objective: evaluation of mothers’ perspective on therapeutic deliv-
ery during breastfeeding. (Endpoint: qualitative/quantitative assessment of
maternal views pre and post study feed)
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6.1.2 Tracer molecule considerations
Prior to experimental considerations for therapeutic delivery to infants during breast-
feeding, as outlined in the chapter’s objectives, a suitable tracer molecule had to
be chosen. An overview of compounds considered for delivery from an ultra-thin
contact nipple shield, and applied selection criteria are provided in the following.
(a) In-vivo tracer selection. To identify a suitable therapeutic for delivery and
subsequent in-vivo detection, tracer molecules reported in published literature and
those commonly used in clinical diagnostics were considered. Amongst others four
different in-vivo tracers were shortlisted: D-xylose, [1]-13C-glucose and [6,6]-2H2-
glucose, as well as vitamin B12. Each tracer molecule is discussed in more detail
below. Particular focus was given to their use in paediatric practice, as well as their
associated risk profile.
D-xylose: In a clinical setting, D-xylose is commonly used to detect diseases of the
upper intestine, which result in a decreased uptake of sugar molecules (“malabsorp-
tion test”). Xylose is a 5-carbon monosaccharide that is absorbed in the duodenum
and jejunum, nearly not metabolized, and eliminated renally [203, 204]. Generally,
a concentration of 0.4 g D-xylose kg-1 body weight (with a maximum dose of 5 g
D-xylose) is used [203]. Although side effects like diarrhoea, vomiting, nausea, and
flatulence are possible, previous research has reported no to minimal side effects
when using a dose of 5 g D-xylose [203]. In neonates and infants, D-xylose has
been used to detect pathological conditions of gut absorption, as well as to invest-
igate gut permeability, during paediatric surgery, or with focus on its development
in preterm neonates [204, 205]. In-vivo samples are usually analysed following a
5-hour long urine collection based on an adapted protocol by Roe and Rice, whereby
D-xylose forms a pink colour, which can be read at 520 nm on heating with para-
bromoaniline [206, 207]. Approximately 25 % can be expected to be recovered in
healthy subjects [206, 207].
13C- and 2H-labelled glucose: Metabolic isotope tracers are defined as mo-
lecules identical in chemistry and function to their naturally occurring in-vivo coun-
terpart, which only differ in their stable or radioactive isotope label [208]. Generally,
non-radioactive isotope tracers are preferred, due to fewer side effects and their wide
applicability for a variety of kinetic investigations within the human metabolism.
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Most commonly, hydrogen, carbon, and nitrogen isotopes are used for in-vivo kinetic
studies, with tracers exhibiting a heavier weight than their corresponding tracees,
the naturally occurring unlabelled molecules [208]. Based on the weight difference of
tracer and tracee, the tracer to tracee ratio (TTR, also referred to as “enrichment”)
can be evaluated by means of Gas Chromatography/Mass Spectrometry (GC/MS)
or Liquid Chromatography/Mass Spectrometry (LC/MS) [208, 209]. For research
in this chapter particularly [1]-13C- and [6,6]-2H2-glucose were considered as tracer
molecules, both of which were used in neonatal research or diagnostics before. Use
of 13C labelled compounds (here: 13C-octanoic or 13C-acetic acid) is most commonly
known as part of the 13C-breath test to evaluate gastric emptying [210, 211], while
literature also reports the use of 13C-labelled glucose for 13C magnetic resonance
scans (MRS) in neonates and children [212–214], and to investigate pulmonary sur-
factant kinetics of the newborn infant [215]. [6,6]-2H2-glucose is a common tracer
molecule in clinical research of glucose and amino acid metabolism in infants and
neonates [208]. Past literature reported its application as a tracer to study intra-
venous amino acid intake in very low birth weight infants [216], as well as infantile
hypoglycaemia in infants born small for gestational age [217], and in preterm in-
fants (gestational age between 26 to 36 weeks) [218]. Only milligram amounts of
both [1]-13C- and [6,6]-2H2-glucose are needed for in-vivo applications, differing in
price: 3 g of [1]-13C-glucose amount to £509 (Sigma-Aldrich, Dorset, UK), 5 g of
[6,6]-2H2-glucose to £360 (CK Isotopes Ltd, Ibstock/UK).
Vitamin B12: Vitamin B12, transformed into cobalamin, is an important cofactor
for the two enzymes methionine synthase and L-methylmalonyl-CoA mutase: Me-
thionine synthase enables the methylation of homocysteine to methionine, requiring
B12 in the form of methylcobalamin, while L-methylmalonyl-CoA mutase is respons-
ible for the “reversible rearrangement” ([219], p. 312) of methylmalonyl-CoA to
succinyl-CoA, requiring B12 in the form of 5’-deoxyadenosylcoba-
lamin [219, 220]. Since the human body cannot synthesize vitamin B12, supply
has to be met through the consumption of animal products, such as fish and meat,
as well as egg and dairy products [219, 221]. Deficiency can be inherited, occur as
a result of vegan or vegetarian diet, or due to an abnormal absorption in the small
intestine [219, 221], causing an accumulation of the precursors of both previously
mentioned processes. This accumulation subsequently leads to a disruption of both
DNA synthesis, the production of red blood cells, as well as the central nervous
95
Chapter 6
system’s development [219]. A particular risk for vitamin B12 deficiency exists for
breastfed infants of a strictly vegetarian or vegan mother, as their B12 store is gen-
erally low at birth and cannot be increased due to low amounts of vitamin B12 in
their mother’s human milk [220]. Vitamin B12 has no reported toxicity, even being
safe when administered at 300 − 3000 times the recommended dietary allowance
through intramuscular injection [220].
Table 6.1 provides an overview of important tracer characteristics, including the
method of detection, costs, its use in neonates, and its suitability for delivery from
a nipple shield during breastfeeding. The final selection was conducted sequentially
by i) identifying tracers suitable to be delivered from a nipple shield, ii) taking into


































3.71 442 − 496 1.04 0.12
ns use x x x
Table 6.1: Overview of tracers considered for the proposed feasibility study and key
characteristics with relevance for selection. Thereby, “x” is indicating the applicab-
ility of a characteristic for the relevant tracer; BW stands for “body weight”, NS for
“nipple shield”.
*Note: Cost per dose is shown exemplary for an infant of 4 kg BW.
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With exception of the CE-manufactured sublingual vitamin B12 tablets listed in
Table 6.1, expenses refer only to the purchasing costs of the respective tracers in
pharmaceutical grade powder form, and additional costs need to be considered for
dosage form manufacture. From Table 6.1, the following ranking of tracer molecules
suitable for delivery from a nipple shield during breastfeeding was created:
1. Vitamin B12: Due to its importance for infant health and development, its
non-toxicity, commercial availability as a solid dosage form, and alignment with par-
ents’ and nurses’ preference for the delivery of vitamins from a nipple shield during
breastfeeding (see Chapter 3), vitamin B12 was considered as the favourable in-vivo
tracer to be administered during the feasibility study. Its commercial availability in
form of tablets was perceived as particularly advantageous, as it reduces potential
risks and challenges associated with self-preparing formulations for clinical use.
2. [1]-13C-glucose and [6,6]-2H2-glucose: Both tracer molecules were con-
sidered to be feasible for delivery during breastfeeding. While [1]-13C-glucose was
perceived as advantageous with regard to its less invasive mode of detection (pos-
sibility of detection through both breath test and blood test as opposed to exclusive
blood sampling for [6,6]-2H2-glucose detection), [6,6]-2H2-glucose was more cost-
effective. Although both labelled glucose molecules could serve as an in-vivo tracer
for the proposed feasibility study, it was anticipated that their use might make
parents more reluctant to provide their consent for participation. Projected reas-
ons included amongst others worries about the use of an “unknown” molecule which
might be perceived as “harmful” by parents, and which does not provide any benefits
to their infants’ health. At the same time, interaction with parents in the University
of Cambridge Addenbrooke’s Hospital had shown that use of the words “isotope”
or “tracer” were discouraging parents from being interested in the study. In addi-
tion, intended use in the feasibility study would require costly CE-manufacture of
[1]-13C-glucose or [6,6]-2H2-glucose containing solid dosage forms.
3. D-xylose: Delivery within a nipple shield for potential in-vivo application was
identified as problematic, as the required amount of 5 g cannot be fitted within
the silicone teat of a medium-sized commercially available nipple shield. Since only
smaller amounts of D-xylose could be delivered from a nipple shield during breast-
feeding, recovery of D-xylose in the infants’ urine might subsequently be below the
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detection minimum. As a consequence, suitability of D-xylose as a tracer molecule
was believed to be limited.
6.1.3 Blood sampling and assay considerations
In order to identify the blood sampling time at which maximum absorption of ad-
ministered vitamin B12 delivery is achieved, literature on the mechanism of vitamin
B12 absorption in both adults and neonates was reviewed.
Absorption in adults: The process of absorption in adults is mediated by
a vitamin B12-binding protein called intrinsic factor (IF), and requires the pres-
ence of digestive enzymes and gastric acid [222]. IF is excreted by the stom-
ach’s parietal cells, while the intrinsic factor receptors (IFRs) are located in the
ileum [222]. Based on the limited capacity of IFRs, it was reported that only
1.5 − 2.9 µg of vitamin B12 per meal can be absorbed following binding to the in-
trinsic factor protein, with an additional 1 − 3 % of any oral dose being uptaken
by means of passive diffusion [223]. Doscherholmen et al. suggested that with in-
creasing dose, passive diffusion becomes the more dominant factor of vitamin B12
control [224]. Carkeet et al. reported appearance of B12 in the human blood plasma
only 2 − 3 h after administration, aligning with gastric emptying and subsequent
ileum-based absorption [225]. On average, a peak of 3 % the administered dose
(1.5 µg of labelled vitamin B12) was detected at 7 h after oral administration [225].
Absorption in neonates: The process of vitamin B12 absorption is believed to
differ in neonates. Adkins et al. presents findings that suggest two mechanisms
for vitamin B12 absorption in the neonate: IF-mediated and haptocorrin (HC)-
mediated vitamin B12 absorption [222]. The latter mechanism was previously re-
ported in suckling piglets and rat pups; yet the glycoprotein HC (68 − 100 kDa)
can also be found in pico-molar amounts in human milk [222]. Due to literature
highlighting low secretion levels of gastric acid and IF (both secreted by the stom-
ach’s parietal cells), and pepsin in the neonatal GI tract required for IF-mediated
absorption, an IF-independent mechanism was believed to occur [222, 226, 227].
Adkins et al. proved i) that an IF-mediated vitamin B12 absorption mechanism
seems to exist in breastfed infants, with IF receptors present in the infant’s ileum,
but indicated that IF levels may be too low in early life to participate in vitamin B12
absorption [222], ii) that until the IF-mediated absorption mechanism is completely
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matured, HC may mediate vitamin B12 uptake [222]. IF excretion in breastfed in-
fants was shown to gradually increase throughout the first four months of life [222].
Although the exact mechanisms of vitamin B12 absorption in neonates is unknown,
studies with preterm infants by Haiden et al. and Wothington et al. provide a
potential indication of the expected increase in serum vitamin B12 levels following
supplementation: Hereby, supplementing vitamin B12 over 8 − 12 weeks led to an
approximate three-fold rise in the infants’ serum B12 levels [228, 229].
Implications for using vitamin B12 as a tracer in breastfed infants:
No evidence seems to exist about i) the rate of HC-mediated vitamin B12 uptake,
and ii) how both vitamin B12 absorption mechanisms of adults (IF-mediated and
diffusion-based) and term neonates correlate with the absorption mechanisms in in-
fants born prematurely. Based on the limited information available, it was decided
to apply the findings of IF-mediated and diffusion based absorption in adult popu-
lations, as well as its relevant peaks obtained as a guideline for blood sampling of
both term and preterm neonates.
6.1.4 Study design considerations
Experimental work in this chapter was based on the following considerations.
(a) Selection of research methodology. In addition to the quantitative assess-
ment of vitamin B12 delivery, the feasibility study aimed to also assess maternal
expectation, experience, and acceptability. Due to the complex nature of therapeutic
delivery during breastfeeding, and its evaluation with inpatient mother-infant dy-
ads in a clinical setting, a parallel mixed method approach was chosen over purely
qualitative interviews. Hereby, qualitative and quantitative data were collected sim-
ultaneously, aiming to enhance the breadth and validity of study findings.
(b) Ethical considerations and timing. Research was meant to occur at a
time that is characterised by emotional and physical challenges, including maternal
recovery, adjustment to parental responsibilities, as well as to experiences of birth
and unexpected infant health challenges, e.g. preterm birth. As a consequence, an
engaging combination of tablet-based interactions and in-person conversations was
chosen: to collect quantitative data, tablet-based questionnaires (Likert scale) were
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used as an interactive tool, following which semi-structured open-ended interviews
were performed to more broadly discuss the questionnaires’ content.
(c) Selection of a nipple shield design. The clinical study was conducted us-
ing commercially available ultra-thin contact nipple shields (Medela, UK) of either
16 mm, 20 mm, or 24 mm size.
(d) Selection of vitamin B12 tablets. Sublingual vitamin B12 tablets from
JustVitamins Ltd, UK (1000 µg Methylcobalamin) were identified as a commercially
available formulation, based on their suitability for vegetarians and vegans, and the
absence of known allergenic components.
6.1.5 Proprietary studies
To investigate the JustVitamin tablets’ disintegration properties and to evaluate
whether they can serve as a suitable dosage form/formulation for the feasibility
study, the following proprietary studies aimed at investigating i) the capability of
JustVitamins’ sublingual vitamin B12 tablets to dissolve in human milk at physiolo-
gical parameters representative of in-vivo breastfeeding, ii) the duration for disin-
tegration to be achieved.
Methods. In-vitro breastfeeding simulation experiments were performed using pas-
teurised standardised homogenised whole cow’s milk (Coop British Whole Milk,
UK), characterised by a lipid content of 36 g L-1, and a protein content of
32 g L-1. The vitamin B12 tablet was placed in the silicone teat of a medium-
sized (20 mm) ultra-thin contact nipple shield (Medela, UK), and breastfeeding
simulation experiments conducted (according to Chapter 4) in triplicate for a dura-
tion of 5 min, 10 min, and 20 min. Pressure values averaged between those of term
and preterm infants were applied. Tablets and tablet leftovers after breastfeeding
simulation were weighted in a petri dish at room temperature before, and for 7 days
after experimental procedures until < 5% change in weight was observed.
Results. The percentage of tablets released within 5 min, 10 min, and 20 min are
summarised in Table 6.2. No tablet break-off during disintegration or dislocation of
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5 25.49 ± 0.18 41 ± 6
10 48.94 ± 0.40 62 ± 2
20 91.90 ± 0.08 74 ± 9
Table 6.2: Percentage of tablet released and milk passed through the nipple shield
for breastfeeding simulation experiments of 5 min, 10 min, and 20 min duration.
Discussion. Results obtained revealed the suitability of JustVitamins B12 tablets
for delivery during breastfeeding. Reasoning included the following: i) Substantial
tablet disintegration even after a short duration of breastfeeding, indicating that in-
vivo detection of vitamin B12 will also be possible for short feeds. ii) Steady tablet
disintegration ensuring adequate mixing of vitamin B12 with human milk during
the feed, and thus continuous delivery over time. Since the breastfeeding simulation
apparatus can neither simulate infant tongue movement [43], nor the elongation of
the maternal nipple during breastfeeding, enhanced disintegration properties can be
anticipated during in-vivo delivery.
Conclusion. The experimental procedures revealed that JustVitamins’ sublingual
vitamin B12 tablets are capable of dissolving in human milk at physiological para-
meters resembling the breastfeeding process, and thus, that sufficient delivery during
in-vivo breastfeeding can be expected. Due to their high safety profile and estab-
lished efficacy for delivery from a nipple shield, JustVitamins’ sublingual vitamin
B12 tablets are suitable for delivery during the feasibility study.
6.2 Materials and methods
6.2.1 Study design
As part of the presented single centre feasibility study, mothers administered vitamin
B12 in form of a sublingual tablet (Just Vitamins Ltd, 1000 µg vitamin B12 as
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Methylcobalamin), placed within the silicone teat of a commercially available ultra-
thin contact nipple shield, to their infant during breastfeeding. A qualified nurse
or lactation consultant known to the mother was present, provided breastfeeding
support, and advised on the appropriate use and application of nipple shields to the
breast. The study involved both the evaluation of quantitative changes in vitamin
B12 through blood serum tests, and assessment of maternal expectation, experience,
and acceptability via a mixed methods approach. An overview of the study’s design
is provided in Figure 6.1. Nipple shield and vitamin tablet used in this study are
illustrated in Figure 6.2.
Identifying eligible mother-infant dyads
Providing patient information sheet (PIS)




Pre study feed blood sample

































Figure 6.2: Illustration of the commercially available ultra-thin contact nipple shield
design (Medela, UK) and the vitamin B12 tablet (JustVitamins Ltd, 1000 µg
Methylcobalamin) used during the clinical feasibility study.
6.2.2 Study population and participant recruitment
The presented feasibility study was conducted from July to November 2018 on a UK
level 3 Neonatal Intensive and a Transitional Care Unit of the University of Cam-
bridge Addenbrooke’s Hospital Trust using purposive sampling. Inpatient breastfed
infants below 12 months of age, without medical conditions preventing them from
participation, were eligible for inclusion. No restrictions with regard to gestational
age or birth weight were made. The research team identified eligible infants in con-
sultation with both the nursing and medical staff, as well as the units’ Speech and
Language Therapists and feeding lead, following which mothers were approached
and study information provided. In addition, parents were informed about the
study through posters located in the unit’s communal area. Detailed inclusion and




• Breastfeeding is established (exclusively or non-exclusively)
• Infant is aged below 12 months
• No known allergy or hypersensitivity of mother or infant against any
ingredient of the commercially available vitamin B12 tablets
(JustVitamins Ltd, UK) used in the study
Exclusion criteria
• Breastfeeding not established
• Infant not feeding properly
• Allergy or hypersensitivity of mother or infant against any ingredient
of the commercially available vitamin B12 tablets (JustVitamins Ltd,
UK) used in the study
• Medical conditions that could negatively influence swallowing, and
thus breastfeeding
• Infant suffers from short bowel syndrome or malabsorption
Table 6.3: Inclusion and exclusion criteria for study recruiting.
6.2.3 Data collection and analysis
(a) Vitamin B12
Data collection. In order to assess the increase in vitamin B12 in the infants’ blood
following delivery, two infant blood samples were taken: a pre study feed sample
within one week before the study feed serving as the infants’ baseline vitamin B12
level, and a sample 6 − 8 hours after the study feed to evaluate the infants’ vitamin
B12 level increase and percentage uptake. Hereby, sampling time was based on
literature referencing vitamin B12 absorption in adult patients [225].
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Vitamin B12 assay. Blood serum was separated from whole blood following
clotting by centrifugation at 6100 rpm for 10 min, transferred into a separate vial,
and frozen at -80°C until further analysis. Serum vitamin B12 levels were analysed
using a LOCI Vitamin B12 assay (Siemens Healthcare, Munich/Germany) by the
Core Biochemical Assay Laboratory (CBAL) at the NHS Addenbrooke’s Hospital
Cambridge.
Analysis of assay data. The percentage increase of blood serum vitamin B12 was
calculated based on the difference in vitamin B12 levels pre and post study feed. The
percentage uptake of the administered dose was obtained via the following steps:
i) The infant’s haematocrit (Hct) data was used to calculate the infant’s correspond-
ing percentage of serum. ii) The infant’s blood volume was subsequently calculated
by means of published correlations [230], taking into account the infant’s current
weight. iii) The infant’s blood volume and the increase in vitamin B12 serum level
concentration was used to calculate the percentage uptake of the administered dose.
Data of the infants’ haematocrit and weight were taken from the medical notes,
ideally recorded/evaluated for clinical reasons on the study day itself or - if unavail-
able - from a day as close to the study day as possible.
(b) Mixed methods approach
Data collection. A mixed methods approach was used to evaluate maternal ex-
pectation, experience and acceptability, including both tablet-based questionnaires
(offline survey app: Feed2go) and recorded semi-structured interviews, developed
based on established guidelines [73]. Mothers were asked to compare their expect-
ations and experience of vitamin B12 delivery during breastfeeding to the previous
use of an oral syringe via the Likert scale from 0 to 10. The tablet was also used
to collect demographic data, e.g. asking mothers about their infants’ gestational
age or their previous experience of breastfeeding using a nipple shield. Excerpts
of the semi-structured questionnaire script and structured tablet-based questions




Figure 6.3: Excerpt of structured interview questions used before the study feed,
illustrated as presented to mothers on a tablet via the Feed2go survey app.
Semi-structured pre-delivery interview questions
• In the past, has your baby been given medicines/nutrients using
commercial devices, e.g. oral syringes, and how did you feel about it?
• What is your biggest worry for giving medicines or nutrients to your
baby during breastfeeding, and why?
• Why are you/are you not worried about using a nipple shield to give
medicines or nutrients to your baby during breastfeeding?
Table 6.4: Excerpt of semi-structured interview questions used (pre study feed).
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Figure 6.4: Excerpt of structured interview questions used after the study feed,
illustrated as presented to mothers on a tablet via the Feed2go survey app.
Semi-structured post-delivery interview questions
• What did surprise you the most when you compare your expectations
to your experience of giving the vitamin to your baby during
breastfeeding?
• Which of your expectations was least met, i.e. which experience was
not at all similar to your expectation?
• Why do you/do you not prefer to give medicines or nutrients during
breastfeeding over oral syringes? What would have to be changed, so
that you would prefer it?
Table 6.5: Excerpt of semi-structured interview questions used (post study feed).
107
Chapter 6
Data analysis. Semi-structured interviews were transcribed verbatim and po-
tentially identifiable data anonymized; tablet-based questionnaires were evaluated
quantitatively. Interview analysis was facilitated by ATLAS.ti (Scientific Software
Development GmbH) using an inductive approach of thematic content analysis
[53, 74]. Hereby, an initial coding framework emerged following both pre-reading, a
line-by-line open-coding approach, and re-grouping steps. The final coding frame-
work was developed by means of iterative revisions within the research team.
6.2.4 Ethics approval
The study was approved by the London - Brighton & Sussex Research Ethics Com-
mittee (18/LO/0551), with subsequent approval by the Health Research Authority
(HRA), as well as the Cambridge University Hospitals R&D and Insurance De-
partment. Applications were submitted via the IRAS system, comprising almost
100 pages of documentation. All participants provided their written informed con-
sent to be quoted anonymously in this publication.
6.3 Results
Out of a total of 60 infants screened, including four twin pairs, 43 were eligible
for participation. Reasons for ineligibility included: Health problems or feeding
difficulties (9), change to bottle feeding (4), discharge (4). 26 mother-infant dy-
ads provided their consent, of which 20 dyads completed the full study protocol
(Table 6.6). Reasoning to decline participation included: Mother felt overwhelmed
with the establishment of breastfeeding (3), mother refused non-clinical
blood samples (3), mother refused vitamin administration (1), mother had stopped
using a nipple shield (2), no reason provided (8). Non-completion and exclusion from
analysis was a result of one of the following: change to bottle feeding (1), discharge
before study feed (2), blood sampling time not kept (2), parent-led withdrawal (1).
The total number of participants was determined according to guidelines for qualit-




Characteristics Mean (range) or
N (%)
Mother’s age, mean (range) [years] 32.4 (23 - 39)




Infants’ gestational age at birth, N (%)
Extremely preterm (<28 weeks) 1 (5)
Very preterm (28 to <32 weeks) 2 (10)
Moderately preterm (32 to <37 weeks) 4 (20)
Full term (37 to <41 weeks) 8 (40)
Late term (41 to <42 weeks) 5 (25)
Infants’ birth weight, mean (range) [gram] 2769 (890 - 4145)
Stay of infant on NICU, N (%)
Yes, up to 1 week 5 (25)
Yes, 1 week or longer 7 (35)
No 8 (40)
Infants’ age at time of study, mean (range) [days] 16.2 (2 - 70)
Infants’ corrected gestational age at time of
study, mean (range) [days]
-3.7 (-30 - 15)
Duration infant has been breastfeeding, mean
(range) [days]
6.7 (2 - 17)
Exclusive breastfeeding at time of study, N (%)
Yes 7 (35)
No, also NG 9 (45)
No, also bottle 4 (20)
Use of nipple shield, N (%)
For current infant 9 (45)
Only for a previous infant 1 (5)
Never 10 (50)
Table 6.6: Characteristics of study participants (mother-infant dyads, N = 20).
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6.3.1 Vitamin B12 delivery
In all study feeds, complete tablet disintegration and delivery of the full vitamin
B12 dose was achieved. No residual tablet was left after the study feeds, and the
tablet’s presence in the shield did not appear to affect feeding. Percentage uptake
of the administered dose and the percentage increase in blood serum vitamin B12
are illustrated in Table 6.7. A pharmacokinetic-dependent increase to 3856 pg/mL
(1506 − 8413) from a baseline of 498 pg/mL (236 − 681) in infants aged 19-70 days,
and 1136 pg/mL (610 − 1743) from a baseline of 549 pg/mL (303 − 925) (infants
<7 days of age) was observed. Detailed blood serum vitamin B12 levels pre and
post study feed for each infant are illustrated in the Appendix section.
Increase of blood
serum vitamin B12 [%]
Uptake of the
administered dose [%]
Infants aged <7 days 126 ± 79 0.0072 ± 0.0029
Infants aged 19-70 days 656 ± 619 0.0329 ± 0.0173
Table 6.7: Vitamin B12 serum increase and uptake of the administered dose
(n = 16). Four pairs of blood samples (pre and post study feed) were excluded
from analysis due to haemolysis, affecting accuracy of the vitamin B12 assay used.
6.3.2 Mixed methods approach
Semi-structured interviews before and after the study feed, assessing maternal ex-
pectations and experiences, lasted 7.7 min (range 4.4−16.6 min) and 7.0 min (range
3.5 − 12.2 min), respectively. Results and relevant quotes of expectation are illus-
trated in Table 6.8. A summary of the maternal experience and perceived accept-
ability of therapeutic delivery from a nipple shield during breastfeeding, including
quotes of experience, is provided in Table 6.9 and Table 6.10. For all quotes used,
content in square brackets was edited to improve clarity and brevity. The abbrevi-
ation “NS” (nipple ´shield) and “no NS” (no nipple shield) provides an indication




Maternal expectations about therapeutic delivery during breastfeeding can be clas-
sified into two dyads of themes: worry and curiosity, as well as perceived emotional
and practical benefits. Concerns arose with regard to the nipple shield itself, as well
as to the vitamin inside its nipple teat. Mothers without previous experience of us-
ing a nipple shield, worried predominantly about the infants’ reaction and behaviour
during the study feed, including both the infants’ latching and overall feeding.
"It might take some [time] getting used to. I don’t know how she is going
to do with a nipple shield. And I don’t know whether it is going to affect
her, I mean the way that she latches." [M12, no NS]
"I guess it feels like this barrier in between the breast and them feeding.
[...] And it might feel a bit alien to the baby [...]." [M4, no NS]
For mothers who had previously used nipple shields, worries focused exclusively
on the tablet’s disintegration properties, its potential taste, and implication on
breastfeeding practice.
"[...] will it dissolve, and will she taste, be able to taste it?" [M2, NS]
"I don’t have any particular worries. Oki, I suppose if I was going to
have a worry it would be that it would give them a negative experience
of breastfeeding and then would put them of breastfeeding." [M6, NS]
In spite of their worries, mothers expressed their positivity and curiosity in attempt-
ing vitamin delivery from a nipple shield during breastfeeding.
"I think it’s worth looking into. It is something I have never thought
about. I think it is a good idea." [M12, no NS]
"It is just quite exciting to see how it works."[M2, NS]
Therapeutic delivery whilst breastfeeding was associated by all participants with
the expectancy of an improved emotional situation and enhanced convenience (see
Table 6.8). On an emotional level, mothers assumed a reduction of stress for both
mother and infant, while some mothers also referred to an enhancement in physical
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intimacy (see Table 6.8). With regard to practical considerations, anticipated be-
nefits were related to time saving, as well as fewer dosing errors using solid dosage
forms and its association of being “less messy” [M2, NS]. Both emotional and prac-
tical benefits were associated by all mothers with breastfeeding as a more “natural”
method of delivery compared to oral syringes.
"It seems a more natural way of administering medication. Because he
would have to nurse in this manner. So this shouldn’t be too different
from that natural process."[M5, no NS]
Reported experiences
Discussing their experience of therapeutic administration during breastfeeding, moth-
ers most frequently discussed the following: the experience as being positive, their
feeling of surprise about its ease and the infant’s positive perception, as well as con-
solidated positive thoughts around the use of nipple shields for therapeutic delivery.
Aligning with their previous expectations, mothers associated use of the nipple
shield with the vitamin B12 tablet with an ease of use and comfort, and referred
to it as positive. At the same time they shared their surprise about their infant’s
contentment during both feeding and vitamin delivery (Table 6.9), admitting that
they had expected a difference in the infant’s breastfeeding behaviour. Hereby,
mothers attributed their worries prior to the study feed to the lack of experience
and emotional circumstances.
"I think those worries were probably fear of the unknown. Not ever using
a nipple shield before. Sort of remembering how they were three years
ago, when I saw them in the shops, and they were a little bit alien-
looking. [...] I suppose not having that practice or that experience made
me think ’Oh, what is this going to feel like? And is it going to be a
barrier to feeding? And is he going to latch properly?’ But actually, all
of that was fine." [M4, no NS]
Based on the positive reaction of breastfed infants and the maternal assessment that
“the nipple shield didn’t hinder that natural breastfeeding sensation or process” [M5,
no NS], 95 % of mothers expressed that they are not worried to use a nipple shield




"I think the thing is, the benefits outway any of the potential problems.
So I think that [since I am a midwife] I would definitely advocate the use
of nipple shields under those circumstances to give medication, because
actually, I think the benefits of this far outway the risks of any nipple
confusion, which - to be honest with you - if you are gonna use a nipple
shield for ten minutes and the drug dissolves, I don’t really think you
can cause any harm." [M6, NS]
Appropriate guidance was requested for feeds, during which only incomplete delivery
of the full dose was achieved.
"So my thought would be: What would you do - if it was an actual drug
- and [you had] given only part of a dose? " [M2, NS]
Overarching themes: perceived advantages and acceptability
When asked to comment on the overall method of therapeutic delivery during breast-
feeding, considering its implications for future use, mothers expressed their belief
that it was “less invasive” [M7, no NS], and “not an aggressive method of deliv-
ery” [M16, no NS], which meant to them that “you are not forcing them” [M20,
no NS]. It emphasised the potential of therapeutic delivery during breastfeeding to
de-medicalise infant treatment by combining it with the natural process of breast-
feeding. This was seen as a particular advantage for mothers with prior neonatal
intensive care experience, providing a means to ease the emotional burden of the
infants’ past medical journey.
"I think what’s really nice, especially for [my daughter] - because she
started off her life being poked and prodded, and having things stuck in
her - that this is such a lovely... like for babies who’ve had to undergo
all that, to have something so natural, is lovely." [moved to tears] [M12,
no NS]
"In particular, I think, for my daughter, because she has been in a hos-
pital for three weeks, I would like something more natural for her from
now on. She had - she has - a tube in her nose, and I hope that in the
future, we don’t have anything clinical, you know, to deal with. [...] the
thought [of it] brings us back here. And not that it has been a hor-
rible experience [on the NICU], but it has been very scary. [...] at the
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moment, for us everything that has to do with syringes and medication
makes me think of NICU and, you know, this very scary part of her life"
[M19, NS]
All mothers advocated for oral infant therapeutic administration during breastfeed-
ing to become available to parents in the future, with the majority preferring this
method of infant therapeutic delivery to existing options (see Table 6.10). Reason-
ing for availability included that it would increase the range of technologies available
to them, and provide “choices to make things simpler” [M8, no NS]. A range of dif-
ferent technologies was seen as a possibility to respond to a mother’s and infant’s
individual preferences, to adjust to the type of therapeutic to be administered, while
also making it possible for the partner and family to help with therapeutic admin-
istration.
"[...] at the end of the day, as parents we have to make sure to give
our children medications when they need them, and in the most calm,
you know, not upsetting way possible for them. So, having the choice,
since every child is different... there isn’t just one way to make it easier,
I think. So having more ways means that there will be more children




Before After Change Quote of expectation
study feed




7.0 ± 1.6 8.3 ± 1.8 +19 % “They are upset, but you need to give the
medicine first. So then you have to get
that all sorted out. Then they are crying,
because they are hungry, and by the time
you actually start to feed, they are
already really distressed. Whereas I
guess, if you can do it all in one go, then
that is just going to be a bit easier.”
[M9, NS]
“[. . . ] you are doing breastfeeding
anyway. Hopefully it will be less messy.
There is no sort of error with calculating,
mismeasuring with the syringes. You
have just one tablet and that’s the dose.”
[M2, NS]
“Because you are already breastfeeding, it
makes it a bit simpler in that sense. That
it’s faster with what you are already
naturally anyways doing.” [M8, no NS]
. . . will make/
made me less
worried.
7.2 ± 2.0 8.6 ± 1.5 +19 % “[...] I think it would be positive for the
mother, if it is positive for the baby. [. . . ]
So I am just making the assumption it
will be nicer for [my baby] and in turn it
will be nicer for me.” [M6, NS]
“Probably [I’d be] more confident in
giving medicine, to be honest. Because
then it’s not having to stress him out, nor
do I stress me out.” [M10, NS]
“I would probably feel more comfortable
doing it this way, just ‘cause it’s
something we are already doing.” [M17,
NS]
Table 6.8: Comparison of maternal experience and expectation of vitamin B12




Before After Change Quote of expectation
study feed




7.7 ± 1.6 8.4 ± 1.7 +9 % “I would probably going to be closer to
him and it would feel more like a natural
part of the feed, rather than kind of going
away, taking the medicine out of a bottle,
putting it in a syringe, and then feeding
it to him.” [M9, NS]
“I don’t know if it really changes
closeness, because it is such a short. . .
it’s such a snapshot of time.” [M4, no NS]





7.7 ± 1.5 8.6 ± 1.4 +12 % “I think, if you are able to give your baby
medication in a more natural way where
it is just part of their routine anyway, I
think that’s good. I think it’s less
stressful.” [M12, no NS]
“I think it’s a good idea, ‘cause it’s a way
of them getting the medication that’s
doing something they would normally do.
You are not forcing them. It’s a natural
process.” [M20, no NS]
“I imagine the nipple shield would be less
stress for the baby. Because it’s part of a
regular interaction. Whereas a syringe
would be something completely new,
external coming in.” [M16, no NS]
“I guess, if baby is already familiar with a
nipple shield, it shouldn’t notice the
difference of receiving something else as
well. So I guess that would be the least
invasive way of delivering. If a baby is
not familiar with a nipple shield, then I
don’t know if it would be as smoothly
received. Because that’s another thing
that the baby has to adapt to, that would
change.” [M16, no NS]
Table 6.8 continued: Comparison of maternal experience and expectation of vitamin






The nipple shield with a vitamin tablet. . .






“I think it surpassed my expectation. Mainly because I was slightly
concerned about using this silicone and having the tablet, and how
it would all work. Whereas now that I have done it, I can see that
it is actually quite a natural process. [. . . ] I wish I’d be able to
administer all medicines like that rather than using syringes.”
[M5, no NS]
“It was pleasantly surprising, really. [. . . ] You know, it was just an
idea before, and now having done it, I feel good about it. I would
say that it exceeded my expectations.” [M1, NS]
“I think after doing it, using the shield, and having him
breastfeeding normally on it, I’d say it was a really positive
experience. [. . . ] I really think it is a more natural way to deliver
the vitamin.” [M4, no NS]





“I think this method of being able to give medication is so much
easier. [. . . ] You are not having to use a syringe necessarily to give
the medication, which can be quite difficult. [. . . ] It’s part of what
would have been your everyday routine anyway, instead of having to
include something that’s not necessarily something that they would
want to do.” [M20, no NS]
“It was really easy to put on.” [M7, no NS]
“[. . . ] I didn’t feel that I was giving him medicine at all.” [M6, NS]
“[. . . ] this was just such a smooth, easy process.” [M5, no NS]






“[Breastfeeding] is a bit different with a shield, ‘cause you don’t
necessarily get the same contact. But I think for the benefits it’s
not enough to worry about. Because the benefits far outway that.”
[M20, no NS]
“How comfortable the shield was for me [. . . ] - I was quite
surprised.” [M5, no NS]
“You know, I was aware that there was a layer in between. But
then it was less painful for me - the whole idea of the nipple shield
is to ease the pain of the nipple, so that actually made it more
comfortable anyway.” [M4, no NS]
“I thought it might be. . . I don’t know awkward or difficult. I
thought the shield might slip off, or something. But it was actually
very comfortable.” [M12, no NS]
Table 6.9: Maternal experience of vitamin B12 delivery during breastfeeding using











“I was surprised how easily he still latched, and that he didn’t even
notice that there was a nipple shield in the way.” [M7, no NS]
“I think he thought it was a bit strange at first, because he has not
had to use a breast shield before. So it was obviously a different
texture to what he was used to. But once he got used to it, it didn’t
stop him at all. [. . . ] it [also] hasn’t stopped him then going onto
the other side, which didn’t have the breast shield on – which is a






“I couldn’t tell any difference between feeding him with the tablet
in there or without. [. . . ] it was completely flawless, it just worked
perfectly.” [M6, NS]
“I was expecting more hurdles there. But there weren’t any. She
did very well. She didn’t have any problems with taste or anything
changing. [. . . ] I think that was my main concern initially: How
would she react to it having the change? And she was absolutely
comfortable with it.” [M8, no NS]
“That surprised me the most, that he just didn’t seem bothered.”
[M5, no NS]
Table 6.9 continued: Maternal experience of vitamin B12 delivery during breast-














“It’s because [breastfeeding is] what she’s used to. And that
means there is not gonna be a traumatic experience. It’s not
gonna be something scary or something that she doesn’t know,
that she doesn’t understand what’s going on. Which is always
helpful [. . . ] especially when the baby is poorly you don’t
want to add more stress to the whole procedure.” [M19, NS]
“It would definitely be something I would consider doing over
a syringe, if I had the option.” [M17, NS]
“Just because it’s natural, it’s the best. That’s how she is
been giving her food.” [M12, no NS]
“To have something simple as that. . . then I would always
choose the nipple shield, and that option.” [M6, NS]
“Whether I would use it all the time, I don’t know. [. . . ] I
might use a combination of ways. But definitely the fact that
it caused him less stress having it, was a major plus. [. . . ] I
am glad I tried this way as well.” [M4, no NS]
“It has not been a bad experience at all. But I just don’t










“I would say vitamins would be more preferable, because (for)
medicine it depends on how distressed the baby is. Because
sometimes you have to hold them and give them the medicine.
They are not interested in feeding, they are not feeling that
well, and everything. And then it could become a bit hard.”
[M8, no NS]
“I think anything you can save a baby from having to kind of










“I think, as long as it’s proved that they absorb the amount
they need to absorb, I wouldn’t have an issue with it being
medication as well at all. If anything it’s less stressful, so [. . . ]
you are actually more likely to get the full amount of it
[delivered] in this scenario.” [M20, no NS]
“It could be anything, as long as there is a way to know that
he has definitely got everything. Which. . . It was really easy
to tell, that the tablet had completely dissolved, and therefore
he had taken the whole tablet. So it’s just making sure he got
the right dose.” [M7, no NS]


















“I think it would be good, if it is possible. As long as there is
proper training on how to give the medicine. But then you
have to have training on how to give a syringe anyway. So it
shouldn’t make much difference, it’s just a different way of
doing it. Similar, but in a less invasive way.” [M7, no NS]
“It’s very intimate with the baby. [. . . ] You are not imposing
anything on the baby, it’s not an aggressive method of
delivery. I think if someone is breastfeeding, this should
definitely be presented as an option, as a way to deliver the
medicine or the nutrient supplement.” [M16, no NS]
“I think it is a perfectly good option. Just ‘cause I don’t
particularly get on with the shield, I think for other mums,
[. . . ] it would be a good idea for some. [...] I think options are
always a good idea.”[M11, no NS]
“It would be much easier in the future if that’s a method.
Because the syringe. . . yes, you have the odd child that likes
the syringe, but not every child does. It varies quite a lot.”
[M20, no NS]
“I think it is more of a personal choice. It would always come
down to having a choice there. But having a choice is good.”
[M8, no NS]
Table 6.10 continued: Perceived acceptability of vitamin B12 delivery during breast-
feeding (N = 20).
6.4 Discussion
This study is the first to demonstrate the feasibility and acceptability of therapeutic
delivery during breastfeeding using a commercially available silicone nipple shield.
Vitamin B12 delivery
The study showed that vitamin B12 (in tablet form) can be delivered from a
commercially available silicone nipple shield during breastfeeding. Since none of
the administered dose was lost, a common held anxiety with oral syringes and
dosing spoons, uptake of only 0.0072 ± 0.0029 % (infants <7 days of age), and
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0.0329 ± 0.0173 % (infants aged 19 − 70 days) of the administered dose can be at-
tributed to vitamin B12 pharmacokinetics. Observations of this study align with
reported literature on a less matured mechanism of absorption in infants, e.g. the
gradual increase in IF excretion throughout the first 4 months of life [222], lead-
ing to a lower uptake of vitamin B12 in infants than suggested for adult subjects
(1 − 3 % of the administered dose). In addition, dependence of vitamin B12 absorp-
tion on the infants’ actual age, independent of prematurity or birth weight, repres-
ents a previously unreported finding. Based on the infants’ creatinine
values, no concerns about renal function existed. In accordance with the
literature [224, 225], adjustment of vitamin B12 values within 10 − 24 hours to
those detected in the infants’ blood serum prior to the study feed were expected.
Themes of advocacy
The study also demonstrated maternal advocacy for the availability of therapeutic
administration during breastfeeding, which was motivated by two main themes:
choice and absence of worry. Throughout the study, mothers emphasised the im-
portance of choice, a factor shown to be liberating parents from experiencing a lack
of control [235, 236], while at the same time enabling them to assume responsibility
of their infants’ care and to further their ability in making informed decisions in
favour of their infants’ well-being [237, 238]. The advocacy of choice in oral delivery
technologies, particularly for neonates, might also be driven by a projected relief in
fear of potentially being “kind of stuck when they are not taking the medication” (see
Chapter 3), enabling to elevate the emotional burden associated with therapeutic
delivery to infants. Oral syringes, albeit commonly supplied with commercially
available infant liquid formulations, were associated with a predominantly negative,
medical sensation by mothers. Reasoning included their stimulation of worry and
their role as a reminder of previously experienced medical challenges, with the latter
being especially pronounced for mothers whose infants had undergone a variety of
intensive care procedures. It can be assumed that previously experienced emotional




Use of nipple shields
The exceedingly positive evaluation of therapeutic delivery from a nipple shield
was at odds with literature-based reporting on maternal beliefs around the use of
nipple shields: hereby, nipple shields were characterised to have both significant
benefits in establishing and maintaining breastfeeding [10,11], as well as negative
associations of discomfort, inconvenience, and the fear of nipple confusion [12].
While it was anticipated that recruitment and the interventions’ overall assessment
might be affected by potential negative prejudice, mothers in fact presented a very
positive and curious attitude towards this novel approach of therapeutic delivery,
indicated by a 60.5 % recruitment rate. Moreover, mothers, supported by nursing
staff in the application of the nipple shield to the breast, described the experi-
ence as positive for both themselves and their infants, and indicated that their
infant did not show problems in latching following removal of the nipple shield
after vitamin delivery. Even though half of the participants were not acquainted
with the use of a nipple shield, and the majority of mothers referred to breast-
feeding as their infant’s sole method for oral feeding at the time of study, concerns
about nipple confusion were limited. On the contrary, mothers in fact reported
their relief in having become familiar with the use of a nipple shield under nurs-
ing supervision, enabling them to be prepared if temporary use might be required
in the future. While this observation highlights the need for maternal education
on the practice of feeding with a nipple shield, it also stimulates considerations to
relieve maternal fear of nipple confusion, empowering them to make use of avail-
able tools - if needed - to support them in breastfeeding. The observation of com-
plete tablet disintegration and positive infant acceptance aligns with literature on
the infant’s acquaintance with a variety of tastes and the milk’s taste masking
properties [13–16]. Yet, based on maternal idioms of expressing surprise following
vitamin delivery during breastfeeding, it seems likely that in spite of their hope
for a positive experience, previous encounters of therapeutic delivery and potential
prejudice for the use of nipple shields might have reinforced the connotation of a
more challenging encounter.
Limitations
Limitations of this study include its design as a single centre study with a limited
sample size. Moreover, participants might have been biased towards a more favour-
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able evaluation of therapeutic delivery during breastfeeding, as only mothers willing
to use a nipple shield for the delivery of vitamin B12 consented to participate in
the study. It has to be highlighted however that the majority of participants had
not used a nipple shield before for feeding their current infant, and that potentially
biased expectations would have been resolved when reporting on their experience
after the study feed. Further research is needed to investigate use of a variety of
formulations for different medical indications and with an increased sample size in
both developing and developed countries.
6.5 Conclusion
This study evaluated the feasibility and acceptability of therapeutic delivery to in-
fants during breastfeeding by means of i) vitamin B12 delivery from a commercially
available ultra-thin contact nipple shield, ii) measurement of the infants’ vitamin
B12 blood serum levels 6 − 8 hours after the study feed, and iii) a mixed method
approach. Delivery of the full dose was achieved, and results showed that thera-
peutic delivery during breastfeeding was perceived as a feasible approach. Mothers
provided their unanimous advocacy for its availability to parents in the future, re-
lating to the following two themes of advocacy: (1) the desire of parents to be
given choices with regard to their infants’ health, (2) their preference of replacing a
mostly medically associated practice of delivery with one dominated by the natural
process of breastfeeding. Further investigations could focus on a variety of infant






The exploration of therapeutic delivery from a nipple shield during breastfeeding
has taken place within the Department of Chemical Engineering and Biotechnology
since 2010, and progress was made in establishing a means to enable in-vitro breast-
feeding simulation in order to analyse different formulations and modified nipple
shield designs. Yet, due to incomplete therapeutic delivery, the need for further
formulation investigations for delivery into human milk remained, so did the evalu-
ation of the in-vivo feasibility and acceptability of therapeutic delivery from a nipple
shield during breastfeeding. The presented doctoral work provided insight into both
areas of need by means of lab-based and clinical investigations. In the following, the
objectives outlined in Chapter 1 will be reviewed and study findings summarised.
Subsequently, their contribution to previous knowledge will be presented, resulting
implications synthesised, and suggestions for further research provided.
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7.1.1 Overview of results
Objective 1: To investigate novel therapeutic dosage forms for de-
livery from a nipple shield into human milk
(a) Fibrous matrix: non-woven Texel fibre mats for zinc sulphate deliv-
ery. The ability of Texel non-woven fibre mats to deliver zinc sulphate pentahydrate
from a modified lip-containing nipple shield into human milk was investigated, and
quantitatively compared to previous research by Scheuerle et al., using rapidly dis-
integrating tablets. Two types of Texel non-woven fibre mats of varying thickness
and different gram per square metre values were used, and zinc detection performed
via Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES). A total
recovery of 64.00 ± 0.01 % and 61.64 ± 0.01 % was achieved after 93.09 ± 1.08 g
and 98.15 ± 0.97 g of human milk had passed through the modified lip-containing
nipple shield. This totals 20 − 48 % superior release compared to previous zinc
delivery studies using rapidly disintegrating tablets. Incomplete delivery is believed
to be attributed to the accumulation of milk components within the porous mat
structures, and structural changes of loaded fibres. Further research is required to
establish Texel non-woven fibres as a generalized matrix for oral therapeutic delivery.
(b) Hydrogel: liquid-core sodium alginate calcium lactate hydrogels for
iron sulphate delivery. The feasibility of liquid-core hydrogels for therapeutic
delivery from a nipple shield during breastfeeding simulation was investigated by
means of ferric sulphate pentahydrate. It was the first time that a semi-solid dosage
form and a commercially available ultra-thin silicone nipple shield have been used
during in-vitro breastfeeding simulation into human milk. Release of ferric sulphate
pentahydrate was quantified using absorbance measurements of a salicylic assay. An
absolute recovery of 44.35±5.43 % loaded ferric sulphate pentahydrate was obtained
after 10.58 ± 0.09 g of human milk had passed through the nipple shield. This
finding is superior to the recovery of previously studied dosage forms. Consequently,
based on their superior delivery properties, ease of fabrication, and cost-efficiency,
liquid-core alginate hydrogels represent a promising dosage form for delivery during
breastfeeding. Incomplete recovery may be attributed to a combination of both iron
retention within the hydrogel’s core shell, as well as formation and accumulation of
iron-casein precipitates within the complex apparatus’ network. Further research is
required to improve the gel’s handling stability and shelf life characteristics.
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Objective 2: To explore the clinical implications of therapeutic de-
livery during breastfeeding
(a) Descriptive qualitative study: need and design preferences in a high-
resource setting. The concept of drug delivery during breastfeeding has originally
been developed as a means to overcome the challenges associated with therapeutic
administration to infants in low-resource settings. In this low-resource environment,
therapeutic delivery during breastfeeding was considered “potentially acceptable”
([45], p. 68). Yet, its suitability in a developed country, where dosing spoons and
oral syringes are readily available, had not been previously explored. The qualit-
ative descriptive study conducted at the University of Cambridge Addenbrooke’s
Hospital NHS Trust provided evidence that use of a nipple shield for therapeutic
delivery during breastfeeding was believed to be acceptable to parents and staff in
a high-resource environment and to address previously neglected challenges faced
with current delivery technologies. Particular benefits were anticipated for infants
in neonatal special care, among others the potential to foster mother-infant bond-
ing and encourage parental empowerment. Concerns raised related among others
to taste masking and timing of feeding and therapeutic administration. Parents
advocated for use of a commercially available ultra-thin contact nipple shield over
a modified lip-containing design.
(b) Clinical feasibility study: experience, acceptability, and advocacy in a
high-resource setting. Feasibility and acceptability of therapeutic delivery from
a nipple shield during breastfeeding was investigated as part of a clinical study with
twenty mother-infant dyads below 12 months of age. The study involved the de-
livery of vitamin B12 to infants during breastfeeding from a commercially available
ultra-thin contact silicone nipple shield, and the assessment of maternal expecta-
tion and experience by means of a mixed methods approach. Participants reported
a positive experience, noting that the nipple shield, containing a small tablet in
its silicone teat, did not affect their infants’ feed or comfort of breastfeeding. It
also demonstrated delivery of the full dose of vitamin B12. Mothers unanimously
advocated for this approach to become available to parents in the future, with
85 % expressing their preference for therapeutic administration from a nipple shield
during breastfeeding over the use of oral syringes. Reasoning included the desire
(1) of being provided with choices in relation to their infants’ health, (2) to replace
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a mostly medically annotated practice of therapeutic delivery with one dominated
by the natural process of breastfeeding.
7.1.2 Synthesis
Formulation investigation. Three formulation types have been investigated,
using both the modified lip-containing nipple shield and a commercially available
ultra-thin contact nipple shield. While the work on formulation development for dis-
integration during breastfeeding is far from being exhaustive, research findings com-
plement previous investigations using rapidly disintegrating tablets and HPMC cap-
sules, both of which were inferior to non-woven fibres and liquid-core
hydrogels [4, 44]. A summary of previously studied formulations and therapeut-
ics via in-vitro breastfeeding simulation experiments is provided in Table 7.1, key
information on formulation evaluations conducted as part of this doctoral thesis is
illustrated in Table 7.2. Out of all formulations studied for use in human milk, liquid-
core hydrogels allowed for the highest and non-woven fibres for the second highest
release within 2 min of breastfeeding simulation, amounting to 44.35 ± 5.43 % of
loaded ferric sulphate pentahydrate (Chapter 5, [47]), as well as 28.95 ± 9.52 % and
30.50 ± 4.33 % of zinc sulphate pentahydrate (Chapter 4, [38]), respectively. In
comparison, only about 3 − 5 % of zinc sulphate was released from rapidly dis-
integrating tablets within the same time and no detectable amount from HPMC
capsules [4, 44]. When comparing the total release values, it has to be noted that
experimental procedures for the investigation of liquid-core hydrogels were adapted
to account for breastfeeding physiology of premature infants, with a decreased pres-
sure amplitude and a less effective mean pressure to drive milk from the breast and
through the nipple shield, and that Fe3+-casein precipitation occurred. To date,
liquid-core hydrogels are the only dosage form, studied using breastfeeding simu-
lation, that enable therapeutic release simply by means of mechanical drivers, i.e.
flow rate, suction frequency, and vacuum applied. In contrast, previous research has
shown the dependence of tablet disintegration on the milk’s fat content, homogen-
eity, and macromolecule composition, also assumed to be affecting the release from
fibrous networks. Differences in release between in-vitro and in-vivo breastfeeding
have been highlighted as part of the feasibility study, demonstrating limitations of
breastfeeding simulation experiments. These include its lack of mimicking tongue
peristalsis, shown to be an important factor for therapeutic release from dosage
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forms within a nipple shield [43], as well as the apparatus’ void space, making it
possible for therapeutic-milk precipitates to be trapped and accumulate. Sublingual
vitamin B12 tablets were also analysed by means of in-vitro breastfeeding simula-
tion, before being used for in-vivo delivery from a nipple shield.
Parameter Rapidly disintegrating tablets HPMC
capsules
Reference [42] [4] [44]










Diameter [mm] 8 8.08 − 8.09 4.8
Height [mm] N/A 3.65 − 4.65 12






















<80 32 − 51 No recovery
detected










Reference Chapter 4, [38] Chapter 5, [47] Chapter 6












Diameter [mm] 10 14.28 8
Height [mm] 1.8/2.1 4.91 5































44.35 ± 5.43 74 ± 9
Table 7.2: Summary of conducted in-vitro breastfeeding simulation experiments
conducted as part of this doctoral thesis.
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Thereby, release of 74 ± 9 % was achieved within 20 min of breastfeeding simula-
tion, contrasting to findings from the feasibility study, whereby vitamin B12 tablets
dissolved completely in all study feeds of 15 − 20 min duration. For those infants
whose breastfeeding was paired (feeding on both breasts) or who were losing their
latch at some time during the study feed, it could be noted that tablet disintegration
was already completed after 5 − 10 min of breastfeeding. These findings emphasize
both the importance of in-vitro experiments in order to provide a general assess-
ment of formulation suitability for delivery into human milk, but likewise the need
for clinical investigations in order to account for current limitations in breastfeeding
simulation.
Qualitative research. Presented qualitative data complements research conduc-
ted in Kenya and South Africa [45, 46], by providing views of parents in a de-
veloped setting. In addition, the descriptive qualitative study also benefited from
enabling trained medical staff to contribute their thoughts on the potential of thera-
peutic delivery from a nipple shield during breastfeeding. It was the first time that
this potential end-user group and staff, likely to act as advocates or opponents for
therapeutic administration from a nipple shield, were interviewed. As the work on
therapeutic delivery during breastfeeding is of interdisciplinary nature, particularly
medical input is key, but unfortunately had been lacking prior to research presented
in this doctoral thesis. These studies have been helpful in identifying previously
unrealized limitations of the modified nipple shield designs, presented in Chapter 2.
These included among others the decreased space within the modified nipple shield,
which was believed to be not compatible with maternal physiology. Likewise, par-
ents gave preference to a reusable commercially available ultra-thin contact nipple
shield, which contrasts to findings by Hart et al. and Flynn et al. [45, 46]. In both
studies, mothers had advocated for a disposable nipple shield with a circular shape,
based on the fear that a reduced base would increase the likelihood of the shield to
fall off the breast [45, 46]. No assessment on the lip contained within the shield’s
teat was made, indicating that maternal preference for a modified nipple shield was
likely based on appearance of the shield’s base. Following multiple years of work
with modified nipple shields, research presented in this doctoral thesis thus sets a
new direction for the development of therapeutic delivery during breastfeeding. It
moved its focus away from the design of a modified nipple shield towards the iden-
tification of approaches to enable use of commercially available ultra-thin contact
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nipple shields for convenient and reliable administration of therapeutics to breastfed
infants.
Clinical study. Clinical work presented in Chapter 6 was unique in being the
first in-vivo assessment of therapeutic delivery during breastfeeding. Previously,
interactions with parents and staff had only been based on the visual assessment
of nipple shields and dosage forms, as well as its hypothetical use during breast-
feeding (Chapter 3, [45, 46]). Findings of the presented feasibility study confirmed
the assumption that therapeutic delivery from a nipple shield could serve as an al-
ternative to existing oral infant delivery technologies. Even more so, 95 % of mothers
were happy using a nipple shield for therapeutic delivery and 85 % preferred this
method to oral syringes. This highlights that therapeutic delivery during breastfeed-
ing is not just a tolerated alternative, but in fact, an alternative regarded as superior
by the majority of mothers who participated in the study. Irrespective of personal
preference, experience in using nipple shields, or exposure to neonatal intensive care,
the mothers’ unanimous advocacy of therapeutic administration during breastfeed-
ing acknowledges the need to provide parents with a choice in oral infant therapeutic
delivery. “Choice” was identified as a main driver for advocacy of therapeutic deliv-
ery from a nipple shield, alongside the desire to turn the negative, medical sensation
of therapeutic administration into a positive experience associated with the natural
process of breastfeeding. As both themes are not constrained to a country’s state of
development or available resources, it can be hypothesised that therapeutic delivery
from a nipple shield during breastfeeding has the potential to serve as an alternative
for therapeutic administration to infants globally.
7.2 Outlook
Further progress is needed to move closer towards making therapeutic delivery from
a nipple shield during breastfeeding available to parents in the future. The work of
interdisciplinary nature focuses on complementing formulation investigations, fur-
thering clinical research, as well as seeking support in the translation of research




Non-dissolvable and dissolvable fibres. In order to continue presented work on
Texel non-woven fibre mats (Chapter 4), research to confirm its in-vivo suitability
could be undertaken, including the investigation of fibre cohesion to exclude the
possibility of fibre break-off, palatability, biocompatibility, and long-time stability.
In addition, further research using different polymeric networks could be conduc-
ted, including the use of different fibre types and materials, such as the natural
polymers cellulose and xanthan with enhanced biocompatibility
characteristics [239–241]. Particularly fast-disintegrating electrospun fibres could be
promising for two reasons: they are capable of enhancing the solubility of even poorly
water-soluble drugs through incorporation in their amorphous form or as nanocrys-
tals [242, 243], and enable their full delivery when disintegrating, thereby actualising
the end-users’ preference to visually observe the delivery process (Chapter 3). Dur-
ing electrospinning, electrostatic forces are used to achieve fibre formation of both
natural and synthetic polymers [243].
Dissolvable films. To date four out of the five types of dosage forms, believed to be
suitable for delivery into human milk as outlined in Chapter 2, have been explored,
leaving dissolving films as an investigation yet to pursue. Such films, designed to
dissolve in the oral cavity, are referred to by the European Medicines Agency (EMA)
and the Food and Drug Administration (FDA) as orodispersible films (ODFs) and
soluble films, respectively [244]. Originally developed to help address the needs of
geriatric patients as well as younger children with swallowing difficulties, dissolvable
films are designed to enable release of a full dose within less than one minute when
being exposed to saliva [244, 245]. In addition, ODFs enable convenient alteration of
doses by adapting the number of strips used for administration [87]. Most common
are polymeric films fabricated using a single or a mixture of polymers, comprising
celluloses, starch, semi-synthetic, synthetic, and other polymer classes [244], but
also protein or protein-polymer films [246]. Particularly promising in the context of
therapeutic delivery into human milk is the investigation of films or ’melts’ made
from casein, a protein naturally occurring in milk. Films of CaCas or NaCas blen-
ded with glycerol (Gly) are transparent and tasteless [246], characteristics preferable
for administration during breastfeeding. Originally developed for intended use as
edible food packaging [246], these films would also possess the stability needed to
be placed within the nipple shield’s teat. For each type of therapeutic and its inten-
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ded concentration, iterative adaption of the original fabrication protocol is required
to ensure film formation despite the presence of a therapeutic in the CaCas/Gly
or NaCas/Gly mixture. Film formation is achieved by spreading the mixture on
a silicone baking tray, followed by a controlled trying process in an environmental
chamber [246].
Liquid-core capsules fabricated through crystallization. Another poten-
tial approach for the fabrication of liquid-core dosage forms is the encapsulation
of molecule solutions by means of crystallisation. The literature documents its
wide range of applications, such as the fabrication of dissolvable milk capsules
for use in hot drinks or of small pastilles with liquid content for pharmaceutical
applications [247, 248]. The process is also already used commercially, e.g. in the
confectionery industry for the manufacture of sugar coated liquid-core sweets [248].
Formation is most commonly based on the presence of a sugar or sugar substitute,
such as xylitol, in a saturated liquid formulation, poured into moulds lined with
seeded particles [247, 248]. A cooling steps subsequently leads to the formation of
a crystal shell [247, 248]. Crystallisation protocols have to be optimised for each
therapeutic or food product solution, the type of sugar or sugar substitute used, and
the size of pastille/capsule to be obtained [247, 248]. This method of dosage form
fabrication seems particularly suitable for formulations containing a high amount of
sugar, such as CALPOL® Infant Suspension. One dose of CALPOL® Infant Sus-
pension (5 mL) contains 2.2 g of sucrose.
3D-printed dosage forms. Computer-assisted three-dimensional printing is a
technique whereby an ink-jet printing technology enables a binder material to be
printed into layers of powder, resulting in a 3D object [249]. 3D printed dosage
forms provide a range of beneficial characteristics, such as personalization, precise
dose control, and the production of dosage forms with complex therapeutic release
profiles [250, 251]. This technique is particularly advantageous for paediatric applic-
ations, allowing for the production of smaller quantities and providing an incentive
for the development of formulations optimised for use in paediatrics, particularly in
its even smaller neonatal sub-population. It can also help to reduce potential ad-
verse reactions and enhance tolerance [251]. Evidence of the potential of 3D printed
dosage forms is shown in the literature, and gains increasing commercial interest.
The first 3D printed orally disintegrating tablet was approved by the Food and
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Drug Administration (FDA) in 2015 [252]. A range of 3D printed dosage forms are
possible, for example tablets or films [87, 253].
7.2.2 Clinical investigations
The positive feedback received by mothers as part of the clinical feasibility study
is promising and encourages further clinical research with the objective to increase
total sample size, as well as to evaluate use of different formulations and their ap-
plication for a range of therapeutic indications. Since acceptability can vary based
on the cultural, social, and geographical setting, investigations should be designed
to account for a range of factors believed to impact acceptability of therapeutic
delivery from a nipple shield during breastfeeding.
High-resource settings. In order to further presented clinical work in a high-
resource environment, future research could investigate use of additional commer-
cially available formulations for delivery during breastfeeding, aiming at supporting
therapeutic administration for a range of clinical neonatal indications. Investig-
ations could among others include the delivery of dextrose gel for the treatment
of neonatal hypoglycaemia, affecting 5 − 15 % of newborns and putting them at
risk for irreversible brain injury [254]. It was hypothesized that administration of
dextrose gel from a nipple shield during breastfeeding could be beneficial in two
respects. i) It could support the stimulation of maternal milk production. ii) It
could enable a slower, more favourable rise of the infants’ blood glucose levels, as
the dextrose is swallowed as opposed to absorbed via the buccal mucosa. Yet, care
has to be taken with regard to the gel’s viscosity, which could hamper its delivery
from a nipple shield, and with regard to early use of a nipple shield, requiring guid-
ance based on the expertise by both trained midwives and healthcare professionals.
Additional applications could include the delivery of vitamin and antioxidant sup-
plements to premature neonates [255], probiotics [256], and adjustable human milk
fortification [257]. Since commercially available formulations, both with regard to
suitable solid or semi-solid dosage forms and appropriate dosing for the delivery




Low-resource settings. Due to the high prevalence of breastfeeding [11], and by
drawing on previous qualitative interviews conducted in Kenya and South
Africa [45, 46], investigations in low-income countries are of particular interest.
Hereby, literature indicates the importance of focusing on the intervention’s suit-
ability for cultural and religious circumstances, while also considering obstacles in
realising its availability and access [45]. The Cambridge University Hospital Global
Network has established links with maternal and neonatal hospital units, and aca-
demic institutions in Botswana and El Salvador, which could facilitate in expanding
investigations internationally. A range or research interventions could be considered.
First, the study protocol could be designed to have the same objectives and end-
points as the feasibility study presented in Chapter 6, enabling direct comparison
of findings in a low- and a high-income environment. In addition, use of alternative
therapeutics could be considered, whereby use of vitamin and mineral supplements
seem most appropriate due to their safety and commercial availability in form of
sublingual tablets or capsules. Due to the high prevalence of anaemia in children
below five years of age, amounting to more than 40 % in Botswana and 30 % in El
Salvador [25], administration of ferrous salt would seem particularly suitable. Lit-
erature reports that oral delivery of 25 mg ferrous iron in six healthy adult subjects
led to a maximum increase in serum iron (µmol L-1) concentration by 10 µmol L-1
4 h post delivery [258], enabling detection by means of blood serum analysis.
7.2.3 Support for translation into medical practice
As indicated previously in the context of design considerations for therapeutic deliv-
ery during breastfeeding, guidance and support by external organisations is required
to make its translation into clinical practice possible. This includes both support
on a policy as well as on an industrial pharmaceutical level. Initial responses to
the overall concept of therapeutic administration from a nipple shield, obtained in
2016 from the Deputy Programme Director at the UNICEF UK Baby Friendly Ini-
tiative, as well as the Research Engagement Officer and VOICES Co-ordinator at
NCT Excellent Practitioner (Antenatal), were generally positive, but highlighted
the need for further investigations, including clinical research. Based on results
presented in Chapter 6, further opportunities for conversations can now be sought.
Likewise, the Royal College of Paediatrics and Child Health, focusing to increase
breastfeeding rates within the UK, could assists in providing advice. To enhance
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visibility of this potential alternative to existing infant therapeutic delivery tech-
nologies, publications of short articles in magazines for professional practice and
research communication, such as “Infant”, a journal for neonatal and paediatric
healthcare professionals available on all neonatal units within the UK, the Univer-
sity of Cambridge Magazine “Research Horizons”, as well as the IChemE magazine,
are intended. Engaging in discussions with healthcare experts, policy professionals,
and the pharmaceutical industry is of high importance in emphasising the need of
and parents’ interest in innovation of infant oral therapeutic administration. Ul-
timately, only in collaboration it will be possible to provide parents with a choice
to facilitate drug and nutrient delivery and lessen current struggles in children - an




A1. A parent nursing perspective (page 140 − 146)
Appendix A1 illustrates study recruitment material used as part of the qualitative
descriptive study, presented in Chapter 3, including patient information sheets for
parents and healthcare professionals, as well as consent forms.
A2. FEDD feasibility study (page 147 − 153)
Appendix A2 illustrates study recruitment material used as part of the FEDD feas-
ibility study, presented in Chapter 6, including a poster, the patient information
sheet, as well as consent forms for mother and infant.
A3. FEDD vitamin B12 blood serum levels (page 154)
Appendix A3 relates to the clinical investigation in Chapter 6, and illustrates raw







































4 (*) 371 705 Pre study feed
sample
















19 (*) 452 8413 Post study feed
sample
20 352 1506
Table A3.1: FEDD vitamin B12 blood serum levels in breastfed infants pre and
post study feed. Blood samples of infants indicated by (*) were not considered for
data analysis, since at least one blood sample was haemolysed. Four pairs of blood
samples (pre and post study feed) were excluded from analysis due to haemolysis,
affecting accuracy of the vitamin B12 assay used.
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